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ABSTRACT 
Epilepsy is a neurological disorder that is characterised by spontaneous seizures. After 
various epileptogenic injuries, astrocytes become dysfunctional and experimental evidence 
indicates that these cells contribute to seizure mechanisms. The generation of 
inflammatory molecules in astrocytes appears to play a key pathogenic role in seizures. 
However, astrocytes may also contribute to repair the hyperexcitable neuronal networks 
underlying seizures. 
We focused our studies on understanding the role of astrocytes in epilepsy by (1) 
developing a new in vivo imaging method to monitor astrocytic cell activation during 
epileptogenesis and coupled this with their phenotypic characterization; (2) studying the 
role of Toll-like receptor 3 (TLR3) signaling in seizure mechanisms.  
We report that in vivo bioluminescence imaging is a powerful tool for monitoring astrocytic 
activation in diseased conditions. Characterization of astrocytic activation during 
epileptogenesis showed a rapid cell activation corresponding to their inflammatory 
phenotype while homeostatic (neuroprotective) mechanisms were activated with a delay. 
Moreover, we demonstrate that in vivo imaging of astrocyte activation allows to study the 
potential involvement of these cells in the therapeutic effects of anti-inflammatory drugs.  
We also show that priming TLR3 activation in astrocytes with the use of a synthetic agonist 
results in remarkable anti-inflammatory and anti-ictogenic effects. Mechanistic studies 
revealed that interferon regulatory factor (IRF)-3/Interferon-β mediated cascade is likely 
responsible for the inhibitory effects of TLR3 priming on seizures and neuronal excitability.   
In summary, astroglia activation during the critical epileptogenesis phase provides a 
potential target for interfering in a timely manner with the inflammatory phenotype of 
these cells contributing to seizures. Importantly, there are astrocytic cell functions that 
16 
 
mediate decreased neuronal excitability and they should be carefully considered when 
developing treatments targeting these cells for therapeutic purposes.  
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1.1 EPILEPSY 
1.1.1 Definition and classification 
Epilepsy is one of the most common neurological disorders affecting about 1% of the 
population worldwide. Epilepsy is characterized by an enduring predisposition to generate 
epileptic seizures, and by the neurologic, cognitive, psychological, and social consequences 
of this condition. The definition of epilepsy requires the occurrence of at least two 
unprovoked or reflex seizures > 24 h apart or one unprovoked or reflex epileptic seizure 
and a probability of having another seizure similar to the general recurrence risk after two 
unprovoked seizures (≥ 60%) over the next 10 years, or an epilepsy syndrome (Fisher, 2014). 
An epileptic seizure is a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain (Fisher, 2014). Seizures can be 
divided in those that have focal onset, involving one hemisphere of the brain, in those that 
have generalized onset and involve both hemisperes of the brain and those of unknown 
onset (Figure 1.1.1).   
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Figure. 1.1.1. Seizure classification a) Basic seizure classification according to the International 
League Against Epilepsy 2017. b) Expanded seizure classification where motor and non-motor 
categories are further divided according to features that might be present during seizures, such as 
automatisms and myoclonus. Adapted with permission from Fisher, R. S. et al. Operational 
classification of seizure types by the International League Against Epilepsy: Position Paper of the 
ILAE Commission for Classification and Terminology. Epilepsia 58, 522–530 (2017)(Devinsky et al., 
2018).  
 
Epilespy is classified as focal, generalized, combined generalized and focal which refers to 
epilepsy syndromes such as Dravet and Lennox-Gastaut, and finally as unknown when the 
onset is unknown. Furthermore, epilepsy is divided into six categories based on its etiology. 
The first category includes structural alterations visualized by imaging, that can increase 
the risk of being associated with epilepsy (Berg et al., 2010). The second group is genetic 
20 
 
epilepsies that can result from a genetic mutation that leads to seizure manifestation as a 
core symptom. One of the most common etiologies of epilepsy in less developed countries 
that can have specific treatment implications is infection (Vezzani et al., 2016). Metabolic 
etiology involves a known or presumed metabolic disorder that is associated with epilepsy 
development. Moreover, autoimmune-mediated epilepsies are described in both adults 
and children (Vezzani et al., 2016). Lastly, epilepsies that do not have a known cause fall 
into the category of unknown etiology epilepsies. Classification of epilepsies based on the 
seizure type and etiology is summarized in Figure 1.1.2. 
 
 
Figure. 1.1.2. Framework for the classification of the epilepsies. This framework begins with the 
diagnosis of an epileptic seizure, following which, the diagnosis of an epilepsy type and, if possible, 
an epilepsy syndrome. After diagnosis of an epileptic seizure, the etiology should be identified where 
possible. Associated comorbidities should also be considered. *Denotes seizure onset. Adapted with 
permission from Scheffer, I. E. et al. ILAE classification of the epilepsies: Position paper of the ILAE 
Commission for Classification and Terminology. Epilepsia 58, 512– 521 (2017)(Devinsky et al., 2018). 
 
Temporal lobe epilepsy (TLE) is a form of focal epilepsy and is typically resistant to anti-
seizure drugs (ASDs). Mesial temporal sclerosis (MTS) is most often associated with TLE 
(Blair, 2012). Status epilepticus (SE) is one of the causes of TLE and is often induced in 
animal models to ignite the development of epilepsy. 
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SE is defined as a clinical situation in which a seizure is manifested continuously for more 
than 5 minutes, or in which multiple seizures are repeated at very short intervals 
representing a continuous condition of epileptic activity (Trinka et al., 2015). It is a 
condition resulting either from the failure of the mechanisms responsible for seizure 
termination or from the initiation of mechanisms which lead to abnormally prolonged 
seizures, or both. It is a clinical condition that can result in long-term neurological 
consequences, including neuronal death and maladaptive neuronal network alterations 
which contribute to further seizures and neurological deficits (Trinka et al., 2015). 
 
1.1.2 Unmet clinical needs 
Despite the availability of a number of ASDs, it is estimated that up to 40% of newly 
diagnosed epilepsy patients will remain resistant to drug therapy and continue to have 
seizures (Abraham and Shaju, 2013; Löscher et al., 2013). Drug resistant epilepsy is defined 
as failure of adequate trials of two tolerated and appropriately chosen and used ASDs 
schedules (whether as monotherapies or in combination) to achieve sustained seizure 
freedom (Kwan et al., 2010). This condition impacts negatively on the patients’ quality of 
life and increase the risk of injury and even death. Continuing seizures can also interfere 
with memory, cognitive functions, educational opportunities and also implicate a socio-
economic disadvantage (Abraham and Shaju, 2013; Löscher et al., 2013). Another major 
unmet clinical need is the lack of treatments for preventing epilepsy in patients at risk of 
developing seizures after acute brain insults such as traumatic brain injury, stroke and 
prolonged acute symptomatic seizures such as complex febrile seizures or SE (Löscher et 
al., 2013). In fact, the available ASDs offer only symptomatic control of seizures without 
providing preventative or disease-modifying effects. Disease modification applies to 
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therapeutic strategies which resolve or lessen the pathologic mechanisms underlying 
epileptogenesis (i.e. the development and extension of tissue capable of generating 
spontaneous seizures), therefore, preventing or alleviating the development of epilepsy or 
its progression, or the associated co-morbidities. Thus, the need for more effective 
therapies remains urgent. 
 
1.2 EPILEPTOGENESIS 
1.2.1 Definition 
Epileptogenesis is triggered by genetic or acquired causes as shown both in humans and in 
animal models (Pitkänen et al., 2015). It is a continuous process by which a brain network, 
previously normal, is altered towards increased excitability, thus showing enhanced 
propensity to generate seizures. Epileptogenesis encompasses both the period preceding 
seizure onset as well as disease progression (Dudek and Staley, 2012)(Figure 1.2.1A, B).  
This is supported by experimental and clinical studies providing evidence of increased 
frequency of spontaneous seizure over time and development of neurological 
comorbidities (Pitkänen et al., 2015). Furthermore, the molecular, cellular and functional 
alterations that precede the occurrence of the first unprovoked seizure, often continue 
thereafter likely contributing to disease progression (Dudek and Staley, 2012; Pitkänen and 
Lukasiuk, 2011; Pitkänen and Sutula, 2002; Rakhade and Jensen, 2009). This concept has 
implications both for therapy and biomarker discovery (Pitkänen and Engel, 2014; Pitkänen 
et al., 2013). 
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Figure 1.2.1. Definition of epileptogenesis. (A) Epileptogenesis was considered as the latent period 
between the precipitating insult and the occurrence of the first unprovoked clinical seizure. (B) Based 
on experimental and clinical observations, epileptogenesis is now considered to extend beyond the 
onset of epilepsy (Pitkänen et al., 2015). 
 
Epileptogenesis is often associated with neurological comorbidities such as anxiety, 
cognitive deficits and depression (Kanner, 2016; Keezer et al., 2016). It is still unclear 
whether comorbidities originate from networks overlapping or distinct from those 
provoking seizures. Notably, animal studies have shown that cognitive deficits may arise 
before the first manifestation of spontaneous seizures indicating that they may not be a 
mere consequence of seizures (Hort et al., 2000; Kobow et al., 2012; Pascente et al., 2016; 
Pitkänen and Kubova, 2004). 
Anti-epileptogenesis is defined as a process that counteracts the effects of epileptogenesis, 
including prevention, seizure modification and cure (Pitkänen et al., 2015). Since the 
current preclinical and clinical research is focused on developing anti-epileptogenesis or 
disease modifying drugs, the identification of biomarkers that can reliably predict which 
patients have a high likelihood of developing epilepsy is essential for clinical studies.  
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1.2.2 Mechanisms underlying epileptogenesis 
The studies in experimental models of epilepsy have provided the main source of current 
knowledge on the mechanisms underlying the epileptogenic process. Epileptogenesis in 
these models is induced either by structural brain alterations or by infectious or genetic 
causes (Table 1.2.1). Most often epileptogenesis is studied in models of SE or neurotrauma 
(Table 1.2.2) (Pitkänen and Lukasiuk, 2009). 
Table 1.2.1. Epileptogenesis models. 
ETIOLOGIES RODENT MODELS 
STRUCTURAL  
Neurotrauma* Fluid percussion; Controlled cortical impact; Cortical undercut 
De novo status 
epilepticus* 
Electrical stimulations; Chemoconvulsants; Hyperthermia 
Unilateral hippocampal 
sclerosis* 
Intrahippocampal or intracortical kainic acid; Perforant path 
stimulation 
Stroke* Cortical phototrombosis; Permanent  middle cerebral artery 
occlusion; Intracortical endothelin-1 
Blood-brain barrier 
damage* 
Sub-chronic albumin or TGF-β1 intracerebroventricular infusion 
Developmental epileptic 
encephalopathies 
Hypoxia-ischemia injury in rats; 
Infantile spasms: Multiple hit rat model; Tetrodotoxin in rats 
Cortical dysplasia Genetic: Pten, Dcx, Otx1 knock-out mice; Knock-in of human Lis1; Arx 
mutations in mice 
Congenital acquired: In utero rat irradiation or alkylant agents (MAM, 
BCNU) 
Glioblastoma Neocortical transplantation of human glioma cells in SCID mice or 
glioma cell lines in rat 
INFECTIOUS  
Viral encephalitidies Theiler murine encephalomyelitis virus 
Cerebral malaria Plasmodium berghei ANKA murine model 
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*Models apply to both rats and mice if not otherwise indicated. Mutiple hit rat model: 
doxorubicin+lipopolysaccharide±p-chlorophenylalanine. 
Abbreviations: apc, adenomatous polyposis coli; Arx, aristaless related homeobox; BCNU, 
carmustine 1-3-bis-chloroethyl-nitrosurea; Dcx, doublecortin; GAERS, Genetic absence epilepsy rat 
from Strasbourg; Gabrg2, GABA-A receptor 2 subunit; HSV, high voltage spike-and-wave spindles; 
Lis1, lissencephaly 1; MAM, methylazoxymethanol; Otx,1 orthodenticle homeobox 1; Pten, 
phosphatase and tensin homolog; Scid, severe combined immundeficient; Scn1A,B, sodium voltage-
gated channel (Nav1.1α,β subunit); scn8a, sodium voltage-gated channel alpha subunit 8 (Nav1.6); 
TGF-β1, transforming growth factor-beta1; Tsc1-2, tuberous sclerosis complex 1,2; WAG/Rij, Wistar 
Albino Glaxo from Rijswijk. 
 
 
 
 
 
 
 
GENETIC OR PRESUMED 
GENETIC 
 
Tuberous sclerosis 
complex (TSC) 
Cell specific-conditional Tsc1 or Tsc2 knock-out mice 
Spontaneous mutations Rat absence epilepsy: GAERS, WAG/Rij, HVS; 
Murine absence epilepsy: Tottering, Lethargic, Stargazer, Mocha 2j, 
Slow-wave, Ent, Ducky, Gabrg2 conditional knock-in mutation 
Induced monogenic 
mutations 
Mouse knock-out or knock-in mutation of voltage-gated ion channels 
subunits (Na+, K+, Ca2+), neurotransmitter receptor subunits (GABAA, 
nicotinic) and transporters, accessory synaptic proteins; cystatin B 
(Cstb) knock-out 
Developmental 
epileptic 
encephalopathies 
Dravet syndrome: SCN1A, SCN1B: Knock-in of human mutations in 
mice; Constitutive or conditional knock-out mice; 
Infantile spams: ARX: Knock-in of human mutations in mice; 
Constitutive or conditional knock-out mice; Apc: Conditional knock-
out mouse 
SCN8A: Knock-in of human mutations in mice 
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Table 1.2.2. Epileptogenesis models induced by acute brain injury (modified by Pitkanen and 
Lukasiuk, 2009). 
 
 
The molecular and cellular alterations along with their pathological outcomes have been 
best characterized in the hippocampus although the epileptogenic process may involve also 
other limbic and extralimbic areas (Jutila et al., 2002). The hippocampus has a well known 
neuronal circuitry and plays a key role in network hyperexcitability in various models of 
acquired epilepsy (Pitkänen and Lukasiuk, 2009). Figure 1.2.2. summarizes the cellular and 
molecular alterations identified in the hippocampus during epileptogenesis. 
 
TYPE MODEL REFERENCES 
Immature brain 
SE 
Kainic acid (PN14) (Stafstrom et al., 1992) 
Li-Pilocarpine (PN12 or PN21) 
(Kubova et al., 2004; 
Marcon et al., 2009; Roch 
et al., 2002) 
Prolonged febrile seizures (PN10) (Dube et al., 2006) 
Mature brain 
SE 
Kainic acid 
(Ben-Ari and Lagowska, 
1978; Mouri et al., 2008) 
Pilocarpine (Turski et al., 1983) 
Li-pilocarpine (Jope et al., 1986) 
Perforant pathway stimulation (Mazarati et al., 1998) 
Intrahippocampal stimulation (Lothman et al., 1989) 
Amygdala stimulation 
(Mazzuferi et al., 2013; 
Nissinen et al., 2000)  
Trauma 
Lateral fluid percussion 
(D’Ambrosio et al., 2004; 
Kharatishvili et al., 2006a) 
Controlled Cortical Impact 
(Bolkvadze et al., 2009; 
Clausen et al., 2009) 
 Cortical or icv albumin (Seiffert et al., 2004) 
Stroke 
Cortical photothrombosis 
(Karhunen et al., 2007; 
Kelly et al., 2001) 
Cortical endothelin (Karhunen et al., 2006) 
Cortical albumin (Seiffert et al., 2004) 
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Figure 1.2.2. Cellular and molecular alterations occurring during epileptogenesis. Acute brain 
insults, such as SE, TBI or stroke trigger molecular, cellular and functional alterations in the 
hippocampus, a brain area implicated in epileptogenesis in experimental models and in humans. 
These alterations include neurodegeneration, neurogenesis, inflammation and gliosis, blood brain 
barrier (BBB) damage, extracellular matrix reorganization, axonal sprouting and injury, dendritic 
plasticity and alteration in voltage- and ligand-gated ion channels (channelopathy). They may 
determine the generation of seizures and neurological deficits and are modulated by epigenetic 
mechanisms and the genetic background (Pitkänen and Lukasiuk, 2009). 
 
Neurodegeneration. Neuronal cell loss may occur in the brain after an acute epileptogenic 
insult. After SE, the two areas of the hippocampus mostly affected by neuronal cell loss are 
the hilus of the dentate gyrus, where inhibitory interneurons have a key role in controlling 
the excitability of the granule cells, and the CA1 pyramidal cell layer of the cornu ammonis. 
Damage often also involves CA3 pyramidal cells. The amygdala and parahippocampal 
cortices as well as the thalamus may be also affected. Neuroprotection (i.e. rescue of 
neuronal cells) does not prevent epilepsy development (Brandt et al., 2003; Nehlig, 2007) 
but it may be associated with improvement of behavioral dysfunctions (Brandt et al., 2006).  
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Hippocampal neurogenesis. This is a phenomenon observed in both healthy and epileptic 
animals. In healthy animals newly born neurons correctly migrate to the subgranular cell 
layer of the dentate gyrus and they integrate into the functional neuronal circuitry (van 
Praag et al., 2002; Toni et al., 2008). However, in epileptic animals increased neurogenesis 
is detected within a few days from SE onset and some of these cells aberrantly migrate into 
the hilus (i.e., ectopic neurogenesis) which results in enhanced dentate excitability (Parent, 
2007; Parent et al., 1997; Scharfman et al., 2000). This altered neurogenesis is associated 
with several comorbidities such as learning and memory impairment and depression and 
might contribute to epileptogenesis (Cho et al., 2015; Jakubs et al., 2006). 
Reactive gliosis. Gliosis and neuroinflammation are two of the most pronounced 
phenomena induced in the brain by an epileptogenic insult. They are common hallmarks of 
epilepsy foci (Aronica and Crino, 2011; Vezzani et al., 2011a). A more detailed description 
of this phenomenon is given in Section 1.3.  
Blood brain barrier (BBB) alterations. BBB dysfunction is a common finding described after 
epileptogenic insults such as SE, TBI and stroke (Friedman and Heinemann, 2012). When 
BBB permeability is massively altered, serum proteins such as albumin can extravasate into 
the brain parenchyma and activate transforming growth factor (TGFβ) receptors in 
perivascular astrocytes. This activation induces modifications in astrocyte phenotype and 
functions such as (1) reduced expression of potassium inward rectifying channels (Kir4.1) 
and water channels (aquaporin 4, AQP4), (2) reduced gap junctions, (3) reduced glutamine 
synthase and changes in its intracellular distribution, (4) impaired glutamate reuptake and 
(5) increased transcription of inflammatory genes generating mediators with ictogenic 
properties such as IL-1β, tumor necrosis factor (TNF)-α and HMGB1. Recently, astrocytic 
release of extracellular matrix proteins such as thrombospondin has been shown to 
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mediate excitatory synaptogenesis (Weissberg et al., 2015). These functional modifications 
in concert increase neuronal network excitability thus contributing to establish an epileptic 
network (Devinsky et al., 2013; Robel et al., 2015; Vargas-Sánchez et al., 2018). Blocking of 
TGF-β signaling, effectively prevents the development of spontaneous seizures in animal 
models of BBB dysfunction while mimicking BBB dysfunction is sufficient to induce epilepsy 
in animals (Bar-Klein et al., 2016; Weissberg et al., 2015). In addition, BBB damage is 
associated with increased adhesion molecules on endothelial cells which promote the 
interaction of circulating leukocytes (Fabene et al., 2008). Brain-infiltrating monocytes 
were identified as a myeloid-cell subclass that contributes to neuroinflammation and 
morbidity after SE, and preventing monocyte recruitment accelerated weight regain, 
reduced BBB degradation, and attenuated neuronal damage (Varvel et al., 2016).  
Acquired channelopathies. Both voltage-gated and receptor-gated ion channels are 
functionally altered by brain insults such as SE (Bernard et al., 2004; Chen et al., 2001; Su 
et al., 2002). This phenomenon, called acquired channelopathy, has been described in the 
dendritic, somatic, and axonal channels. For example, dendritic HCN channels in 
hippocampal pyramidal cells are dysregulated after prolonged febrile seizures as well as 
pilocarpine-induced SE in rodents (Brennan et al., 2016; Brewster et al., 2002; Jung et al., 
2011). Acquired channelopathies in epileptogenesis are not restricted to HCN but affect a 
number of different ion channel subtypes including A-type potassium and sodium (Navs1.2, 
1.6) channels and voltage-gated pore-forming Ca2+-subunit CaV3.2 (Becker et al., 2008; Su 
et al., 2002). Increase of CaV3.2 mRNA and protein levels as well as up-regulation of the T-
Type current after SE increases intrinsic burst firing in CA1 pyramidal neurons (Becker et 
al., 2008). Notably, neuroinflammation can independently trigger an acquired HCN1 
channelopathy in CA1 pyramidal cell dendrites that alters their integrative properties 
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(Frigerio et al., 2018). Some of the functional changes persist after the brain injury thus 
contributing to lower seizure threshold (Su et al., 2002). 
Mossy fibre sprouting. Axonal and dendritic plasticity in the dentate gyrus include granule 
cell axon sprouting (mossy fibre sprouting) which establishes excitatory connections with 
somata and dendrites of both normal or ectopic granule cells (Buckmaster, 2012). Mossy 
fibre sprouting is often associated with degeneration of excitatory mossy cells and loss of 
inhibitory γ-aminobutyric acid (GABA)-ergic and neuropeptidergic hilar interneurons 
(Buckmaster, 2012). The aberrant mossy fibres might either establish excitatory feedback 
loops with the somata and dendrites of normal and ectopic granule cells in the inner 
molecular layer and hilar region or innervate inhibitory basket cells located in the granule 
cell layer and reduce neuronal excitability (the so-called "dormant basket cells hypothesis"; 
(Buckmaster, 2012; Sloviter et al., 2006). Moreover, several factors released by granule 
cells can promote this aberrant sprouting such as neuromodulin/GAP43 brain derived 
neurotrophic factor (BDNF), extracellular matrix proteins and induction of mTOR pathway 
(Heck et al., 2004; Hester and Danzer, 2014).  
Transcriptomic and epigenetic mechanisms. Various genes are differentially expressed 
during epileptogenesis and microarray analysis of epileptogenic tissue in animal models 
has revealed common molecular pathways, such as alterations in voltage-gated and 
receptor-operated ion channels, neuropeptides, neurotrophins, and immune-related 
molecules (Dingledine et al., 2017; Pitkänen et al., 2015). DNA methylation, histone 
modification and changes microRNA (miRNAs) biosynthesis are some of the epigenetic 
mechanisms described in epileptogenesis (Henshall and Kobow, 2015; Henshall et al., 
2016). For instance, DNA hypomethylation (leading to gene activation) and DNA 
hypermethylation (gene silencing) were described in seizure-generating areas in epilepsy 
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models and in patients with TLE (Henshall and Kobow, 2015). Reduction in seizure-like 
activity in rodent brain slices and attenuation of seizure progression in vivo were induced 
by DNA methylation inhibitors and adenosine-induced DNA hypomethylation (Machnes et 
al., 2013; Williams-Karnesky et al., 2013). Histone acetylation and phosphorylation also 
affect the expression of genes that have a potential role in epileptogenesis through 
mechanisms that involve neuroprotection and reduction of aberrant neurogenesis 
(Henshall and Kobow, 2015).  Several studies identified changes in more than 100 miRNAs 
in rodents and human TLE tissue.  These miRNAs target dendritic spines, neurotransmitter 
receptors, transcriptional regulators and inflammatory signalings (Henshall et al., 2016; Iori 
et al., 2017). Their role in epileptogenesis was identified with the application of either 
small-molecule inhibitors of miRNA (such as antagomir) or with oligonucleotides that mimic 
the action of miRNA in animal models. It has been shown for example that targeting 
miR146a, which controls the activation of the neuroinflammatory IL-1 receptor/Toll-like 
receptor 4 pathway or miR134, which negatively regulates dendritic spine volume both 
resulted in strong inhibition of epileptogenesis (Iori et al., 2017; Reschke et al., 2017). 
miRNAs control broad epileptogenic pathways and their exact role in vivo remains to be 
better identified. 
 
1.3 NEUROINFLAMMATION IN EPILEPSY 
1.3.1 Definition and role in epilepsy  
Inflammation is a defensive response of the host tissue against infections, sterile injuries 
or immune cell activation, for example in the context on autoimmunity. It consists of the 
generation of a cascade of inflammatory mediators, as well as anti-inflammatory molecules 
and lipid mediators that are induced to resolve the inflammatory response. Inflammation 
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is characterized by the production of an array of cytokines, chemokines and related effector 
molecules released from tissue-resident cells and circulating immunocompetent cells, and 
involves the activation of innate and adaptive immunity (Vezzani et al., 2011a). Both arms 
of the immune system have been implicated in epilepsy. In the brain, microglia, astrocytes, 
neurons and endothelial cells of the BBB chiefly contribute to the innate immunity 
response that generates neuroinflammation by producing and releasing pro-inflammatory 
cytokines, chemokines and inducing adhesion molecules on endothelial cells of the BBB 
(Aronica et al., 2012; Vezzani et al., 2011a). In healthy brain tissue, the activation of the 
immune system acts to eliminate the injurious event, and astrocytes and microglia act in 
concert to promote tissue repair (Stoll et al., 2000). However, under pathological 
conditions, the resolution of inflammation is compromised, leading to proliferation of 
microglia and astrocytes with cytotoxic functions (Walker and Sills, 2012). Changes 
occurring during epileptogenesis likely comprise both pathogenic and homeostatic 
functions of glia that depend on the timing of cell activation after the brain insult and the 
concomitant events occurring in the tissue microenvironment.  
Neuroinflammation is a common event in various epileptogenesis models of brain injury 
such as SE, stroke, neurotrauma, and in structural and genetic human epilepsies (Vezzani 
et al., 2011a). Importantly, the inflammatory mediators measured in epilepsy brain 
specimens also act as “neuromodulators” (Vezzani et al., 2011a). In fact, they activate their 
cognate receptors expressed by neurons, thus directly affecting neuronal functions and 
excitability (Vezzani et al., 2011b; Viviani et al., 2007). Specific inflammatory mediators 
significantly contribute to the mechanisms of seizure generation and to 
pharmacoresistence in experimental models and neuroinflammation is perpetuated by 
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neuronal damage and recurrent seizures (Dupuis and Auvin, 2015; Vezzani et al., 2011c; 
van Vliet et al., 2010). 
 
1.3.2 Astrocytes  
Astrocytes provide trophic support to neurons, they contribute to synaptic transmission 
and control BBB function (Lundgaard et al., 2014; Verkhratsky et al., 2013). In the 
hippocampus, two distinct astrocytic cell populations have been described: 1. astrocytes 
expressing glutamate transporter are enriched in glial fibrillary acidic protein (GFAP, a 
cytoskeletal protein), they have irregular cell bodies and branched processes and are 
involved in glutamate reuptake and gap-junction coupling. 2. astrocytes expressing 
functional α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate 
receptors (GluRs) but lacking glutamate reuptake are characterized by relatively low GFAP 
expression and no gap-junction coupling (Matthias et al., 2003). Neuroinflammation 
promotes the phenotypic switch of astrocytes to AMPAR-expressing cells thereby 
promoting extracellular glutamate accumulation and hyperexcitability. Indeed, astrocytes 
form a large intercellular network that regulates extracellular glutamate (Wetherington et 
al., 2008), ion homehostasis through expression of Kir4.1 channels and AQP4 and 
dissipation of metabolites that could be detrimental if they accumulate in the extracellular 
space (Devinsky et al., 2013; Farina et al., 2007; Pekny and Nilsson, 2005). Astrocytes 
modulate synaptic transmission by releasing gliotransmitters such as D-serine, ATP, 
glutamate and GABA that act on their cognate neuronal receptors. Gliotransmission is 
promoted by increased intracellular Ca2+ oscillations in astrocytes in response to neuronal 
stimulation (Devinsky et al., 2013; Farina et al., 2007). For example, glutamate released by 
neurons activates metabotropic glutamate receptor subtypes (mGluR5 and mGluR3) in 
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reactive astrocytes thus modulating the release of gliotransmitters and cytokines (Aronica 
et al., 2005). Together with the pre- and post-synaptic terminals of neurons, astrocytes are 
part of the tripartite synapse indicating a bidirectional communication between neurons 
and astrocytes (Wetherington et al., 2008).  
Astrocytes are key regulators of BBB integrity since their endfeet wrap around the 
endothelial cells and by releasing chemical signals they help to form and maintain tight 
junctions between endothelial cells. Astrocytes also regulate the movement of water and 
molecules between the blood and brain parenchyma (Devinsky et al., 2013). Pro-
inflammatory chemokines and cytokines released by astrocytes activate their cognate 
receptors in brain microvessels thus affecting BBB permeability at multiple levels and 
contributing to its dysfunction in epilepsy (Morin-Brureau et al., 2011).  
Reactive astrogliosis is a typical feature of many CNS disorders, such as neurotrauma, focal 
brain ischemia, CNS infections and epilepsy (Pekny and Pekna, 2014). Upregulation of GFAP 
is most commonly used as a hallmark of reactive astrocytes (Eng et al., 2000). Astrogliosis 
and scar formation have been often regarded as a tissue-harmful response but it became 
apparent that they may exert beneficial functions including wound healing, neuronal cell 
protection, BBB repair and resolution of CNS inflammation (Kang and Hébert, 2011; Pekny 
and Nilsson, 2005; Sofroniew, 2014).  
Reactive astrocytes can be either neurotoxic or neuroprotective depending on their 
phenotype (Anderson et al., 2016; Benner et al., 2013; Faulkner et al., 2004; Fitch and 
Silver, 2008; Rodríguez-Arellano et al., 2016). Zamanian et al. (2012) reported that 
neuroinflammation induced by ischemia and by systemic injection of lipopolysaccharide 
(LPS), an agonist of TLR4 receptors expressed on microglia and other immune cells, induces 
two different types of reactive astrocytes, termed ‘‘A1’’ and ‘‘A2,’’ respectively. In this 
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study, gene transcriptome analysis revealed that many genes involved in synaptic 
degeneration were upregulated in A1 neuroinflammatory reactive astrocytes induced by 
LPS, suggesting that A1 may have ‘’harmful’’ function (Zamanian et al., 2012). On the 
contrary, A2 reactive astrocytes induced by ischemia, upregulated neurotrophic factors, 
which promote neuronal survival and growth and synapse repair suggesting a ‘’repairing’’ 
function of A2 reactive astrocytes (Zamanian et al., 2012). Tarassishin et al. (2011) reported 
that overexpression of transcription factor interferon regulatory factor (IRF)-3 in primary 
human astrocytes induced shifting of cytokine production profile from A1 to A2 phenotype 
and was associated with neuroprotection through suppression of the proinflammatory 
miR-155 (Tarassishin et al., 2011a). 
The mechanism of A1 phenotype induction is thought to be mediated by secretion of IL-
1alpha, TNF-α, and C1q by activated microglia (Liddelow et al., 2017). A1 astrocytes lose 
their ability to promote neuronal survival and axonal outgrowth, to promote synapse 
formation and function, while they secrete neurotoxins that induce neuronal death 
(Liddelow et al., 2017). In fact, A1 astrocytes are abundant in neurodegenerative diseases, 
where their presence contributes to neurodegeneration and help to drive disease 
progression. Under specific circumstances, astrogliosis has the potential to lead to harmful 
effects, such as contributing to persistent neuroinflammation or to excitotoxicity (Silver 
and Miller, 2004; Sofroniew, 2014, 2015; Sofroniew and Vinters, 2010). In contrast, the 
activation of A2 astrocytes is suggested to be mediated by the JAK-STAT3 pathway which is 
implicated in scar-forming astrocyte reactivity after acute injury (Anderson et al., 2016; 
Ceyzériat et al., 2016; Herrmann et al., 2008). This pathway regulates multiple cell 
functions, including cell proliferation, differentiation and growth, and some anti-
inflammatory functions (Ceyzériat et al., 2016). 
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Figure 1.3.1. Heterogeneity of reactive astrocytes.  Following tissue injury, astrocytes become 
reactive assuming either an A1 neurotoxic phenotype or an A2 neuroprotective phenotype. 
Neuroinflammatory stimuli such as LPS activate microglia that secretes the inflammatory cytokines 
IL-1a and IL-1β, TNF-α, and C1q which yield A1 reactive astrocytes that promote neurodegeneration 
and neurotoxicity, and are not synaptogenic. In vitro application of TGF-b1 reverts this neurotoxic 
A1 type to a non-reactive state. Ischemia induces the formation of A2 reactive astrocytes that 
secrete neurotrophic factors (Baldwin and Eroglu, 2017). 
 
In several human CNS diseases, including epilepsy, astrocytes can initiate, regulate, and 
amplify immune-mediated mechanisms that are involved in these pathologies (Farina et 
al., 2007; Seifert et al., 2010). Both in experimental and in human epilepsy brain tissue, 
astrocytes produce a wide range of immunologically relevant cytokines and chemokines 
such as HMGB1, IL-1β, IL-6, TNF-α, TGF-β and monocyte chemoattractant protein-1 (MCP-
1; chemokine, C-C motif, ligand 2; CCL2) (Aronica and Crino, 2011; Vezzani et al., 2008). 
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1.3.3 Microglia 
Microglia are the CNS-resident immune cell population (Kreutzberg, 1996). In the adult 
healthy brain, microglia have a ramified morphology with a small soma and fine cellular 
processes that are highly mobile in order to patrol the microenvironment (Garden and 
Möller, 2006; Kettenmann et al., 2011). Several molecules and conditions can induce the 
transition of microglia from a resting-like to an activated or reactive state (Hanisch and 
Kettenmann, 2007). Microglial responsiveness can be influenced by factors such as 
microbial molecules, genomic material, cytokines, ATP and protein aggregates (Block et al., 
2007; Hanisch and Kettenmann, 2007; Nakamura, 2002; van Rossum and Hanisch, 2004). 
Microglia can sense even minor changes in the microenvironment that provoke their rapid 
morphological changes. Activated microglia assume an amoeboid appearance by retracting 
their processes (Hanisch and Kettenmann, 2007; Kettenmann et al., 2011) although 
different reactive phenotypes are described depending on the type and modality of applied 
stimuli and the microenvironment (Figure 1.3.2). 
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Figure 1.3.2. Microglial activity states. Microglia at a resting-surveillance state is in a lookout for 
changes in the microenvironment that can disturb the homeostasis of the neuronal and glial-
vascular networks. Appearance of activating signals or loss of inhibitory signals can trigger 
transitions to alerted and activated state endowed of distinct reactive phenotypes depending on the 
nature of the stimuli. These phenotypes can be further influenced neurons and astrocytes as well as 
invading immune cells from the periphery. Microglia may be ‘’primed’’ suggesting that 
preconditioning with a first stimulus prepares the cell for an enhanced and efficient response to a 
second stimulus (Kettenmann et al., 2011). 
   
Microglial cells express a variety of receptors on their cell membrane. Purinergic receptors 
of both ionotropic and metabotropic receptor subtypes mediate the effect of ATP released 
from damaged cells after brain injuries (Garden and Möller, 2006; Kettenmann et al., 2011). 
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Activation of these receptors in microglia mediates the release of superoxide that induces 
neurotoxicity, cytokine release and autophagy (Brough et al., 2002; Inoue, 2006; 
Parvathenani et al., 2003; Takenouchi et al., 2009). Purinergic signaling is known to be 
activated in epilepsy. The P2X7 receptors are sensitive to low concentrations of ATP and an 
increase in their expression in microglial cells is found in rodent epilepsy models (Avignone 
et al., 2008; Rappold et al., 2006). Moreover, these receptors are involved in 
neurodegeneration and neuroinflammation after SE and in seizure recurrence in epileptic 
mice (Engel et al., 2012; Henshall and Engel, 2015; Jimenez-Pacheco et al., 2013; 
Takenouchi et al., 2009). P2X4, P2Y6 and P2Y12 receptor expression is also upregulated in 
microglial cells in rodent hippocampus during seizures (Avignone et al., 2008; Ulmann et 
al., 2013). Interestingly, microglial P2Y12 receptors were shown to have an anti-
epileptogenic effect when upregulated following SE (Eyo et al., 2016).  
Microglia express neurotransmitter receptors for glutamate, GABA, monoamines and CB1 
and CB2 cannabinoid receptors (Kettenmann et al., 2011). Activation of mGluR2-3 
receptors has been associated with microglial activation and neurotoxicity mediated by 
TNF-α release (Taylor et al., 2005). On the other hand, activation of cannabinoid receptors 
has been shown to increase microglia proliferation and may reduce microglia-mediated 
neurotoxicity (Carrier et al., 2004; Stella, 2009).  
Receptors for cytokines (IL-1β), chemokines, danger signals and trophic factors are 
expressed by microglia and play a role in communication between microglia and the 
surrounding cells as well as in the initiation and regulation of the immune response (Garden 
and Möller, 2006). Fractalkine (CX3CL1) is one of the molecules mediating the 
communication between neurons and microglia (Paolicelli et al., 2014; Wolf et al., 2013). 
CX3CL1 is a chemokine expressed principally by neurons and binds to the CX3CR1 receptor, 
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which is uniquely expressed in the brain by microglia (Ransohoff and Perry, 2009). Neuronal 
CX3CL1 acts as an inhibitory signal reducing the activation of CX3CR1-expressing microglia 
and genetic deletion of CX3CR1 enhanced microglia-mediated neurotoxicity (Cardona et 
al., 2006; Kettenmann et al., 2011). However, blocking this pathway by administering the 
anti-CX3CR1 antibody reduced microglial activation induced by SE, neurodegeneration and 
neuroblast formation in the adult rat hippocampus suggesting a more complex role of this 
chemokine in microglial activation (Ali et al., 2015).  
Toll-like receptors are widely expressed in microglia and directly control their activation 
(Garden and Möller, 2006; Kettenmann et al., 2011). Activation of TLR4 by LPS exacerbated 
pilocarpine-induced neurogenesis whereas TLR9 activation following kainic acid seizures 
reduced aberrant neurogenesis (Matsuda et al., 2015; Yang et al., 2010). Moreover, 
activation of TLR3 in microglia by its agonist polyinisinic:polycytidylic acid (Poly I:C) or TLR4 
by LPS mediates proinflammatory effects in vitro (Olson and Miller, 2004) and TLR4 
deficiency or pharmacological blockade reduced spontaneous recurrent seizures in 
epileptic mice (Maroso et al., 2010a).  
Microglia rapidly respond to seizures and release proinflammatory cytokines, that lead to 
neuronal hyperexcitability and neurodegeneration contributing to the development of 
spontaneous seizures and cognitive decline in epilepsy models (Brewster et al., 2013; Heo 
et al., 2006; Kwon et al., 2013; Nishimura et al., 2006; van Vliet et al., 2016; Yilmaz et al., 
2006; Zeng et al., 2009). However, there is a morphologically heterologous population of 
microglia in the hippocampus that can potentially promote neuroprotection (Wyatt-
Johnson et al., 2017).  
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1.3.4 Blood-brain barrier 
 
The BBB comprises a monolayer of brain capillary with endothelial cells distinguished by 
the presence of tight junctions that form an impermeable wall to xenobiotics and other 
circulating molecules and cells in physiological conditions. Endothelial cells are 
interconnected with basement membrane, pericytes, astrocytes, microglia (Correale and 
Villa, 2009; Pardridge, 1999; Persidsky et al., 2006). The BBB is both a physical and 
metabolic barrier that regulates the blood-to-brain exchange of nutrients, xenobiotics, 
blood components, and cellular elements by passive diffusion or catalyzed transport of 
large and/or polar molecules (Pardridge, 1999). BBB maintains brain tissue homeostasis 
necessary for physiologic neuronal function. BBB dysfunction has been proposed as a 
causal pathogenic factor in many CNS pathologies including epilepsy (Dallasta et al., 1999; 
Marchi et al., 2011a; Neuwelt et al., 2011; Ryu and McLarnon, 2009; Tomkins et al., 2011; 
van Vliet et al., 2007; Weis et al., 1996). Experimental and clinical studies suggest that BBB 
dysfunction leads to increased propensity for seizure generation in epilepsy (Aronica et al., 
2008; Friedman et al., 2009; Frigerio et al., 2012; Marchi et al., 2007; Marcon et al., 2009; 
Raabe et al., 2012; Seiffert et al., 2004; Shlosberg et al., 2010; Tomkins et al., 2001; van 
Vliet et al., 2007). BBB dysfunction is a common feature among patients with 
pharmacoresistant epilepsy (Michalak et al., 2013; Rigau et al., 2007).  
Mechanisms responsible for BBB dysfunction include inflammation (Fabene et al., 2008; 
Librizzi et al., 2012; Vezzani and Friedman, 2011), endothelial apoptosis and dysfunctional 
perivascular glia, loss of tight junction (TJ) proteins (Abbott et al., 2010; Neuwelt et al., 
2011) and altered expression of multidrug transporters such as the ABC efflux transporters 
that influence the uptake of a variety of xenobiotics, including many ASDs (Abbott et al., 
2006; Eugenin et al., 2011; Golden and Pollack, 2003; Wolburg et al., 2003). Loss or 
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dissociation of proteins responsible for the organization of the TJ such as Zonula occludens-
1 (ZO-1), or enhanced transcytosis is associated with increased barrier permeability (Abbott 
et al., 2010; Bednarczyk and Lukasiuk, 2011). The brain extravasation of serum proteins and 
in particular of albumin, is one of the consequences of BBB dysfunction following SE. 
Albumin extravasated in the brain parenchyma can be uptaken by neurons and glia (van 
Vliet et al., 2015). The presence of albumin in the human epilepsy tissue and in 
experimental models may contribute to lower seizure threshold through different 
mechanisms (Cacheaux et al., 2009; Ravizza et al., 2008a; Rigau et al., 2007; van Vliet et al., 
2007). In particular, albumin activates transforming growth factor β receptors (TGFβRs) 
signaling in astrocytes which leads to down regulation of inward rectifying potassium (Kir 
4.1) channels and the water channel aquaporin-4 (AQP4) that in turn accounts for the 
reduced extracellular buffering of potassium and water thus promoting hyperexcitability 
and epileptiform activity (Ivens et al., 2007). Furthermore, albumin induces transcriptional 
activation of inflammatory genes via TGFβ signaling (Cacheaux et al., 2009; Ralay Ranaivo 
and Wainwright, 2010; Ralay Ranaivo et al., 2010) and induces formation of new excitatory 
synapses by inducing the astrocytic release of trombospondin and other extracellular 
matrix components (Weissberg et al., 2015). Since albumin binds some ASDs, its presence 
in brain parenchyma may reduce free ASDs concentrations thereby reducing their 
effectiveness (Kwan et al., 2011; Neels et al., 2004).  
Autoantibodies against neuronal receptors and channels can be transported into the brain 
tissue through a leaky BBB thus providing another mechanism for alterating neuronal 
function (Bien and Scheffer, 2011; Rigau et al., 2007; van Vliet et al., 2007) (Figure 1.3.3). 
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Figure 1.3.3. Schematic representation of processes involved in blood–brain barrier dysfunction. 
Leukocytes enter the brain via a dysfunctional BBB or via upregulated adhesion molecule, such as 
ICAM-1 and VCAM-1, thus contributing to brain inflammatory responses. Increased extracellular K+ 
and glutamate due to inflammatory activated astrocytes may also modify neuronal excitability and 
physiological functions. These changes ultimately may lead to epilepsy (van Vliet et al., 2015). 
 
1.3.5 Neuroinflammatory ictogenic pathways 
 
The IL-1 receptor/toll-like receptor superfamily (IL-1R/TLR) has been shown to be involved 
in the generation of neuroinflammation in epilepsy and in seizure mechanisms (Aronica 
and Crino, 2011; Maroso et al., 2011a; Vezzani et al., 2008, 2010, 2011b). The IL-1R/TLR 
superfamily is part of the cell surface pattern recognition receptors (PRRs) sharing a 
conserved intracellular region termed the Toll/IL-1R (TIR) domain (O’Neill, 2008; O’Neill 
and Dinarello, 2000). TLRs are expressed in immunocompetent cells and several TLRs such 
as TLR2, TLR3, and TLR4 have been measured in glia, neuronal cells and endothelium in the 
CNS (Farina et al., 2007). In resting astrocytes, IL-1R1 or TLRs are expressed at low levels 
but they are upregulated in reactive astrocytes and microglia under different pathological 
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CNS conditions, including epilepsy (Maroso et al., 2010, 2011a; Ravizza et al., 2006a, 2008a; 
Vezzani et al., 2011b; Zurolo et al., 2011). TLRs have a key role in pathogen recognition 
(Kawai and Akira, 2007) but in the absence of pathogens, TLRs can be activated by 
endogenous molecules, named damage-associated molecular patterns (DAMPs), released 
from injured or activated cells (sterile inflammation). One of these molecules is the high 
mobility group box 1 (HMGB1) (Bianchi and Manfredi, 2009), a ubiquitous chromatin 
binding protein that is actively secreted by immuno-competent cells in response to immune 
challenges (Muller et al., 2004). Both in vitro and in vivo findings showed that astrocytes 
are a source of extracellular HMGB1 (Maroso et al., 2010a; Zurolo et al., 2011). HMGB1 
release has been shown to be induced in both rat (Hayakawa et al., 2010) and human 
astrocytes in culture (Zurolo et al., 2011) in response to the proinflammatory cytokine IL-
1β, and nuclear to cytoplasmic translocation, a step required for extracellular release, has 
been observed in human and experimental epilepsy tissue (Maroso et al., 2010a).  
Activation of IL-1R1-mediated signaling by IL-1β induces, via an NF-kB-dependent 
mechanism, the transcription of other genes encoding downstream mediators of 
inflammation, including IL-6, TNF-α, cyclooxygenase-2 (COX-2), (Andjelkovic et al., 2000; 
Dinarello, 2004). IL-1β, by acting on IL-1R type 1, can inhibit the astrocytic reuptake of 
glutamate (Hu et al., 2000; Ye and Sontheimer, 1996) and increases its glial release likely 
via induction of TNF-α (Bezzi et al., 2001). TNF-α is a cytokine released from activated 
astrocytes and microglia, and tightly associated with IL-1β, since the two molecules 
reciprocally induce their respective release from glia and mutually activate their gene 
transcription. TNF-α has been shown to increase the mean frequency of AMPA-dependent 
miniature excitatory postsynaptic currents in hippocampal neurons and to decrease 
GABAA-mediated inhibitory synaptic strength. These effects are mediated by the 
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recruitment of AMPA receptors lacking the GluR2 subunit at neuronal membranes (thus in 
a molecular conformation which favors Ca2+ influx into neurons) and by endocytosis of 
GABAA receptors respectively (Beattie et al., 2002; Stellwagen et al., 2005). IL-1β can also 
increase neuronal glutamate release via the activation of inducible nitric oxide synthase in 
glial cells (Casamenti et al., 1999; Hewett et al., 1994). Activation of NF-kB signaling 
pathway and induction of a large array of inflammatory mediators in astrocytes in 
experimental and human TLE suggest that these cells are pivotal for generating and 
sustaining neuroinflammation (Desjardins et al., 2003; Holtman et al., 2009; Ravizza et al., 
2008a; Wu et al., 2008). 
TLR4, one of the first Toll-like receptors identified in mammals, has a particular role in 
epilepsy. It shares its cytosolic domain with IL-1R1 and detects the major component of the 
gram-negative bacteria lipopolysaccharide LPS. TLR4 signals through both MyD88-
dependent and TRIF-dependent pathways in order to induce pro-inflammatory genes 
through NF-κB and/or MAPK pathways or type I interferons through TRIF/IRF3 axis (Liu and 
Ji, 2014; O’Neill and Bowie, 2007; Yamamoto et al., 2003). This receptor is rapidly up-
regulated in neurons and astrocytes both after seizure onset and during the chronic 
epileptic phase insults in rodent epileptogenic brain areas (Maroso et al., 2010). 
Interestingly, knock-out mice lacking this receptor exhibit low seizure susceptibility 
(Maroso et al., 2010). Its activation by LPS or HMGB1 results in a decreased seizure 
threshold and is linked to increased hippocampal excitability (Galic et al., 2008; Li et al., 
2015a; Rodgers et al., 2009; Sayyah et al., 2003). Moreover, IL-1R1/TLR4 activation leads 
to a rapid increase in Ca2+ influx through phoshorylation of the NR2B subunit of NMDA 
receptors (Balosso et al., 2008, 2014; Viviani et al., 2003). Activation of the IL-1β and IL-1R1 
axis and HMGB1-TLR4 axis in brain tissue from TLE patients is associated with BBB leakage 
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and albumin extravasation (Aronica et al., 2007; Maroso et al., 2010a; Ravizza et al., 2008b; 
Rigau et al., 2007; van Vliet et al., 2007). Activating transcriptional factor 3 (ATF-3), a 
negative regulator of TLR4, has lower expression in patients with frequent seizures whereas 
TLR4 expression positively correlates with seizure frequency (Pernhorst et al., 2013). 
Among the epigenetic modulators studied in animal models of epilepsy and in human brain 
tissue (Dębski et al., 2016; Sweatt, 2013), miRNA146a is of particular relevance for 
neuroinflammation since it is tightly linked to the feedback inhibition of IL-1R1/TLR4 
signaling (Iyer et al., 2012; van Scheppingen et al., 2016) and is up-regulated in astrocytes 
and neurons in TLE and focal cortical dysplasia (FCD) and ganglioglioma patients (Aronica 
et al., 2010; Omran et al., 2012; Quinn and O’Neill, 2011; van Scheppingen et al., 2016). 
miRNA profiling studies revealed brain region and temporal specific changes in miRNA146a 
expression in various animal models of epilepsy (Gorter et al., 2014; Roncon et al., 2015). 
This miRNA downregulates the levels of IL-1R/TLR downstream signaling molecules thus 
reducing the activation of this pathway (Taganov et al., 2006). Recently, Iori et al.(2017), 
using a synthetic mimic of miRNA146a injected in an animal model of acquired epilepsy, 
reported a dramatic reduction in neuronal excitability and chronic seizure recurrence and 
this treatment prevented disease progression (Iori et al., 2017).  
TLR3 has been also implicated in epilepsy. Its stimulation activates NF-kB and the 
transcription factor interferon regulatory factor (IRF)-3, thereby inducing the production of 
type I interferon (IFN)-responsive genes (Kawai and Akira, 2010). Differently from TLR4, 
TLR3 is primarily expressed intracellularly where it acts as a sensor for double-stranded 
RNA, a product of viral replication.The activation of TLR3 by the synthetic double-stranded 
RNA polyinosinic-polycytidylic acid (Poly I:C) mimics the effects of viral infection and leads 
to the production of type I IFNs, IFNα and IFNβ via activation of IRF-3 and IRF-7 
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(Cunningham et al., 2007). Experimental evidence indicates that the activation of TLR3 by 
Poly I:C induces the transcription and biosynthesis of cytokines and chemokines (Kirschman 
et al., 2011; Michalovicz and Konat, 2014). The pro-inflammatory action of Poly I:C in 
immature rats, is associated with long-lasting hippocampal hyperexcitability and enhanced 
seizure susceptibility as assessed in adult animals (Galic et al., 2009). Activation of TLR3 
may also alter glutamatergic transmission, contributes to epileptogenesis and to the 
impairment of working and contextual memory in rodents (Costello and Lynch, 2013; Gross 
et al., 2017; Galic et al., 2009; Okun et al., 2010). However, neuroprotective effects have 
been also reported specifically mediated by TLR3 activation in astrocytes therefore 
suggesting that this receptor may have a dual role possibly mediated by different cell types 
(Bsibsi et al., 2006; Tarassishin et al., 2011b).  
 
 
1.3.6 Clinical evidence of brain inflammation in human epilepsy 
 
Brain tissue analysis from patients with different forms of epilepsy such as TLE, 
Rasmussen’s encephalitis, FCD and tuberous sclerosis complex (TSC), has revealed 
inflammatory markers and the presence of activated innate and adaptive immune cells 
(Boer et al., 2006; Iyer et al., 2010; Maroso et al., 2010; Ravizza and Vezzani, 2006; Ravizza 
et al., 2006a, 2008a; Vezzani et al., 2011b).  
In hippocampal tissue from TLE patients, glial cells display an inflammatory phenotype with 
overexpression for example of NF-kB, activation of IL-1/TLR4 axis and of the complement 
system and cytoplasnatic translocation of HMGB1 (Aronica et al., 2007; Crespel et al., 2002; 
Ravizza et al., 2008a; van Vliet et al., 2007). Despite a common astroglia and microglia 
activation in human epilepsy specimens, peripheral immune system contribution depends 
on the epilepsy type. For example, leukocytes are not prominent in TLE specimens except 
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for the presence of macrophages (Ravizza et al., 2008a). Differently, in patients affected by 
Rasmussen encephalitis there is an increased expression of inflammatory genes (IL-1β, TNF-
α) and the presence of cytotoxic lymphocytes (Baranzini et al., 2002). Interestingly, a 
marked increase in the expression of TLR3 and TLR9, in the brain tissues of Rasmussen’s 
encephalitis patients was associated with severe brain atrophy suggesting a key role of TLR-
related pathway in this rare pediatric disorder (Wang et al., 2017). 
Epilepsy is the most common neurologic symptom in patients (70-80%) affected by TSC. 
TSC is an autosomal dominant and multisystem disorder that results from a mutation in 
Tsc1 and Tsc2 genes that encode for two proteins that act as a negative regulator for the 
mTOR pathway. This pathway is involved in cell metabolism, growth, proliferation and 
death as well as synaptic plasticity, neurogenesis, dendritic morphology and axonal 
sprouting (Ostendorf and Wong, 2015). Cortical tubers, subependymal nodules and giant 
cell tumors are characteristics of this disorder (DiMario, 2004; Mizuguchi and Takashima, 
2001) along with the presence of macrophages, TNF-α and NF-kB expression alterations 
and activation of the complement system and IL-1β pathway (Boer et al., 2008; Maldonado 
et al., 2003).  Lymphocytes with a T-cytotoxic phenotype and evidence of BBB dysfunction 
were also observed in the perivascular zone and adjacent brain parenchyma (Boer et al., 
2008; Wong, 2008).  
FCD represents cytoarchitectural malformations of the cerebral cortex which are among 
the causes of refractory epilepsy in young individuals (Blumcke, 2009). Specimens from 
type II FCDs were shown to express the complement system and activation of the IL-1β and 
TLR pathways, induction of the chemokine CCL2, microglial and astroglial cell reactivity, 
BBB breakdown, and the presence of cytotoxic T-lymphocytes (Iyer et al., 2010; Zurolo et 
al., 2011). 
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Pro-inflammatory mediators were measured in biological fluids such as CSF and plasma 
from patients with epilepsy of various etiologies (Gallentine et al., 2017; Lehtimaki et al., 
2004). In children with febrile SE, the IL-6 cytokine was found elevated in plasma (Gallentine 
et al., 2017). Moreover, in the same study IL-1RA/IL-6 ratio as a potential biomarker of 
acute hippocampal injury following febrile status epilepticus (FSE) was identified 
representing a potential serologic biomarker which offers rapid identification of patients at 
risk for ultimately developing mesial temporal lobe epilepsy. 
Immunomodulatory drugs provide further evidence that inflammation has an important 
role in epilepsy. Glucocorticoids such as dexamethasone, and adrenocorticotropic 
hormone (ACTH) can reduce seizure burden in some forms of drug-resistant epilepsies 
(Marchi et al., 2011b; Vezzani and Granata, 2005). Anti-inflammatory drugs that act on the 
IL-1β pathway such as VX765 (an ICE/Caspase-1 inhibitor) and Anakinra (IL-1R1 antagonist) 
have shown therapeutic effects in experimental models and reduced seizures in patients 
(Bialer et al., 2013; DeSena et al., 2018; Jyonouchi, 2016; Kenney-Jung et al., 2016). The 
efficacy of VX765 has been tested in a phase II clinical trial where it has shown a positive 
effect in patients with treatment-resistant partial epilepsy (Bialer et al., 2013). Anakinra 
induced a reduction on seizure activity and improved cognitive skills in patients with febrile 
infection-related epilepsy syndrome (FIRES) (Jyonouchi, 2016; Kenney-Jung et al., 2016). 
Adalimumab (a monoclonal anti-TNF-α antibody) was evaluated in a pilot clinical study in 
patients with Rasmussen’s encephalitis and showed seizure improvement along with 
functional deficit stabilization in half of the patients recruited (Lagarde et al., 2016). In an 
open-label trial, patients with severe drug-resistant epilepsy were treated with cannabidiol 
and motor seizure frequency reduction was reported (Devinsky et al., 2016). In another 
study, 6 out of 7 patients with FIRES demonstrated improved seizure frequency and 
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duration after cannabidiol treatment; an anti-inflammatory effect of this drug may in part 
mediate its therapeutic effects since cannabinoid receptors are found also in cells of the 
immune system.  Furthermore, minocycline, a tetracycline family antibiotic with known 
inhibitory effects on microglia activation and proinflammatory cytokine release, has been 
shown to reduce significantly seizure frequency in a patient with severe symptomatic 
epilepsy (Nowak et al., 2012). In a patient with multiple sclerosis (MS) that manifested 
tonic-clonic generalized seizures at disease onset, natalizumab (an anti-alpha4 integrin 
antibody) improved MS condition and reduced seizures (Sotgiu et al., 2010).   
 
 
1.3.7 Effect of anti-inflammatory treatments in experimental models of 
ictogenesis and epileptogenesis 
 
Experimental and clinical evidence suggest the involvement of several inflammatory 
mediators in the generation of seizures and their recurrence. Interestingly, some ASDs, 
such as valproic acid (VPA) and phenytoin (PHT) have anti-inflammatory properties. VPA 
inhibits activation of NF-kB and production of TNF-α and IL-6 whereas PHT decreases T- cell 
activity (Hashiba et al., 2011; Ichiyama et al., 2000). 
Some key inflammatory pathways activated in epilepsy along with the effect of anti-
inflammatory treatments in experimental studies are discussed below (see also Tables 
1.3.1 and 1.3.2).  
Interleukin-1 receptor/Toll-like receptor (IL-1R/TLR) signaling 
Studies in experimental models have proven that the IL-1R1/TLR4 axis is rapidly activated 
in brain areas involved in seizure generation and propagation during epileptogenesis 
(Pauletti et al., 2017; Ravizza et al., 2008a).  Activation of this signaling by brain application 
of endogenous agonists is ictogenic (Balosso et al., 2013; Maroso et al., 2011a; Vezzani et 
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al., 2011b). Pharmacological blockade and genetic interference with this signaling showed 
its contribution to seizure mechanisms. Inhibitors of this signaling such a IL-1Ra, caspase-1 
inhibitors, TLR4 antagonists, anti-HMGB1 monoclonal antibodies and specific microRNAs 
(e.g., miR-146a) mediate anti-seizure effects often associated with reduction of the BBB 
dysfunction and neuroprotection (Balosso et al., 2014; Fu et al., 2017; Maroso et al., 2010, 
2011b; Ravizza et al., 2006b; Vezzani et al., 2000; Wang et al., 2018; Zhao et al., 2017). 
Moreover, this signaling is activated in clinical specimens from patients with 
pharmacoresistant epilepsies such as low-grade epilepsy-associated glioneuronal tumors 
(GNT), FCD, TLE and RE (Fuso et al., 2016; Luan et al., 2016; Maroso et al., 2010; Pernhorst 
et al., 2013; Prabowo et al., 2013; Ravizza et al., 2006a, 2008a; Roseti et al., 2015; Zhang et 
al., 2018; Zurolo et al., 2011). 
Simultaneous targeting of IL-1R1 and TLR4 signaling after SE induction in mice or at disease 
onset, mediated significant reduction in chronic seizure recurrence and prevented disease 
progression after treatment withdrawal (Iori et al., 2017; Walker, 2017).  In a similar way, 
inhibition of HMGB1 by a monoclonal antibody reduced seizure frequency and improved 
cognitive deficits (Zhao et al., 2017).  In an experimental model of TBI, treatment with IL-
1Ra resulted in a rise in seizure threshold to pentylenetetrazol (PTZ)  accompanied by 
improvement in spatial memory (Semple et al., 2017). Further support for the involvement 
of this pathway in epilepsy comes from studies in transgenic mice with defective IL-1R1-
TLR4 signaling that show reduction in acute seizure susceptibility and in spontaneous 
seizures evoked by SE (Iori et al., 2013; Maroso et al., 2010; Ravizza et al., 2006b; Vezzani 
et al., 2000).  
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Tumor necrosis factor-alpha (TNF-α) 
TNF-α is a cytokine with a dual role in seizures. During seizures TNF-α is expressed by glia 
and endothelial cells in rodents (De Simoni et al., 2000; Dhote et al., 2007; Lehtimaki et al., 
2003; Turrin and Rivest, 2004). TNF-α receptor type 2 (TNFR2) levels are reduced in neurons 
and TNFR1 is increased in neurons and astrocytes (Balosso et al., 2013; Weinberg et al., 
2013). TNF-α and its receptors undergo similar changes in TLE and in TSC patients (Balosso 
et al., 2013; Maldonado et al., 2003). 
Activation of TNFR2 in the mouse hippocampus after injection of recombinant TNF-α 
resulted in reduction of seizures whereas activation of TNFR1 promoted seizure generation 
(Balosso et al., 2005). The same finding was observed also in two models of amygdala 
stimulation (Weinberg et al., 2013). Transgenic mice with low or moderate overexpression 
of TNF-α were less susceptible to develop seizures while mice with high TNF-α expression 
are more prone to developing seizures (Akassoglou et al., 1997; Balosso et al., 2005). These 
data support the concept that this cytokine exerts its actions depending on its 
concentration and the receptor subtype activated.  
Arachidonic acid-related pathways 
Cyclooxygenase-2 (COX-2), the enzyme responsible for the biosynthesis of prostanoids is 
expressed in physiological conditions in neurons (Hurley et al., 2002; Yamagata et al., 1993). 
COX-2 is upregulated in neurons early after SE and in astrocytes at later time points and 
during chronic seizures (Holtman et al., 2009; Kulkarni and Dhir, 2009; Lee et al., 2007). In 
TLE patients, COX-2 is expressed in neurons and it is found in astrocytes only in patients 
with HS (Desjardins et al., 2003).  
Increased neuronal expression of COX-2 in transgenic mice induced higher seizure 
susceptibility whereas COX-2 deficient mice or in mice treated with the COX-2 inhibitor 
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nimesulide showed reduced seizure susceptibility suggesting thus a proconvulsive role of 
this enzyme (Kelley et al., 1999; Takemiya et al., 2003). However, studies employing 
selective COX-2 inhibitors such as celecoxib, parecoxib, indomethacin and SC58236 have 
highlighted a dual role of this enzyme in epileptogenesis (Aronica et al., 2017; Kulkarni and 
Dhir, 2009). In particular, COX-2 inhibition before SE induction with pilocarpine or kainate 
(KA) had procolvusive effect whereas inhibition after SE and during epileptogenesis 
resulted either in neuroprotection and reduction of spontaneous seizure severity or no 
effects, or even seizure exacerbation (Holtman et al., 2009; Jung et al., 2006; Kunz and Oliw, 
2001a). These differential effects suggest that the timing of COX-2 blockade may determine 
the suppressive or aggravating outcome on seizures.  
These dichotomous results in SE models prompted to target downstream effector 
molecules of the COX-2 signaling pathway such as the prostanglandin EP1 and EP2 
receptors (Jiang et al., 2015; Kawada et al., 2012). The EP1 receptor antagonist SC-51089 
had only a moderate effect on seizure severity but antagonizing the EP2 receptors led to 
reduction of neuronal injury, inflammation, BBB opening and induced neuroprotection 
(Fischborn et al., 2010; Jiang et al., 2012, 2013). A combined treatment with the COX-2 
inhibitor CAY10404 and anakinra resulted in reduction of spontaneous seizure 
development after SE and limited the extend of CA1 injury and mossy fiber sprouting (Kwon 
et al., 2013).  
Recently, Terrone et al. (2018) showed that Monoacyl-Glycerol-Lipase (MAGL), the enzyme 
responsible for the brain synthesis of arachidonic acid, is a potential target for the 
treatment of drug-resistant SE. They reported that administration of a MAGL inhibitor 
(CPD-4645) early during SE reduced significantly severity and duration of SE as well as 
neuronal loss and cognitive deficit in mice (Terrone et al., 2018).    
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Until now no clinical trials using specific COX-2 inhibitors have been conducted in epilepsy 
patients due to the side effects of such drugs (Radu et al., 2017). Despite that, non-selective 
COX inhibitors were studied in epilepsy patients (Ma et al., 2012; Xu et al., 2013). Ibuprofen 
treatment in children with febrile seizures failed to show significant effects (van 
Stuijvenberg et al., 1998). On the other hand, patients with Sturge-Weber syndrome or 
focal onset epilepsy showed reduction in seizure frequency although such results should 
be further validated (Bay et al., 2011; Godfred et al., 2013; Lance et al., 2013; Udani et al., 
2007).  
Transforming growth factor-beta (TGF-β) signaling 
Extravasation of serum albumin into the brain parenchyma after BBB breakdown activates 
transforming growth factor β (TGF-β) signaling in astrocytes that results in neuronal 
hyperexcitability and decreased seizure threshold through many mechanisms as discussed 
before (see sections 1.2.2 and 1.3.4). Transient treatment with losartan, an angiotensin II 
type 1 receptor antagonist which blocks TGF-β signaling, reduced neuronal loss, BBB 
dysfunction, neuroinflammation and incidence as well as severity of epilepsy in animal 
models of vascular injury and SE (Bar-Klein et al., 2014; Tchekalarova et al., 2014). 
Moreover, losartan delayed seizure onset, showed neuroptotection and alleviated seizure 
frequency and duration after discontinuation of the treatment in SE-exposed rats 
(Tchekalarova et al., 2016).  In a TBI mouse model, other two angiotensin II type 1 receptor 
antagonists, candesartan and telmisartan were tested and were shown to reduce glia 
activation, enchancement of cognitive and motor function along with reduction of lesion 
volume (Villapol et al., 2015).  
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Complement system 
The complement system consists of more than 30 proteins that interact in order to protect 
the organism against invading pathogens and from deposition of immune complexes in 
healthy tissue (Xiong et al., 2003). Both neurons and glia express complement proteins in 
normal conditions but in animal models of epilepsy and TLE patients several of these 
protein were overexpressed (Aronica et al., 2007; Becker et al., 2003; Gorter et al., 2006; 
Jamali et al., 2006; Yu et al., 2002). A number of animal studies has identified a role of the 
complement system in epilepsy. Mice deficient for C3 demonstrated a lower number of 
behavioral seizures after Theiler’s virus infection compared to wild-type mice and rats 
deficient for C6 had a delayed kindling development (Holtman et al., 2011; Libbey et al., 
2010). Intrahippocampal infusion in rats of C5b6, C7, C8 and C9 (complement proteins that 
form the membrane attack complex) induced seizures and neuronal cell loss (Xiong et al., 
2003). PMX53, a C5ar1 antagonist with short half-life, had anticonvulsant effects in both 
acute and chronic seizure models (Benson et al., 2015). The same antagonist or C5ar1 
genetic deletion resulted in reduced seizures and SE associated mortality along with 
neuroprotection in the hippocampus (Benson et al., 2015).  
Chemokines 
Apart from their classic role of chemotactic molecules, they can modulate voltage-gated 
ion channels and neurotransmitter release. Various chemokines and their receptors were 
found to be upregulated in human and experimental epilepsy brain tissue (Cerri et al., 2016; 
Fabene et al., 2010; Guyon and Nahon, 2007; Roseti et al., 2013; Rostène et al., 2007). In 
particular, CCL2 and its receptor CCR2 (CC receptor subtype 2), are upregulated in both 
human and experimental epilepsy and a CCL2 polymorphism causing elevated levels of 
CCL2 is associated with higher susceptibility to drug-resistant epilepsy (Cerri et al., 2016; 
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He et al., 2013). In a chronic epilepsy mouse model, three modulators of the CCL2/CCR2 
pathway, a CCL2 transcription inhibitor (bindarit), a selective antagonist of the CCR2 
receptor (RS102895), or an anti-CCL2 antibody prevented spontaneous seizure 
exacerbation caused by systemic challenge with LPS (Cerri et al., 2016). 
Sphingosine 1-Phosphate Receptors  
Sphingosine 1-phosphate receptors (S1PRs) are a family of 7 helix transmebrane G protein-
coupled receptors that bind extracellular sphingosine 1-phosphate (S1P) and are expressed 
by many cell types, including immune cells, glia and neurons (Bryan and Del Poeta, 2018). 
Fingolimod (FTY720) is an analogue of sphingosine and when phosphorylated in vivo by 
sphingosine kinases, binds S1PR1, 3, 4, and 5 (Albert et al., 2005). Its main mechanism of 
action is sequestration of lymphocytes into lymph nodes which is mediated by S1PR1 that 
leads to a functional antagonism once the receptor has been internalised and degraded 
(Brinkmann et al., 2002; Mandala et al., 2002; Oo et al., 2007). Fingolimod crosses the BBB 
and binds S1P receptors (S1P1, -3, -5) (Foster et al., 2007). It is clinically approved for oral 
treatment of relapsing forms of multiple sclerosis (Brinkmann, 2007). Apart from its 
immunomodulatory effects in periphery, fingolimod has shown neuroprotective and anti-
inflammatory effects in the brain (Rothhammer et al., 2017; Soliven et al., 2011) acting on 
astrocytes and extracellular-signal regulated kinase (ERK) phosphorylation through S1P1 
receptors (Osinde et al., 2007). In vitro data demonstrate that fingolimod can reduce 
transmigration of peripheral blood mononuclear cells through the BBB (Spampinato et al., 
2015). Gao et al. (2012), demonstrated that fingolimod exerts both anti-inflammatory and 
antiepileptogenic effects in a lithium-pilocarpine rat model of epilepsy (Gao et al., 2012). 
Fingolimod also inhibited pathological mossy fiber sprouting and activation of microglia and 
reduced the increased expression of IL-1β and TNF-α in the hippocampus (Gao et al., 2012). 
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Furthermore, the incidence, duration, frequency, and severity of spontaneous seizures was 
significantly decreased in fingolimod-treated animals. In a more recent study, fingolimod 
treatment alleviated overexpression of hippocampal P-glycoprotein (P-gp), an important 
mediator of ASDs efflux that is implicated in drug-resistant epilepsy, and reduced NF-kB 
activity and TNF-α and COX-2 expression in the same model (Gao et al., 2018). Interestingly, 
fingolimod was recently used in an animal model of TLE showing that although it had no 
effect on SE itself, animals developed less seizures associated with attenuation of gliosis, 
neuronal cell loss and immune cell infiltrates (Pitsch et al., 2018). 
Fingolimod also binds and inhibits histone deacetylases (HDACs) (Hait et al., 2014). 
Moreover, it can interact with lipids and inhibits the cannabinoid receptor CB1 and the 
activity of phospholipase A2 in mast cells (Brunkhorst et al., 2014).  
S1PR modulation represents therefore a potential therapeutic target for epilepsy (Huwiler 
and Zangemeister-Wittke, 2018; Pitsch et al., 2018).  
Table 1.3.1. Effects of anti-inflammatory treatments on seizures and epileptogenesis (van Vliet et 
al., 2018). 
Seizure susceptibility/recurrence 
Drug Convulsant stimulus/ 
Experimental model 
Effects Reference 
IL-1R/TLR signaling 
IL-1ra (IL-1 receptor antagonist) acute symptomatic seizures  
(KA) in rats; (Bic) in mice 
↓ total time in 
seizures 
delay in seizure 
onset;  
↓ seizure total 
duration 
(Vezzani et 
al., 1999, 
2000) 
VX-765 (IL-1 synthesis inhibitor) acute symptomatic seizures 
 (KA) in rats; (KA) in mice 
 delay in seizure 
onset;  
↓ seizure number 
and total duration 
(Ravizza et 
al., 2006b; 
Vezzani et 
al., 2010) 
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VX-765 SRS in mice; GAERS rat ↓ total time in SRS   
↓ number and 
duration of spike-
and-waves 
(Akin et al., 
2011; 
Maroso et 
al., 2011b) 
BoxA (TLR4 antagonist) acute symptomatic seizures  
(KA and Bic) in mice; SRS in 
mice  
 delay in seizure 
onset;  
↓ seizure number 
and total duration 
↓ SRS number and 
total duration 
(Maroso et 
al., 2010) 
LPS-Rs (TLR4 antagonist) acute symptomatic seizures  
(KA and Bic) in mice; SRS in 
mice 
 delay in seizure 
onset;  
↓ seizure number 
and total duration 
↓ SRS number and 
total duration 
(Maroso et 
al., 2010) 
Ifenprodil (NR2B antagonist) SRS in mice ↓ SRS number and 
total duration 
(Maroso et 
al., 2010) 
HMGB1 monoclonal antibody MES in mice; PTZ in mice ↑ threshold; ↓ 
time in tonic-clonic 
seizures; ↓ death 
delay onset of 
generalised 
seizures; ↓ seizure 
stage; ↓ incidence 
of tonic seizures 
(Zhao et 
al., 2017) 
A438079 (P2X7 antagonist) Intra-amygdala KA-induced  
SE in mice 
↓ SE duration (Engel et 
al., 2012) 
COX-2 signaling 
Celexocib PTZ in rats delay in seizure 
onset;  
↓ seizure duration 
(Oliveira et 
al., 2008) 
Celexocib acute symptomatic seizures  
(KA) in mice; (KA) in rats 
↑seizure severity 
and mortality 
(Baik et al., 
1999; 
Gobbo and 
O’Mara, 
2004; Kim 
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et al., 
2008) 
Rofecoxib PTZ in mice delay in seizure 
onset;  
↓ seizure duration 
(Dhir et al., 
2006) 
Rofexocib PTZ in mice ↑seizure threshold (Akula et 
al., 2008) 
Rofexocib PTZ in mice No effects on acute 
seizures 
(Claycomb 
et al., 
2011) 
Nimesulide PTZ in mice delay in seizure 
onset;  
↓ seizure duration 
(Dhir et al., 
2006) 
Nimesulide acute symptomatic seizures 
 (KA) in mice; (KA) in rats 
↑seizure severity 
↑seizure severity 
and mortality when 
administered 
before KA 
(Kim et al., 
2008; Kunz 
and Oliw, 
2001b) 
NS-398 acute symptomatic seizures  
(KA) in mice 
↑seizure severity 
and mortality 
(Baik et al., 
1999) 
Complement 
PMX53 (C5ar1 antagonist) 6 Hz and corneal kindling 
model in mice; Pilocarpine-
induced SE in mice; Intra 
amydgala KA-induced SE in 
mice 
↓ seizure severity 
↑ seizure 
threshold 
 mortality, 30% 
fewer mice 
experienced SE 
when treated after 
SE 
 number SRS and 
time spent in 
seizures 
(Benson et 
al., 2015) 
Chemokines 
Bindarit (CCL2 transcription 
inhibitor)  
SRS in mice  inflammation-
induced SRS 
worsening 
(Cerri et al., 
2016) 
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RS102895 (CCR2 antagonist) SRS in mice  inflammation-
induced SRS 
worsening 
(Cerri et al., 
2016) 
CCL2 antibody SRS in mice  inflammation-
induced SRS 
worsening 
(Cerri et al., 
2016) 
RNA interference against CCR5 KA-induced SE in rats delay in SE onset;  
SE severity;  
recovery time  
(Louboutin 
et al., 
2011) 
Epileptogenesis 
Drug Experimental model Effects Reference 
IL-1R/TLR signaling 
VX-765 Electrical rapid kindling in rats No kindling 
development 
(Ravizza et 
al., 2008b) 
VX-765+IL1ra Electrically-induced SE in rats No effects on SRS; 
neuroprotection 
(Noe et al., 
2013) 
VX-765+CyP Intra amydgala KA-induced SE 
in mice 
Blockade of SRS 
progression;  
   number SRS 
(Iori et al., 
2017) 
IL-1ra+BoxA 
+Ifenprodil 
Electrically-induced SE in 
rats 
Blockade of SRS 
progression;  
 number SRS; 
neuroprotection  
(Walker, 
2017) 
Synthetic miR-146a Intra amydgala KA-induced SE 
in mice 
Blockade of SRS 
progression;  
 number SRS 
(Iori et al., 
2017) 
HMGB1 monoclonal antibody Electrical rapid kindling in 
mice 
 severity of 
seizures  
(Zhao et 
al., 2017) 
HMGB1 monoclonal antibody KA-induced SE in mice  number SRS; 
improvement of 
cognitive deficits 
(Zhao et 
al., 2017) 
JNJ-47965567 (P2X7 antagonist) Intra amydgala KA-induced SE 
in mice 
 number SRS (Jimenez-
Pacheco et 
al., 2016) 
COX-2 signaling 
Rofexocib PTZ kindling in mice No effects on 
kindling 
(Claycomb 
et al., 
2011) 
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Nimesulide PTZ kindling in mice; Electrical 
rapid kindling in mice; 
Electrical rapid kindling in rats 
 kindling 
development 
(Dhir et al., 
2007; 
Takemiya 
et al., 
2003; Tu 
and Bazan, 
2003) 
Celecoxib Pilocarpine-induced SE in rats  number and 
duration SRS 
(Jung et al., 
2006) 
Celecoxib or NS-398 Electrical kindling in mice No effects on 
kindling 
(Fischborn 
et al., 
2010) 
Parecoxib Pilocarpine-induced SE in rats  severity SRS (Polascheck 
et al., 
2010) 
SC-58236 Electrically-induced SE in rats No effects on SRS (Holtman 
et al., 
2009) 
SC-58236 Electrically-induced SE in rats  mortality (Holtman 
et al., 
2010) 
SC-58236 Electrically-induced SE in rats  number SRS in 
50% of the rats 
(Holtman 
et al., 
2010) 
SC-51089 (EP1 antagonist) Electrical kindling in mice  seizure severity (Fischborn 
et al., 
2010) 
Bic= bicuculline, GAERS= Genetic Absence Epilepsy Rat from Strasbourg, KA= kainic acid, 
MES=maximal electroshock, PTZ=pentylenetetrazol, SE= status epilepticus, SRS= spontaneous 
recurrent seizures. KA= kainic acid, PTZ=pentylenetetrazol, SE= status epilepticus, SRS= spontaneous 
recurrent seizures. 
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Table 1.3.2. Clinical studies using anti-inflammatory treatments (van Vliet et al., 2018). 
Drug Patients Effects Reference 
IL-1R/TLR signaling 
VX09-765-401 (IL-1 
synthesis inhibitor) 
Phase IIa randomized 
double blind placebo 
controlled study in drug-
resistant focal onset 
epilepsy  
Delayed beneficial effects 
(subject with ≥50% 
reduction in seizure 
frequency) that persist 
after drug discontinuation 
(Bialer et al., 
2013) 
Kineret (IL-1 receptor 
antagonist) 
Case report: super 
refractory SE secondary to 
FIRES 
Drastic improvement of 
seizure control 
(Kenney-Jung et 
al., 2016) 
Kineret  4 case reports: drug 
resistant epilepsy 
Drastic improvement of 
seizure control and 
cognitive skills 
(Jyonouchi, 
2016) 
COX-2 signaling 
Ibuprofen Randomized placebo 
controlled studies in 
children with febrile 
seizures (n=230) 
Failure of preventive 
effects on the number of 
seizure recurrences in 
children at increased risk 
(van 
Stuijvenberg et 
al., 1998) 
Aspirin Sturge-Weber (n=9) 8 of 9 patients were 
seizure-free for 1 year or 
more 
(Udani et al., 
2007) 
Aspirin Sturge-Weber (n=58) Improvement of seizure 
control in 91% of the 
patients 
(Lance et al., 
2013) 
Aspirin Sturge-Weber (n=34) Improvement of self-
reported seizure control 
and reduction of stroke-
like events 
(Bay et al., 
2011) 
Aspirin Focal onset epilepsy 
(n=46) 
Improvement of seizure 
control 
(Godfred et al., 
2013) 
TNF- 
Adalimumab (anti-TNF-α 
monoclonal antibody 
Rasmussen’s  Seizure improvement in 5 
out of 11 patients, 
associated in 3 of these 5 
patients with stabilization 
of functional deficit 
(Lagarde et al., 
2016) 
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1.3.8 Biomarkers of epileptogenesis 
The lack of sensitive and specific biomarkers to identify people at risk of developing 
epilepsy is a major obstacle for developing novel therapeutic interventions to treat, cure or 
prevent epilepsy (Engel et al., 2013).  The ILAE task force's report identifies a biomarker “an 
objectively measured characteristic of a normal or pathological biological process" (Engel 
et al., 2013). Biomarkers of epileptogenesis could (1) predict the development of an 
epilepsy condition, (2) identify the presence and severity of tissue capable of generating 
spontaneous seizures, (3) measure progression after the condition is established, (4) be 
used to create animal models for more cost-effective screening of potential anti-
epileptogenic and anti-seizure drugs and devices, and (5) reduce the cost of clinical trials of 
potential antiepileptogenic interventions by enriching the patients population at high risk 
for developing epilepsy.” 
Ideally, a biomarker should be sensitive, specific, non invasive, of low cost and easily 
accessible. Different types of biomarkers are being characterized and validated in both 
preclinical and clinical studies and these include circulating molecules, genetic markers, 
electrophysiological and imaging biomarkers as well as behavioral biomarkers. Due to the 
complex and vast mechanisms implicated in epileptogenesis a single biomarker is assumed 
to be insufficient for predicting epileptogenesis. Thus, a combined approach may be 
necessary in order to identify suitable biomarkers at different stages of the disease (Loscher 
et al., 2013). To this end, the time-dependent evolution of cellular and molecular 
alterations occurring in the tissue during disease development has to be better understood. 
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1.4 IN VIVO IMAGING OF NEUROINFLAMMATION 
Brain imaging has become fundamental for helping the diagnosis of epilepsy and as a tool 
for identifying surgical candidates. However, a recent application of molecular 
neuroimaging is to detect alterations within brain networks which may be predictive of 
epilepsy development or disease severity and could act as early biomarkers of therapeutic 
effects of interventions (Obenaus, 2013). In this respect, imaging of activated glial cells in 
epilepsy has attracted much attention and research efforts. 
 
1.4.1 In vivo bioluminescence imaging 
Non-invasive bioluminescence imaging (BLI) is based on the ability of several organisms to 
produce light by luciferase-catalyzed reaction of the substrate luciferin in the presence of 
oxygen and ATP. When used for imaging purposes, a “luciferase” gene (bacterial lux, firefly 
luc or Renilla Rluc) is inserted into the genome of cells under the control of a specific 
promoter. Whenever the promoter is active, luciferase is expressed, resulting in the 
emission of light when its substrate luciferin is administered. This technique can be used to 
visualize gene expression, to study protein–protein interactions, and to track cells non-
invasively (Contag, 2007; Welsh and Kay, 2005). 
A number of studies have reported the use of BLI to track neuroinflammation in several 
CNS disorders. In particular, transgenic mice bearing the GFAP promoter upstream of the 
luciferase gene have been used. In an experimental autoimmune encephalomyelitis (EAE) 
model, GFAP-luc mice showed increased signal after immunization and this signal preceded 
the onset of clinical symptoms, correlated with clinical score, weight loss and histological 
markers of activated astrocytes (GFAP) and microglia (Luo et al., 2007, 2008). Zhu et al, 
using the same transgenic mouse detected reactive astrogliosis at 24 h and 48 h after 
65 
 
intracranial injection of kainic acid and this result correlated with endogenous GFAP and 
luciferase RNA levels as well as with hippocampal cell death (Zhu et al., 2004). Another 
study, proposed the use of a dual transgenic reporter mouse for monitoring glial activation. 
Firefly luciferase was under the control of the GFAP promoter and Renilla luciferase under 
the control of glyceraldehyde 3 phosphate dehydrogenase (GAPDH) promoter providing 
thus a normalized GFAP signal under inflammatory conditions (Cho et al., 2009). In the 
same study it was shown that changes in GFAP/GAPDH ratio preceded those in total GFAP 
protein assessed ex vivo after kanic acid-induced seizures (Cho et al., 2009). GFAP-luc mice 
were used successfully to study astrocytic activation in response to peripheral immune 
activation elicited by LPS or Poly I:C and in a model of mild TBI (Biesmans et al., 2015; Luo 
et al., 2014). 
Another approach for studying inflammation using BLI is to develop transgenic mice that 
express luciferase downstream the promoter for a specific inflammatory gene. Accordingly, 
transgenic mouse models were developed for monitoring immune activation in 
synucleinopathies, amyotrophic lateral sclerosis and ischemia (Breid et al., 2017; Keller et 
al., 2009; Lalancette-Hébert et al., 2009, 2017). Transcription factor CCAAT enhancer 
binding protein (C/EBP) and nestin, regulate inflammation through transcriptional 
activation of inflammatory genes and differentiation of astrocytes and microglia under 
neuroinflammatory conditions from nestin-positive cells (Krishnasamy et al., 2017; Lopez 
de Heredia et al., 2011). They both have been used for transgenic mouse generation in 
order to provide information on the cellular mechanisms underlying inflammation and their 
utility for noninvasive pre-clinical evaluation of therapeutic agents targeting inflammatory 
diseases or as context-dependent biomarkers of the inflammatory response has been 
suggested (Krishnasamy et al., 2017; Lopez de Heredia et al., 2011). Interestingly, IL-1β 
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gene promoter was also used for the generation of a transgenic mouse line that expressed 
luciferase (Li et al., 2008). In this study, LPS-induced sepsis and zymosan-induced arthritis 
were used as models of inflammatory diseases and increased luciferase activity was 
correlated with an increase of endogenous IL-1β mRNA and pro-IL-1β protein levels which 
was suppressed in both models by application of the anti-inflammatory drug 
dexamethasone (Li et al., 2008). 
BLI offers several advantages such as high sensitivity, use of non-ionizing radiation and 
requirement for relatively inexpensive and simple instrumentation. One of the main 
limitations is the relatively low spatial resolution due to light scattering (~1 mm) that 
decreases with the depth of the luminescent source. However, the penetration depth is 
sufficient to image most tissue is rodents (Ntziachristos, 2006). This technique is based on 
the insertion of reporter luciferase genes into the organism thus restricting its use only to 
experimental models. Nevertheless, BLI does not require a light source for illumination 
limiting this way the background signal due to auto-luminescence and achieving high signal-
to-background ratios (Troy et al., 2004). 
 
1.4.2 Magnetic Resonance Spectroscopy 
1H-MRS spectroscopy is used in epilepsy models and in the clinic to reveal specific 
metabolic changes in the brain tissue that cannot be identified by MRI. Several metabolites 
implicated in epileptogenesis can be measured by this quantitative technique. In particular, 
glutathione (GSH) and myo-inositol (mlns) are strictly associated with astrogliosis. GSH is 
an antioxidant peptide synthesized mainly in astrocytes (Dringen et al., 1999). It exerts 
major antioxidant activity and may have antagonistic action at NMDA receptors (Janaky et 
al., 1999). Myo-inositol is a metabolic marker of astrocytes and is elevated during 
67 
 
epileptogenesis (Filibian et al., 2012; Lee et al., 2012). Filibian et al. (2012), suggested that 
GSH and mlns in the hippocampus are biomarkers of epileptogenesis (Filibian et al., 2012). 
Moreover, GSH hippocampal levels were negatively correlated with seizure frequency and 
mlns levels were negatively correlated with neuronal loss (Filibian et al., 2012). 
Additionally, in a pilocarpine status epilepticus model, where only a subpopulation of 
animals develops epilepsy, mlns levels were found elevated before the onset of the disease 
and could predict which animals developed epilepsy (Pascente et al., 2016).  
An increase in mlns levels was found in patients with TSC, TLE and Rasmussen’s encephalitis 
and was associated with astrogliosis (Doelken et al., 2008; Mizuno et al., 2000; Turkdogan-
Sozuer et al., 2000) 
 
1.4.3 Positron Emission Tomography 
Several PET ligands have been developed to target specific molecules expressed by immune 
cells in the brain tissue (Amhaoul et al., 2014) such as the translocator protein (TSPO). TSPO 
is a 18kDa protein located in the outer membrane of the mitochondria and has a role in 
physiological processes such as the translocation of cholesterol into the mitochondria 
(Casellas et al., 2002; Papadopoulos et al., 2006; Rupprecht et al., 2010). In healthy brain 
this protein is expressed at low levels but under inflammatory conditions it is upregulated 
both in animal models of epilepsy and in human tissue (Altar and Baudry, 1990; Amhaoul 
et al., 2015; Guilarte et al., 1995; Johnson et al., 1992; Kumlien et al., 1992; Sauvageau et 
al., 2002). Microglia is thought to be the primary cell population expressing this protein 
since TSPO was found to co-localize with markers of microglia (Amhaoul et al., 2015; 
Cosenza-Nashat et al., 2009; Dedeurwaerdere et al., 2012; Ji et al., 2008; Martín et al., 
2010). Higher uptake of the TSPO tracer 18F-DPA-714 has been shown in both epilepsy and 
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stroke models and this uptake was correlated histologically to activated 
microglia/macrophages (Harhausen et al., 2013). Furthermore, in a KA-induced SE rat 
model, [18F]-PBR111 ligand uptake was higher during early epileptogenesis phase in 
different epileptogenic regions including the hippocampus and the amygdala and was 
associated with activated microglia after post-mortem autoradiography (Dedeurwaerdere 
et al., 2012). The same study demonstrated that there is a correlation between SE severity 
and the extent of brain inflammation since animals that had a less severe SE displayed a 
lower TSPO overexpression (Dedeurwaerdere et al., 2012).  
Similarly, TSPO was upregulated in specific brain regions during epileptogenesis in the 
lithium-pilocarpine rat model of TLE (Brackhan et al., 2016; Yankam Njiwa et al., 2017). 
Interestingly, in a self-sustained SE rat model the higher uptake of the TSPO ligand 11C-
PK11195 was associated with drug resistance although the higher uptake might be related 
to higher seizure frequency of the non-responder to phenobarbital animals (Bogdanovic et 
al., 2014).  TSPO imaging was sensitive enough to detect the anti-inflammatory effect of 
minocycline in a stroke model and of fingolimod in an experimental autoimmune 
encephalitis model implying its role as a biomarker of drug response (Airas et al., 2015; 
Martín et al., 2011). 
However, experimental and clinical data provide evidence that TSPO is also increased in 
astrocytes (Chen et al., 2004; Cosenza-Nashat et al., 2009; Dickens et al., 2014; Ji et al., 
2008; Lavisse et al., 2012; Nguyen et al., 2018). In particular, a longitudinal PET imaging 
study in an intra-hippocampal KA mouse model using the TSPO ligand 18F-DPA-714 has 
revealed a time dependent switch of glia cells expressing TSPO. At 7 days the signal reached 
a peak and microglia was the cell population mainly involved in the TSPO PET uptake while 
at 6 months this uptake derived mostly from reactive hypertrophic astrocytes (Nguyen et 
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al., 2018). In the same model, quantitative longitudinal [18F]GE180 PET imaging revealed 
microglia activation early after SE in the KA-injected hippocampus and to a lesser extent in 
the contralateral homotipic area, indicating a neuroinflammatory response also in areas of 
seizure propagation as in humans (Amhaoul et al., 2015; Bogdanovic et al., 2014; Brackhan 
et al., 2018; Gershen et al., 2015). PET imaging of TSPO is therefore a sensitive and useful 
tool for identifying neuroinflammation during epileptogenesis (Amhaoul et al., 2015; 
Brackhan et al., 2016; Dedeurwaerdere et al., 2012; Russmann et al., 2017). 
Since elevated TSPO levels were found in various cell types (microglia, macrophages and 
astrocytes) and its distribution was disease, time and region dependent, combined 
histological evaluation should be performed in order to determine specific cell expression 
of TSPO.  
TSPO PET imaging has already been performed in clinic in order to identify the 
epileptogenic zone or determine the underlying pathology (Banati et al., 1999; Butler et al., 
2013; Goerres et al., 2001; Kumar et al., 2008). Importantly, TSPO has been detected in 
post-surgical tissue from patients with epilepsy: TSPO gene expression was increased in 
patients with HS and a correlation between higher TSPO binding and density of glial cells 
has been shown (Johnson et al., 1992; Kumlien et al., 1992; Sauvageau et al., 2002).  An 
increased TSPO binding has been shown both ipsilaterally and contralaterally to the seizure 
focus in TLE patients (Gershen et al., 2015; Hirvonen et al., 2012). Moreover, activated 
microglia was identified by [18F]-PBR111 uptake in tissue from Rasmussen's encephalitis 
and FCD patients (Banati et al., 1999; Butler et al., 2011). In a recent case report, seizure 
focus with no visible MRI correlate was successfully identified using TSPO PET imaging 
during a seizure-free period (Butler et al., 2016). Importantly, post-seizure imaging 
revealed increased inflammation spreading further from the clinically-defined seizure focus 
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and highlighted that post-seizure evaluation of inflammation may lead to less precise 
localization of the seizure focus (Butler et al., 2016). 
Other molecules are potential targets for developing imaging markers of 
microglia/macrophage activation such as CB2 receptors (Hosoya et al., 2017; Tolón et al., 
2009). In specimens from patients with FCD and cortical tubers, CB2 receptor was 
upregulated in balloon and giant cells and co-localized with astrocytes, microglia and 
macrophages (Zurolo et al., 2010). Some newly synthesised probes such as CB2 tracer 
[11C]NE40 have been shown to be useful for monitoring microglia activation early after 
stoke induction in rats (Hosoya et al., 2017). Another CB2-specific tracer, [11C]A-836339 
failed to monitor changes in CB2 expression in rat models of neuroinflammation whereas 
Moldovan et al. (2016) developed a CB2 ligand with high affinity over CB1 receptors that 
showed a high brain uptake in a mouse model of acute neuroinflammation induced by LPS 
(Moldovan et al., 2016, 2017; Pottier et al., 2017). 
Methionine can be also used to monitor microglia activation (by the PET tracer 11C-
methionine). Higher methionine uptake in epileptic foci of Rasmussen's encephalitis and 
FCD patients was reported and might be related to microglia activation and proliferation 
(Madakasira et al., 2002; Maeda et al., 2003; Sasaki et al., 1998). Tryptophan can be related 
to neuroinflammation since its catabolism by indoleamine 2,3-dioxygenase (IDO) is induced 
by cytokines during inflammatory processes (Chugani and Chugani, 2005; Chugani and 
Muzik, 2000; Haber et al., 1993; Taylor and Feng, 1991; Yamazaki et al., 1985). α-
[11C]methyl-L-tryptophan ([11C]AMT) was used in TSC patients to image epileptogenic 
tubers and provide information on the presence and localization of the tubers (Asano et 
al., 2000; Chugani et al., 1998, 2013; Kagawa et al., 2005; Rubí et al., 2013). Recently, P2X7 
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receptors were proposed as a novel molecular target for neuroinflammation imaging 
(Territo et al., 2017). 
Monoamine oxidase type B (MAO-B) is an enzyme abundantly present in activated 
astrocytes (Eddleston and Mucke, 1993; Ekblom et al., 1993, 1994; Gulyás et al., 2011; 
Saura et al., 1994). MAO-B is the main target for imaging astrocytes with PET and [11C]L-
deprenyl was used both in experimental and in clinical studies (Carter et al., 2012; Santillo 
et al., 2011). In TLE patients, imaging with [11C]-deuterium-deprenyl revealed epileptogenic 
regions with the presence of reactive astrocytes (Kumlien et al., 1995, 2001).  Interestingly, 
recent studies have identified [18F]-fluorodeoxyglucose (FDG) as a possible marker for 
astrogliosis. In particular, in the rat lithium-pilocarpine model of epilepsy, [18F]-FDG-
microPET imaging showed hippocampal glucose hypometabolism during epileptogenesis 
correlating with neuronal loss, but a partial recovery of glucose uptake in the chronic phase 
associated with GFAP-positive astrocytes (Zhang et al., 2015a). In support, Zimmer et al. 
(2017) demonstrated that astroglial glutamate transport via GLT1 can trigger glucose 
uptake suggesting a re-evaluation of [18F]FDG imaging data in different CNS disorders 
(Zimmer et al., 2017).  
Non-invasive PET imaging of inflammation still needs to be improved in order to increase 
cell-specificity and affinity of radioligands. 
 
1.4.4 Magnetic Resonance Imaging 
Magnetic resonance imaging has been used widely as a tool for anatomic imaging since it 
provides strong spatial resolution in soft tissues such as the brain. Several studies have tried 
to employ this imaging technique for visualising neuroinflammation.  
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BBB dysfunction can be monitored using contrast-enhanced MRI (CE-MRI) and contrast 
agents such as Gd-diethylenetriaminepentaacetate (Gd-DTPA) or gadobutrol that leak out 
of the blood vessels and accumulate in the brain parenchyma after BBB disruption in rat 
models of epilepsy (van Vliet et al., 2014, 2016). In an immature rodent model of febrile 
status epilepticus, MRI changes (reduction of T2 relaxation time) in the hippocampus and 
amygdala correlated with energy-demanding intracellular translocation of HMGB1 (Choy 
et al., 2014). VCAM-1, known to mediate extravasation of leukocytes across the vascular 
endothelium is another target molecule for MRI imaging of inflammation. Duffy et al. 
(2012) using an iron oxide labelled VCAM-1 antibody, reported marked focal signal in the 
hippocampus and cortex after SE in rats (Duffy et al., 2012). Other studies have exploited 
nanoparticles for MRI imaging of neuroinflammation. Small and ultrasmall particles of iron 
oxide were used to visualize inflammation in experimental models of encephalomyelitis 
and stroke as well as in patients with multiple sclerosis and stroke (Stoll and Bendszus, 
2009). Non-radioactive alpha methyl tryptophan (AMT) attached to magnetonanoparticles 
(MNPs) composed of iron oxide and dextran helped visualize epileptogenic regions with 
inflammation and correlated with the occurrence of spontaneous seizures in rodent model 
of TLE (Akhtari et al., 2008). Recently, fluorescent and magnetite-labeled nanoparticles 
were injected intravenously to rats with lithium-pilocarpine-induced chronic epilepsy 
(Portnoy et al., 2016). In this study, ex vivo MRI nanoparticle signal was detected in 
macrophages and microglia in areas of seizure origin (Portnoy et al., 2016). VCAM-1 
expression was visualized in vivo in a mouse model of acute neuroinflammation with the 
use of paramagnetic gadolinium (Gd)-loaded targeted micelles (Garello et al., 2017). 
Interestingly, IL-1β was the molecule targeted in another study employing 
superparamagnetic iron oxide nanoparticles (SPIONs). Functionalized SPIONs with anti-IL-
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1β monoclonal antibody attached, were used to simultaneously visualise and target IL-1β 
overexpressed in the brain of an acute rat model of TLE (Fu et al., 2016). The nanoparticles 
were administered intravenously and after crossing the BBB they concentrated in 
astrocytes and neurons of the hippocampus rendering this area visible on MRI and 
delivering neutralizing anti-IL-1β antibody to the epileptic focus (Fu et al., 2016). Indirect 
approaches for visualization of inflammatory mediators were applied in clinic using fluid-
attenuated inversion recovery (FLAIR)-MRI that enhances the visualization of lesions. A 
positive correlation between FLAIR-MRI and expression of nitric oxide and IL-1β was found 
in post-surgical specimens of TLE patients (Varella et al., 2011). 
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CHAPTER 2 - AIMS OF THE THESIS 
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In the past two decades various ASDs have been developed but treatment efficacy on 
pharmacoresistant epilepsies has not been improved significantly. ASDs affect mainly 
neuronal functions and alleviate symptoms rather than targeting the mechanisms 
underlying the disease. Increasing evidence has shown that astrocytes assume a reactive 
functional state in response to epileptogenic insults and they may be major contributors to 
epilepsy development. Thus, shifting the focus of therapeutic targets from neurons to 
astrocytes might improve the development of therapeutic interventions for treating 
patients not responsive to the currently available ASDs and for developing anti-
epileptogenic drugs. 
Based on this premise, the main scope of this research project is to improve our 
understanding of the role of astrocytes in epilepsy. Two principal studies were developed 
as follows: 
1. To develop a new in vivo imaging method to investigate the dynamics of astroglia 
activation during epileptogenesis. By coupling this method with post-hoc 
immunohistochemistry, we aimed at characterizing the inflammatory vs anti-inflammatory 
phenotype of these cells vis-à-vis with their functional activation state. Moreover, we 
wished to determine whether drugs with anti-epileptogenic effects could modulate the 
dynamics of astrocyte activation and/or their phenotype in the early aftermath of a brain 
insult. 
2. To uncover pathogenic vs homeostatic mechanisms related to astrocyte activation 
during seizures by focusing on Toll-like receptor (TLR)-mediated signaling. While the role 
of TLR4 in epilepsy has been deeply investigated, limited evidence is available on the role 
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of TLR3 and results have been reported on their pathogenic vs neuroprotective functions, 
the later possibly mediated by astrocytes.  
The two studies relied upon the use of in vivo models of either epileptogenesis (1) or acute 
seizures (2) in mice focusing our analyses in the hippocampus since this is a key area 
involved in seizure generation in these models and in human temporal lobe epilepsy. 
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CHAPTER 3 – GENERAL MATERIALS AND METHODS 
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3.1 CLONING 
3.1.1 IL-1β promoter 
DNA sequence of IL-1β gene from the Ensembl Genome Browser (gene code: 
ENSG00000125538) was analysed and compared to the previously described human IL-1β 
promoter/enhancer fragment (H-IL-1β) (Shirakawa et al., 1993). H-IL-1β fragments were 
cloned by polymerase chain reaction (PCR) using human genomic DNA as template. Phusion 
High-Fidelity DNA Polymerase (Thermo Scientific) was used to amplify the human IL-1β 
promoter/enhancer DNA. The thermocycling conditions used were: initial denaturation for 
1 min at 98°C, denaturation for 10 sec at 98°C, annealing for 40 sec at 70°C, extension for 
200 sec at 72°C for 35 cycles, final extention for 15 min at 72°C and hold at 4°C. The samples 
obtained from the PCR reaction were loaded in an 1% agarose-TBE gel and bands at the 
correct size were excised and DNA was recovered using Zymoclean Gel DNA Recovery Kit 
(Zymo Research). Each sample was digested with BglII and EcoRI (both from Thermo 
Scientific) at 37°C for 2h. Digestion product was then purified using DNA Clean and 
Concentrator-5 Kit (Zymo Research). For construction of the rAAV luciferase (LUC) reporter 
plasmids, pAAV-Cav3.2-LUC (Kulbida et al., 2015) harboring the AAV2 inverted terminal 
repeats was modified. pAAV-Cav3.2-LUC was digested with BamHI and EcoRI to excise the 
Cav3.2 promoter from the pAAV-backbone and the digested plasmid was loaded in an 
agarose gel. The pAAV-backbone was excised and purified from the gel using Zymoclean 
Gel DNA Recovery Kit (Zymo Research). The quantity and quality of the plasmids were 
assessed using a nanodrop by light absorption at 260/280 nm ratio. All plasmids were 
dissolved in nuclease free water. Fifty ng of H-IL-1β template were ligated, at room 
temperature overnight, to the pAAV-backbone using T4 DNA Ligase (5 U/µL, Thermo 
Scientific). Stbl2 bacteria (Invitrogen) were used for transformation and bacterial cultures 
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to minimize recombination events.  All clones were confirmed by sequencing analysis. 
Plasmid DNA for viral production was prepared using the Qiagen Maxiprep kit, according 
to the manufacturer’s protocol. 
3.1.2 GFAP promoter  
AAV2-GFAP-GFP-WPRE plasmid, which was kindly provided by Prof. Thomas McCown (UNC 
Gene Therapy Center, NC, USA), was digested with BamHI and EcoRI to excise the GFP 
reporter gene. The luciferase-coding sequence (pGL3-basic; Promega) was amplified and 
digested as for the H-IL-1β promoter/enhancer and then ligated into the backbone plasmid 
to form pAAV-GFAP-LUC-WPRE. All clones were confirmed by sequencing analysis. Plasmid 
DNA for viral production was prepared using the Qiagen Maxiprep kit, according to the 
manufacturer’s protocol. The quantity and quality of the plasmids were assessed using a 
nanodrop by light absorption at 260/280 nm ratio. All plasmids were dissolved in nuclease 
free water. 
 
3.2 CELL CULTURES 
3.2.1 Transfection 
Raw 264.7 cells were maintained at 37°C and 5% CO2 in Dulbecco's Modified Eagle's 
Medium (DMEM, Life Technologies) supplemented with 10% (v/v) heat inactivated Fetal 
Calf Serum (FCS) and 100 units/ml penicillin/streptomycin. Viability, which was assayed 
using trypan blue dye exclusion, was typically greater than 95%. Cultures were maintained 
until passage 20 and then discarded.  
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Transfection was performed in 24-well tissue culture plates (80% confluency) using 
Lipofectamine™ 2000 (Invitrogen, USA) following the manufacturer’s protocol. 0.8 µg of IL-
1β luciferase reporter plasmid with firefly luciferase, 0.2 µg of control pRL-TK vector with 
the Renilla luciferase gene (Promega) were mixed with 50 µl Opti-MEM® I reduced serum 
media (Invitrogen, USA). The mixture was incubated for 20 min at room temperature and 
then added to the appropriate wells. Cells were grown in complete culture medium at 37°C 
and 5% CO2. 
 
3.2.2 Luciferase assays 
The luciferase assays were performed using the Dual Luciferase Reporter Assay System 
(Promega) and Glomax Luminometer (Promega) was used for measuring Renilla and firefly 
luciferase activities. The results are given as firefly/Renilla relative luciferase activity and 
fold-induction compared to the basal activity for each construct. 
 
3.3 RECOMBINANT ADENO-ASSOCIATED VIRUSES (rAAVs) 
3.3.1 rAAV serotype 8 production 
For transfection HEK293T cells were seeded at a density of 1.5x106 cells/15 cm dish and 
allowed to reach 50-60% confluency. Three to four hours prior to transfection the DMEM 
medium (Thermo Scientific) (with 10% Fetal Calf Serum, 1% Penicillin/Streptomycin) was 
exchanged with IMDM medium (Thermo Scientific), supplemented with 5% FCS. To the 
transfection mixture containing water, CaCl2 and DNA, 2X HeBS (50 mM HEPES, 280 mM 
NaCl, 1.5 mM Na2HPO4, pH 7.05) buffer was added under vortexing drop-wise fashion and 
further incubated for 2 minutes, to allow complexes formation (Table 3.1). For transfection, 
p5E18-VD2/8 (AAV2 rep and AAV8 cap), pFdelta6 and the AAV plasmid were used. 
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Table 3.1. rAAV8 production method. 
 
3.3.2 rAAV serotype 8 purification 
After 48 h, cells were harvested in 1 ml DMEM medium and centrifuged at 
1.200rpm/20min. The pellet was resuspended in 10 ml lysis buffer (150 mM NaCl, 50 mM 
Tris-HCl, pH 8.5) and three cycles of freezing-thawing were performed. In order to get rid 
of nucleic acids, 20 μl benzonase (50 U/ml suspension) was added to the lysate and 
incubated for 30 min at 37°C. After the incubation, the suspension was centrifuged at 
4.000rpm/30min/4°C and the clear suspension was collected. The purification of the virus 
was performed using four layer discontinuous iodixanol gradients (Zolotukhin et al., 2002). 
The gradients were layered (Table 3.2) in ultracentrifuge tubes (Sorvall) using a peristaltic 
pump (P-1). 
Table 3.2. Iodixanol gradients. 
Components 15% Iodixanol 25% Iodixanol 40% Iodixanol 54% Iodixanol 
PBS 10x 5 ml 5 ml 5 ml 5 ml 
Iodixanol 12.5 ml 20 ml 33.3 ml 45 ml 
NaCl 5M 10 ml - - - 
KCl 2.5M 50 μl 50 μl 50 μl 50 μl 
MgCl2 1M 50 μl 50 μl 50 μl 50 μl 
0.5% Phenol red 75 μl 75 μl - 75 μl 
H2O 22.3 ml 24.9 ml 11.6 ml - 
Volume used for one gradient 
 8-9 ml 5-6 ml 5 ml 2-4 ml 
Components  
Serotype 8 
( 15 cm dish) 
dH2O  2.4 ml 
CaCl2 (2.5 M)  330 μl 
AAV plasmid  5 μg 
pFdelta6- helper virus  10 μg 
p5E18-VD2/8  5 μg 
2x HEBS - added under vortexing  2.6 ml 
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The cellular suspension (8-9 ml) was layered on top of the iodixanol gradients; the tubes 
were sealed, and centrifuged at 60.000rpm/2h/4°C (fixed angle rotor T865, Thermo 
Scientific). rAAV particles were recovered from the 40% iodixanol layer and iodixanol was 
removed by several rounds of washing with PBS, using Amicon centrifugal filters (Thermo 
Scientific). The purity of the virus was determined by SDS-PAGE and Coomassie staining. 
rAAV8 particles for GFAP-promoter-GFP plasmid were produced by triple transfection of 
HEK293T cells and purified by column chromatography at the UCN Vector Core (Chapel Hill, 
NC, USA). 
 
3.4 INTRAHIPPOCAMPAL ADMINISTRATION OF rAAVs 
Animals were anaesthetised with isoflurane 1.5% and head fixed to the stereotaxic device. 
For each injection one µl of viral suspension containing ~108 transducing units of the rAAVs: 
rAAV8-H-IL-1β(-2987/+570)-GFP, rAAV8-GFAP-GFP-WPRE, rAAV8-GFAP-LUC-WPRE or 
rAAV1/2-synI-dtTomato  was used and was infused (100 nl/min) into both the dorsal (from 
bregma, AP: -1.8, L: ±1.5, V: -2) and ventral (AP:-3, L: ±3, V: -3.3) poles of the hippocampus, 
bilaterally, using a 10 µl Hamilton syringe and a microprocessor controlled mini-pump 
(World Precision Instruments). After injection, the needle was left in place for 5 min before 
the incision was closed. Animals were allowed to recover on a heating pad and injected 
subcutaneously daily for 3 days with Ketoprofen (Gabrilen, 5.0 mg/kg,), Enrofloxacin 
(Baytril, 5.0 mg/kg) and twice/day with Buprenorphin (Buprenovet 0.05 mg/kg). Mice were 
daily observed for one week for their general health status. 
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3.5 CELL SORTING 
Mice were anaesthetised with 6 mg/kg xylazine (Rompun; Bayer, Germany) and 90-120 
mg/kg ketamine (Ketavet; Pfizer, Germany) intraperitoneally and decapitated. Hippocampi 
were isolated on ice and transferred into ice-cold HBSS. After 3 washing steps, 200 μl 
trypsin (dissolved in 1.8 ml HBSS) was added for 20 min at 37°C. The cell pellet was washed 
three times with Hank’s Balanced Salt Solution (HBSS, Life technologies) and then DNase 
(0.1 mg/ml; Roche) was added. Cells were dissociated using a 1 ml pipette tip and stored 
on ice until sorted. The fluorescent samples were sorted on a BD FACS Aria III instrument 
using a 100 μm diameter nozzle (University of Bonn, Medical School FACS Core Facility). 
Digital data collection was performed using BD FACS DIVA software (BD Diagnostics, 
Baltimore, MD, USA). 
 
3.6 BIOCHEMICAL ANALYSIS 
3.6.1 RNA isolation and real-time quantitative polymerase chain reaction 
Mice were deeply anaesthetised with 6 mg/kg xylazine (Rompun; Bayer, Germany) and 90– 
120 mg/kg ketamine (Ketavet; Pfizer, Germany) intraperitoneally and then decapitated. 
Four-hundred μm slices were cut on a vibratome in pre-chilled PBS. Hippocampi were 
microdissected under the microscope and subsequently homogenized in 100 µl lysis buffer 
with a tissue mincer (Dynabeads® mRNA DIRECT Micro Kit). Both mRNA from tissue lysates 
and FACS-sorted neurons were isolated using the Dynabeads® mRNA DIRECT Micro Kit, 
according to the manufacturer’s protocol (Life Technologies). mRNA was retranscribed into 
cDNA using the RevertAid H Minus First Strand cDNA Synthesis Kit (ThermoScientific). 
Transcript quantification was performed in triplicates by real-time reverse transcription–
PCR (RT-qPCR) according to the ΔΔCt method. A final reaction volume of 6.25 μl/well was 
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used containing 1.25 μl of cDNA, 0.1875 μl of forward and reverse primer (100 pM stock) 
and 3.125 μl 2x Master mix (Maxima SyBr green/ROX qPCR; Thermo Scientific).  
Primer sets were:  
• IL-1β: forward: 5’-TTGACGGACCCCAAAAGATG-3’  
reverse: 5’-CAGCTTCTCCACAGCCACAA-3’  
• β-actin: forward: 5’-ACCGTGAAAAGATGACCCAGA-3’ 
reverse: 5’-ATGGGCACAGTGTGGGTGA-3’ 
Quantitative PCR was performed in an ABI Prism 7900HT apparatus (PE Applied Biosystems, 
Foster City, CA, USA) with the following conditions: 50°C for 2 min, 94°C for 1 min, 40 cycles 
of 94°C for 20 s, 59°C for 30 s, 72°C for 40 s, 95°C for 15s and a final step of 60°C for 15 s. 
The signal threshold was set within the exponential phase of the amplification to determine 
the Ct values. β-actin, an endogenous non cell-specific gene, was used as a reference gene 
to normalize candidate gene expression. 
 
3.6.2 Western blot 
Hippocampi from mice deeply anaesthetised with ketamine (75 mg/kg) and medetomidine 
(0.5 mg/kg) were dissected out at 4°C and quickly frozen into liquid nitrogen. Tris-HCl 20 
mM buffer (pH 7.4) containing 1 mM EDTA, 5 mM EGTA, 1 mM Na-vanadate, 2 µg/µl 
aprotinin, 1 µg/µl pepstatin, and 2 µg/µl leupeptin was used for homogenization. Total 
proteins (20 µg) assessed with BCA Protein Assay Kit (ThermoScientific) were separated 
using SDS-polyacrylamide gel electrophoresis (PAGE) 10% acrylamide, for 40-50 min at 
200V. Each sample was run in duplicate. Then, proteins were transferred via electroblotting 
to Hybond nitrocellulose membranes overnight at 30mA at 4°C. 
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Non-specific binding sites were blocked by incubating the membranes in milk 10% and TBS-
Tween for 60 min at room temperature. For immunoblotting, an overnight incubation with 
blocking buffer (TBS-Tween and milk 3%) and GFAP (1:15000, Merck, Germany; # 
MAB3402) or anti-rabbit GLT-1 (1:1000, Abcam, USA; #ab178401) or anti-rabbit Kir4.1 
(1:2000, Alomone Labs, Israel; #APC-035) was carried out at 4°C. The following day the 
membranes were washed, incubated with secondary antibody anti-mouse or anti-rabbit 
HRP (1:10000, Sigma Aldrich) for 90 min at room temperature in blocking buffer, and then 
washed. GFAP, GLT-1 or Kir4.1 bands were visualized with ECL Luminata solution (Luminata 
forte, Western HRP substrate, Millipore, MA, USA) and a ChemiDoc Imaging system 
(Biorad). Images of GFAP, GLT-1 or Kir4.1 and the marker lane bands were captured and 
merged together. Afterwards, membranes were washed and incubated with β-actin 
(1:5000, Immunological Sciences, Italy; #MAB24007) in blocking buffer for 2 h at room 
temperature. β-actin was used since it represents an internal control with which to 
compare GFAP protein levels. The membranes were washed, incubated in secondary 
antibody, and protein bands visualized as above.  
Quantification was performed using Image Lab software (Biorad) in which a ROI was drawn 
around the protein bands to determine the optical density and thus the amount of protein 
present, for GFAP, GLT-1 or Kir4.1 and β-actin. Optical density values in each sample were 
normalized using the corresponding amount of β-actin and GFAP. 
 
3.7 EXPERIMENTAL ANIMALS 
Adult C57BL/6N male mice (~50 days, 20-25 g) were obtained from Charles River (Germany 
and Italy). Mice were housed at a constant room temperature (23°C) and relative humidity 
(60 ± 5%) with free access to standard food pellet and water, and with a fixed 12 h light/dark 
87 
 
cycle. Adult animals were housed two or four per cage and environmental enrichment was 
used. 
 
3.8 ANIMAL CARE 
Procedures involving animals were conducted at the University of Bonn and Istituto di 
Ricerche Farmacologiche “Mario Negri” IRCCS which both adhere to the principles set out 
in the following laws, regulations, and policies governing the care and use of laboratory 
animals: guidelines of the University of Bonn Medical Centre Animal-Care-Committee, 
Italian Governing Law (D.lgs 26/2014; Authorization n.19/2008-A issued March 6, 2008 by 
Ministry of Health); Mario Negri Institutional Regulations and Policies providing internal 
authorization for persons conducting animal experiments (Quality Management System 
Certificate - UNI EN ISO 9001:2008 - Reg. No. 6121); the NIH Guide for the Care and Use of 
Laboratory Animals (2011 edition) and EU directives and guidelines (EEC Council Directive 
2010/63/UE). The Statement of Compliance (Assurance) with the Public Health Service 
(PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed 
(9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01). 
3.9 IN VIVO MODELS OF EPILEPTOGENESIS 
3.9.1 Intra-amygdala kainic acid in mice 
Mice were injected under general gas anesthesia (1-3% isoflurane in O2) and stereotaxic 
guidance. A needle was unilaterally lowered into the brain tissue for the intra-amygdala 
injection of kainic acid (from bregma, mm: nose bar 0; anteroposterior -1.06, lateral -3.3, 
ventral -4) (Franklin and Paxinos, 2008). Kainic acid (0.3 μg in 0.2 μl) was unilaterally 
injected in the basolateral amygdala. The needle was left in place for 5 min post-injection 
88 
 
before closing the incision with sutures. Mice recovered from anesthesia within a few 
minutes and SE was developed after approximately 10 min from kainic acid injection. 
Animals were observed for motor convulsions in order to assess the ictal activity since in 
this model ictal activity was always associated with generalized motor convulsions. After 
40 min from SE onset, mice received diazepam (10 mg/kg, intraperitoneally, i.p.) to improve 
their survival rate. Mice were sacrificed at different time points after SE for subsequent 
biochemical or immunohistochemical analysis according to the experimental protocol (for 
details regarding experimental groups, see Chapter 5). Control mice were animals 
subjected to surgery and injected with saline into the basolateral nucleus of the amygdala 
thus they were not exposed to SE (referred to as Saline or Control). No mice from the 
Saline/Control group showed any behavioural convulsions and were used for brain 
histological and biochemical analysis. 
This is an epileptogenesis model were epilepsy develops in 100% of mice exposed to at 
least 1.5 h of SE and is a model extensively described and used (Diviney et al., 2015; Iori et 
al., 2017; Jimenez-Mateos et al., 2012; Mouri et al., 2008). Spontaneous generalized motor 
seizures occur after a short latent period that is of 5.4 ± 0.5 days after the induction of SE 
(Iori et al., 2017). The number of seizures per day is stable for the first 60 days after the 
epilepsy onset and then seizure score increases in 80% of the mice by about 3-fold after 2 
months and remains stable thereafter (Iori et al., 2017). This model recapitulates the major 
co-morbidities found in epilepsy patients showing cognitive deficits and anxiety-like 
behaviours (Liu et al., 2013). Moreover, neuronal cell loss occurs progressively and mostly 
at the unilateral side to the injected amygdala (Mouri et al., 2008). 
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This model was used to characterize the glia activation during the epileptogenesis phase 
and to study the effects of anti-inflammatory treatment during epileptogenesis using the 
in vivo imaging tool developed (see data in Chapter 5). 
 
3.9.2 Intra-cortical kainic acid in mice 
Animals were anaesthetised with 6 mg/kg xylazine (Rompun; Bayer, Germany) and 90–120 
mg/kg ketamine (Ketavet; Pfizer, Germany) intraperitoneally, and head fixed to the 
stereotaxic device. Kainic acid (70 nl of 20 mM solution) was infused unilaterally in the 
cortex above the left dorsal hippocampus (coordinates from bregma, anteroposterior -2, 
lateral -2, ventral -1.3) using a microprocessor controlled mini-pump at a rate of 35 nl/min 
in order to induce status epilepticus. Animals recovered from anesthesia about 90 min later 
and were visually observed for the occurrence of behavioural motor seizures characterized 
by rearing and forelimb clonus which persisted for about 12 h and resulted in epilepsy 
development as previously described (Jefferys et al., 2016).  
The latent period in this model is 5 ± 2.9 days and is not free of ictal activity (Jefferys et al., 
2016). In this model 93% of the mice exposed to SE develop spontaneous recurrent seizures 
associated with motor seizures which vary significantly between animals ranging from 1 to 
20 seizures per day (Jefferys et al., 2016). Sponteaneous seizure frequency increases with 
time reaching a 4-fold increase 7-9 months after SE and does not correlate with the duration 
of SE or the length of the latent period (Jefferys et al., 2016). Neuronal loss is seen in the 
CA1, CA3 and hilus of the ispilateral hippocampus already at 2 days after KA injection and 
pyramidal cell degeneration induced by seizure activity along with reactive gliosis increases 
throughout a 9-month period after SE (Jefferys et al., 2016). This a model that mirrors the 
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morphological and functional alterations seen in human TLE patients thus making it suitable 
for drug testing.   
This model was used for production of the data reported in Chapter 4 where we developed 
an in vivo bioluminescence imaging tool. 
 
3.10 IMMUNOHISTOCHEMISTRY 
3.10.1 Immunohistochemical studies from in vivo preparations 
Mice used in Chapter 4 were anaesthetised with 6 mg/kg xylazine (Rompun; Bayer, 
Germany) and 90–120 mg/kg ketamine (Ketavet; Pfizer, Germany) intraperitoneally and 
perfused via the ascending aorta with 50 mM cold phosphate buffered saline (PBS, pH 7.4) 
followed by chilled 4% paraformaldehyde (PFA) in PBS. Brains were removed and fixed in 
PFA over-night. Forty μm coronal sections were cut using a vibratome (Thermo Scientific) 
throughout the septal-temporal extension of the mouse hippocampus (-0.94 to -3.64 mm 
from bregma; Franklin and Paxinos, 2008) and slices were used for GFP staining and co-
localization with the neuronal marker NeuN and the astrocytic marker GFAP. Two slices per 
animal were used for IL-1β staining and co-localization with GFP were processed as 
described in section 3.10.2. Slices from animals used to localize the GFP signal deriving from 
AAV8-GFAP-GFP-WPRE vector were not stained further for GFP since signal was strong 
enough to co-localize with GFAP and NeuN markers (see details below).  
Mice used in Chapter 5 were deeply anaesthetised with ketamine (75 mg/kg) and 
medetomidine (0.5 mg/kg) and perfused via the ascending aorta with 50mM cold PBS, pH 
7.4 and then with 4% paraformaldehyde (Merck, Darmstadt, Germany) in PBS. Brains were 
removed and post-fixed for 90 min at 4°C and then transferred to glucose solution 20% in 
PBS for 24 h at 4°C. Then brains were frozen by immersion in isopentane at -45°C for 3 min 
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and stored at -80°C until assayed. Using a cryostat serial coronal sections (40 μm) were cut 
and collected from -0.94 to -2.80 mm from bregma (Franklin and Paxinos, 2008). Two series 
of 30 sections each were prepared and in each series the first slice was used for staining 
for GFAP, the second for CD11b, the third for S100β, the forth for HMGB1, the fifth for TNF-
α and the sixth for PTX3. Three slices per animal were used for each marker.  
In order to stain astrocytes and microglia (Chapter 5), sections were incudated for 1h at RT 
with 10% normal goat serum, 1% Triton X-100 in Tris-buffered saline 0.1 m, pH 7.4, then 
overnight at 4°C with the following primary antibodies: mouse anti-GFAP (1:3500, 
Chemicon, Temecula, CA, USA; #MAB3402) and anti-rabbit S100β antibody (1:3000, 
Abcam, UK; #Ab52642) markers of astrocytes, or rat anti-CD11b (1:1000, MAC-1, Serotec; 
Cat# MCA719, Clone 5C6), a marker of microglia followed by visualization with the 
Vectastain ABC kit (Vector Laboratories), with diaminobenzidine (DAB; Sigma, #D8001 or 
nickel-intensified DAB for IL-1β) as chromogen.  
Slices from different animals and experimental groups were matched at comparable 
anteroposterior and dorsoventral levels.  
 
3.10.2 Green fluorescent protein (GFP) 
Slices (see Chapter 4 data) were blocked for 2 h at 37°C in blocking buffer (0.1% Triton-
X100, 0.1%Tween20, 2% BSA in PBS; Invitrogen) and then incubated with primary antibody 
against GFP (1:1000; Abcam, Cambridge, UK; #ab290) overnight at 4°C. After washing with 
PBS, slices were incubated with secondary antibody Alexa Fluor 488 donkey-anti-rabbit 
1:200 (Jackson Immunoresearch Laboratories, Inc., USA) for 2 h at room temperature and 
then mounted on slides with fluorescein mounting medium after a final wash (Vectashield, 
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Vector laboratories, USA). Slices were evaluated for fluorescent signal using Nikon Eclipse 
Ti confocal microscope (Nikon Instruments, Germany). 
 
3.10.3 TNF-α, HMGB1 and PTX3 
Slices were incubated at 4°C for 10 min in 70% methanol and 2% H2O2 in Tris-HCl-buffered 
saline (TBS, pH 7.4), followed by 30 min incubation in 10% fetal bovine serum (FBS), 1-10% 
bovine serum albumin (BSA) in 1% Triton X-100 in TBS. Overnight incubation was 
performed with goat anti-mouse primary antibody against TNF-α (1:1000, Peprotech, NJ, 
USA; #500-P64G) at 4°C in 10% FBS, 1-10% BSA in 1% Triton X-100 in TBS.  
For HMGB1 immunostaining sections were incubated at 4°C for 60 min in 10% normal goat 
serum (NGS) in 0.1% Triton X-100 in PBS (Ravizza and Vezzani, 2006). Then the slices were 
incubated with the primary rabbit polyclonal antibody against HMGB1 (1:1000, Abcam, 
Cambridge, UK; #AB18256) overnight at 4°C in 4% NGS in 0.1% Triton X-100 in PBS. 
PTX3 immunostaining was done as follows: slices were incubated with Triton X-100 0.3%, 
PBS, and normal goat serum (NGS) 2% for 60 min before overnight incubation at 4°C with 
the primary antibody against PTX3 (1:250, rabbit polyclonal anti-hPTX3 1mg/ml purified, 
kindly provided by C. Garlanda, Istituto Clinico Humanitas–IRCCS, Rozzano, Italy) in blocking 
buffer (PBS and NGS 1%). 
For HMGB1 and PTX3 immunostainings, after 1 h incubation with anti-rabbit biotinylated 
secondary antibodies (1:200, Vector Labs), immunoreactivity for HMGB1 and PTX3 was 
assessed using the avidin-biotin-peroxidase technique (Vectastain ABC kit, Vector Labs): 
PBS, avidin 1%, and biotin 1% were applied to the slices for 60 min, before reacting the 
slices and visualising the signal with 3’,3’-diaminobenzidine (DAB, 5mg) (Sigma, Munich, 
Germany), TBS (Tris-HCl-buffered saline, pH 7.4, 10ml), and H2O2 (3 µl). For TNF-α, after 
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incubation for 1 h with anti-goat biotinylated secondary antibody (1:200, Vector Labs), the 
avidin-biotin-peroxidase technique was used and signal was further amplified with addition 
of nickel ammonium into the DAB solution.  
Then sections were washed twice in TBS and once in saline and mounted on gelatin-coated 
slides and allowed to dry at room temperature overnight. The following day, slices were 
dehydrated using a series of ethanol concentrations (70%, 95%, and 100%) and xylene 
before covering with DPX mountant for histology (Sigma, Germany) and a coverslip. 
No immunostaining was observed in control slices when incubating with the primary 
antibody preabsorbed with the corresponding peptides (1 μM, 24 h at 4°C), or without the 
primary antibodies (Ravizza and Vezzani, 2006; Vezzani et al., 1999).  
Quantitative analysis of S100β, HMGB1 and TNF-α staining in DAB coloured sections was 
done by counting automatically the total number of positive cells marked using Fiji 
software. Three slices per mouse were used for quantification of the signal in the whole 
hippocampus captured at 20X using a BX61 microscope equipped with motorised and 
digitised platform (Virtual Slider Microscope, Olympus, Germany) and one field 
representing the CA1 area was captured for representation. GFAP-, CD11b-, S100β-, TNF-
α- and PTX3-positive total area (µm2) occupied by the staining was quantified with the same 
tool. Data obtained in each slice/mouse were averaged, providing a single value per mouse, 
and this value was used for the statistical analysis. 
 
3.10.4 Double and triple immunostaining  
Two slices from 4 mice perfused at 24 h after SE were used in order to identify the cell type 
marked by the H-IL-1β(-2987/+570)-GFP construct (Chapter 4). After incubation with the 
GFP primary and secondary antibody slices were incubated with primary antibody mouse 
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anti-GFAP (1:2500, Chemicon, Temecula, CA, USA; #MAB3402) or mouse anti-NeuN 
(1:1000, Chemicon; #MAB377) followed by the corresponding secondary antibodies (1:400, 
Alexa Fluor 488 and Alexa Fluor 568, Jackson Immunoresearch Laboratories, Inc., USA). 
Two slices from 3 animals were used in order to identify whether the cells expressing 
endogenous IL-1β are the same as the ones marked by the H-IL-1β(-2987/+570)-GFP 
construct (data reported in Chapter 4). Briefly, after GFP staining, slices were incubated at 
4°C for 10 min in 70% methanol and 2% H2O2 in Tris-HCl-buffered saline (TBS, pH 7.4), 
followed by 30 min incubation in 10% fetal bovine serum (FBS), 10% bovine serum albumin 
(BSA) in 1% Triton X-100 in TBS. Overnight incubation was performed with the goat 
polyclonal primary antibody against IL-1β (1:200, Santa Cruz Bio., CA, USA; #sc-1252) and 
followed by incubation with secondary biotylinated anti-goat antibody (1:500, Vector Labs) 
and streptavidin–horseradish peroxidase with amplification of the signal with tyramide 
conjugated to Fluorescein using TSA amplification kit (NEN Life Science Products, Boston, 
MA, USA). Identification of the cell type expressing the endogenous IL-1β was done in the 
same slices after IL-1β and incubation with primary antibody mouse anti-GFAP.  
Two slices from 3 randomly chosen animals and adjacent to those used for single 
immunohistochemistry were used for double or triple immunostaining to identify the cells 
expressing HMGB1, TNF-α and PTX3 (Chapter 5). After incubation with the primary 
antibodies to HMGB1, TNF-α and PTX3, the slices stained for HMGB1 and PTX3 were 
incubated with anti-goat (for TNF-α) or anti-rabbit (for HMGB1 and PTX3) secondary 
antibody conjugated with Alexa488 (1:500; Molecular Probes, Leiden, The Netherlands) 
while sections stained for TNF-α were incubated with streptavidin–HRP and the signal was 
revealed with tyramide conjugated to Fluorescein using TSA amplification kit (SAT-
701001EA; NEN Life Science Products, Boston, MA, USA). Sections for all stainings were 
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subsequently incubated with primary antibodies against GFAP, CD11b and NeuN. 
Fluorescence was detected using secondary antibodies conjugated with Alexa546 (1:500, 
Molecular Probes, Leiden, Netherlands). Cells expressing S100β were co-localised with 
GFAP using the same method. For HMGB1-stained sections, an additional incubation of 15 
min in DAPI (1:500; Molecular Probes) was done in order to visualize the cell nucleus. Slide-
mounted sections were examined with an Olympus Fluoview laser scanning microscope 
(microscope BX61 and confocal system FV500) using excitations of 488 nm (Ar laser), 546 
nm (He-Ne green laser) and 350 nm (ultraviolet) for fluorescein, Alexa546 and DAPI, 
respectively. The emission of fluorescent probes was collected on separate detectors. To 
eliminate the possibility of bleed-through between channels, the sections were scanned in 
a sequential mode. 
 
3.11 IN VIVO BIOLUMINESCENCE IMAGING 
Two weeks after intrahippocampal injection with the AAV8-GFAP-LUC virus, mice were 
randomly divided into the experimental groups and were injected intraperitoneally with D-
Luciferin (150mg/kg; Cayman, USA) and then anaesthetised with 2% isoflurane and placed 
in an IVIS-Spectrum Optical In Vivo Imaging System (PerkinElmer) for baseline 
bioluminescent signal measurement. The head of each mouse was shaved with clippers 
and a depilatory cream before imaging in order to increase the signal detected by the 
ultrasensitive charged coupled device (CCD) camera. At each time point, a sequence of 
images was acquired every 2 minutes for 14 minutes (exposure time: 2 min, binning: 
medium, f/stop: 1) to ensure that the peak luciferase activity was captured. Twenty-four 
hours after baseline measurement, KA was injected into the cortex as described previously 
and the bioluminescent signal was recorded at 24 h and 3 d post-SE (Chapter 4). For data 
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reported in Chapter 5, mice were injected intraperitoneally with saline or with FTY720 
(6mg/kg) 1 h after intra-amygdala injection of KA and then daily, once per day for 7 
consequitive days and monitored at 2 h, 24 h, 3 d and 7 d post-SE (Chapter 5). Control group 
were mice injected in the cortex (Chapter 4) or amygdala (Chapter 5) with PBS or saline and 
treated with saline with the same protocol described above. Images were analysed using 
Living Image 4.5.5 software (PerkinElmer) and regions of interest (ROI) contouring the area 
of bioluminescent signal were drawn in order to quantify the surface radiance in photons 
per second per square centimeter per steradian (photons/s/cm2/sr).  
 
3.12 STATISTICS 
Quantification of each experiment was done blindly. Sample size was determined a priori 
based on previous experience with the respective models and statistical tests were 
prospectively selected. All efforts were made to reduce the number of animals used to 
minimum. GraphPad Prism 6 (GraphPad Software, USA) for Windows was used for 
statistical analysis using absolute values. Data are presented as mean ± S.E.M. (n indicates 
the number of individual samples). For each variable, differences between the groups were 
assessed using Mann–Whitney U test for two independent groups and one-way ANOVA 
followed by Tukey or Dunnet’s post-hoc test or Kruskal-Wallis followed by Dunn’s post-hoc 
test for more than two independent groups (details are reported in the figure legends). 
Differences were considered significant with a p<0.05. 
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CHAPTER 4 – CHARACTERIZATION OF IL-1β PROMOTER 
FRAGMENTS AND DEVELOPMENT OF IN VIVO 
BIOLUMINESCENCE IMAGING OF ASTROCYTES 
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4.1 INTRODUCTION 
Astrocytes are among the principal cells involved in the expression and release of this 
cytokine during epileptogenesis and they are pivotal for sustaining the inflammatory brain 
response (Aronica et al., 2012; Maroso et al., 2011a; Vezzani et al., 2011a). Reactive 
astrocytes with an inflammatory phenotype express high levels of glial fibrillary acidic 
protein (GFAP), a member of the cytoskeleton protein, essential for the process of 
astrogliosis (Eng et al., 2000). Astrocytes become dysfunctional cells during epileptogenesis 
and they contribute to seizure generation by various mechanisms. Pivotal for their 
involvement in epileptogensis is their abilty to release IL-1β and other ictogenic cytokines 
such as HMGB1 and TNF-α as well as promoting an hyperexcitable microenvinronment due 
to their impaired capacity of buffering extracellular glutamate and K+ ions (Devinsky et al., 
2013; Friedman et al., 2009). Thus, one therapeutic option to interfere with epileptogenesis 
is to modulate astrocytic activation and restore their physiological functions, however, this 
intervention requires a better understanding of the extent and timing of the astroglia 
activation after epileptogenic injuries. Since dysfunctional astrocytes express high levels of 
both IL-1β and GFAP, we focused on these two genes and developed an experimental 
design to monitor the dynamics and extent of cell activation during epileptogenesis based 
on in vivo bioluminescence signal of gene promoter activation by viral vector gene delivery.  
Gene promoter activation. The IL-1β gene promoter is well characterised since various 
regions of the gene's promoter and enhancer have been identified (Kominato et al., 1995; 
Shirakawa et al., 1993; Toda et al., 2002). The transcription of the IL-1β gene requires the 
interaction between the promoter sequence (from −131 to +12) that contains the TATA box 
and the far upstream enhancer known as upstream inducible sequence (UIS) located at 
−3134 to− 2179 (Adamik et al., 2013; Figure 4.1). Gene transcription depends on the 
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lineage-specific Spi-1/PU.1 (Spi1) transcription factor. Spi1 acts as an anchor for induction-
dependent interaction with two TLR-activated transcription factors, C/EBPβ and NF-kB, in 
order to induce transcription, likely in the context of a specific chromatin architecture 
(Figure 4.1; Adamik et al., 2013).  
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Schematic depiction of IL-1β gene promoter regulatory region. (A) The upstream 
induction sequence (UIS) is located at −3134 to− 2179 whereas the promoter sequence at −131 to 
+12.  The relative Spi-1, C/EBP and TATA sites are noted. (B) Model for chromatin looping during 
activation of IL-1β (adapted from Adamik et al., 2013). 
 
The GFAP (gfa2) promoter has been thoroughly studied (Brenner et al., 1994; Lee et al., 
2006, 2008; de Leeuw et al., 2006; Yeo et al., 2013). A shorter 681 bp GFAP promoter 
fragment, gfaABC1D, has the same expression pattern of the 2210 bp gfa2 promoter and 
about two-fold greater activity, thus recommending it for gene targeting applications such 
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as insertion in a recombinant adeno-associated viral vector (rAAV) system where the size 
of the construct is a limiting factor (Lee et al., 2008; Figure 4.2). 
 
 
 
 
 
 
 
 
Figure 4.2. Schematic depiction of GFAP (gfa2) gene promoter and of the shorter gfaABC1D 
fragment. Coordinates for the 4 B subregions and the approximate position of the transcription 
factor (TF) binding sites are shown. Three subregions were identified as important contributors to 
activity in addition to the basal promoter (BP), regions A (bp −1757 to −1613), B (−1612 to −1489), 
and D (−132 to −56). The C1 (bp −1488 to – 1256) segment contains sequences required for 
astrocytes to express in certain brain regions, and for suppression of GFAP expression in neurons. 
The 681 bp gfaABC1D promoter drives expression of transgenes with the same developmental, 
spatial, and cell specificity properties as the 2.2 kb gfa2 promoter (Lee et al., 2008). (adapted from 
Yeo et al., 2013). 
 
Expression system. rAAVs are the most commonly used vectors for gene delivery and 
expression in the CNS. They contain a single stranded DNA and their serotype is important 
for targeting specific cell types. AAV hybrid serotypes or pseudo-serotypes have been 
created by viral engineering, and are constructed with integrated genome containing (cis-
acting) inverted terminal repeats (ITR) derived from AAV2 and capsid genes of other 
serotypes (Figure 4.3). This strategy increased viral cell specificity and transduction (Choi 
et al., 2005). In particular, AAV8-based vectors show selective expression in astrocytes of 
the spinal cord, hippocampus, striatum and substantia nigra of adult rats and were 
previously used to drive transgene expression of the human GFAP promoter (Lawlor et al., 
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2009; Li et al., 2014). An important limitation is the restrained construct size that can be 
accommodated in the rAAV genome (about 4.7-5.0 kb).  
Figure 4.3. Structure and characteristics of recombinant adeno-associated viral vectors (rAAVs).  
The gene of interest is inserted between the inverted terminal repeats (ITRs) that contain cis-
elements required for replication and packaging resulting in a vector genome of approximately 4.7 
kb flanked by the viral ITRs. The late SV40 poly A sequence (Simian virus 40 PolyA, also called PolyA) 
possesses the activity of transcription termination and can add PolyA tail to mRNA (adapted from 
Cucchiarini et al., 2015). 
 
In this study we focused on the generation of rAAV expressing reporter genes (GFP or 
luciferase) under the control of either the IL-1β or the GFAP promoters. In order to identify 
the minimal IL-1β promoter fragment with full activity to be accommodated into the AAV 
vector backbone, we first analysed the activity of various promoter fragments in Raw 246.7 
cells exposed to lipopolysaccharide (LPS). For GFAP, we choose the well characterised 
681bp promoter fragment suitable for rAAV (Lee et al., 2008). Both promoters were tested 
in vivo in a mouse model of status epilepticus (SE)-induced epileptogenesis, and their cell-
specific expression was analysed by post-mortem immunohistochemistry and compared 
with the expression of either IL-1β or GFAP proteins. Finally, we studied the induction of 
the GFAP promoter by in vivo bioluminescence imaging at different time points after SE. 
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4.2 SPECIFIC MATERIALS AND METHODS 
Cloning 
Human IL-1β promoter/enhancer fragment and several shorter promoter fragments were 
cloned as previously described in the General materials and methods, Section 3.1.1. Briefly, 
the human IL-1β promoter/enhancer fragment H-IL-1β(-3757/+570), 4327bp, was cloned 
by polymerase chain reaction (PCR) using human genomic DNA as template. Several shorter 
promoter fragments [H-IL-1β(-3757/+12), 3769bp; H-IL-1β(-3132/+570), 3702bp; H-IL-1β(-
3132/+1), 3131bp; H-IL-1β(-2987/+570), 3557bp; H-IL-1β(-2987/+1), 2987bp] were 
subsequently cloned using the H-IL-1β(-3757/+570) sequence as template with the 
following primer sets (Table 4.1; Figure 4.4). Construction of the AAV-GFAP-LUC-WPRE 
plasmid was done as previously described in the General materials and methods, Section 
3.1.2.  
Cell cultures  
Raw 264.7 cells were transfected as described in the General materials and methods, 
Section 3.2.1 and luciferase assays were performed as described in Section 3.2.2. For IL-1β 
promoter induction, Escherichia coli 055:B5 LPS (Sigma, St. Louis, MO, USA) was suspended 
in sterile water and added to the cell culture to obtain the desired concentrations. 
Luciferase assays were performed in four different experiments where Raw 264.7 cells 
were treated 24 h after transfection with LPS (100 ng/ml; Sigma) for 18 h prior to harvesting 
(Figure 4.4).  
Adeno-associated viral vectors 
rAAV8 were produced and purified are reported in the General materials and methods, 
Sections 3.3.1 and 3.3.2.  
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Mouse model of epileptogenesis 
SE was induced by intracortical injection of KA as described in Section 3.9.2 of General 
materials and methods. Mice (n=28) were not implanted with electrodes to minimise tissue 
damage and do not interfere with the bioluminescence signal, thus SE was visually 
monitored for behavioural motor seizures occurrence. Mice injected in the cortex with PBS 
served as controls for immunohistochemistry (n=3), cell sorting (n=5) and bioluminescence 
imaging (n=6). 
Immunohistochemistry 
A group of mice (n=4) was injected with KA to measure IL-1β promoter induction 24 h post-
SE (3.9.2 of General materials and methods). Mice were injected 2 weeks before SE 
induction with AAV8-H-IL-1β(-2987/+570)-GFP and GFP expression was assessed by 
immunohistochemistry (n=4; Figure 4.5; General materials and methods, sections 3.4 and 
3.10.2). Histological evaluation of IL-1β protein levels and its co-localization with GFP and 
GFAP was done in a separate group of mice (n=3) 24 h after SE induction (Figure 4.6; 
General materials and methods, sections 3.4, 3.10.1, 3.10.2 and 3.10.4). AAV8-GFAP-GFP-
WPRE tissue spread and cell specificity were evaluated by immunohistochemistry in 3 mice 
injected with the rAAV and sacrificed 2 weeks later (Figure 4.8 and 4.9; see sections 3.4 and 
3.10.1 from General materials and methods). GFP staining was strong enough to be 
detected directly by confocal microscopy withouth using a secondary antibody.  
Cell sorting 
rAAV1/2-synI-dtTomato that is specifically expressed by neurons was kindly provided by 
Dr. A. Becker. Five mice were injected in the hippocampus with rAAV1/2-synI-dtTomato 2 
weeks before performing neuronal cell sorting (Figure 4.7; sections 3.4 and 3.5 of General 
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materials and methods). A laser (561 nm) was used to excite tdTomato and a 582/15 filter 
was used to detect the tdTomato signal. 
RT-qPCR analysis 
Five animals injected with KA were sacrificed 24 h later and their hippocampi were rapidly 
removed (3.9.2 of General materials and methods). Dissected hippocampi (as well as sorted 
neurons, see above) were used to measure IL-1β mRNA levels as described in section 3.6.1 
of General materials and methods (Figure 4.7). β-actin was used as a reference gene to 
normalize IL-1β mRNA levels. 
In vivo bioluminescence imaging 
Mice (n=6-11/group) were injected with AAV8-GFAP-LUC (section 3.4 of General materials 
and methods). SE was induced 2 weeks later as described in section 3.9.2 of General 
materials and methods. Mice were behaviourally monitored by two investigators before SE 
induction and then at 24 h and 3 days after KA injection using in vivo bioluminescence 
imaging (Figure 4.10; General materials and methods, section 3.11). 
 
4.3 RESULTS 
4.3.1 In vitro characterization of IL-1β promoter fragments  
To identify the minimal H-IL-1β promoter region eligible for in vivo bioluminescence 
imaging, we cloned six H-IL-1β promoter fragments (Table 4.1; Figure 4.4) and we tested 
them for their luciferase activity in RAW 264.7 cells. The three fragments harbouring the 
570 nucleotides downstream of the transcription start site (TSS) (-3757/+570, -3132/+570 
and -2987/+570) showed stronger basal expression compared to the fragments lacking 
these downstream nucleotides (-3757/+12, -3132/+1 and -2987/+1) (Figure 4.4B). This 
indicates that the 570 nucleotides downstream of the TSS are necessary for efficient basal 
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H-IL-1β promoter activity. Next, we tested if stimulation with the pro-inflammatory agent 
LPS (100 ng/ml for 18 h) activates the various promoter fragments transfected in RAW 
264.7 by analysing their luciferase activity. We found that all fragments showed a 
significant activation after stimulation with LPS, with the -3757/+570, 3757/+12 and -
3132/+570 fragments having the strongest activation (12-fold increase, p<0.01). Among 
the shorter fragments, the one including the -2987/+570 region of the promoter showed a  
significant activation up to 8-fold (p<0.01) compared to the basal activity (Figure 4.4C). 
 
Table 4.1. Primers used for H-IL-1β promoter cloning and the respective restriction enzymes. 
Fragment PCR primers 
Restriction 
enzymes 
H-IL-1β(-3757/+570) 
For:5´-GCGAGATCTTCTAGACCAGGGAGGAGAATGGAATG-3´ 
BglII/ EcoRI 
Rev:5´-GCGGAATTCAGACACCTGTGTAAAAAGGAGAAAATGAGTG-3´ 
H-IL-1β(-3757/+12) 
For:5´-GCGAGATCTTCTAGACCAGGGAGGAGAATGGAATG-3´ 
BglII/ EcoRI 
Rev:5´- GCGGAATTCTCGAAGAGGTTTGGTATCTGCCAGTTTC-3´ 
H-IL-1β(-3132/+570) 
For:5´-GCGAGATCTCAGCTGAGAAAGGCTTTAGTGACTCAA-3´ 
BglII/ EcoRI 
Rev:5´-GCGGAATTCAGACACCTGTGTAAAAAGGAGAAAATGAGTG-3´ 
H-IL-1β(-3132/+1) 
For:5´-GCGAGATCTCAGCTGAGAAAGGCTTTAGTGACTCAA-3´ 
BglII/ EcoRI 
Rev:5´-GCGGAATTCTGTTTTTATGGCTTTCAAAAGCAGAAGTAGGAG-3´ 
H-IL-1β(-2987/+570) 
For:5´-GCGAGATCTTCCCTTAGTGCCAACTATGTTTATAGCG-3´ 
BglII/ EcoRI 
Rev:5´-GCGGAATTCAGACACCTGTGTAAAAAGGAGAAAATGAGTG-3´ 
H-IL-1β(-2987/+1) 
For:5´-GCGAGATCTTCCCTTAGTGCCAACTATGTTTATAGCG-3´ 
BglII/ EcoRI 
Rev:5´-GCGGAATTCTGTTTTTATGGCTTTCAAAAGCAGAAGTAGGAG-3´ 
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Figure 4.4. Schematic representation of the human IL-1β promoter fragments and the 
corresponding luciferase activity. (A) The full-length H-IL-1β promoter (upper fragment: -
3757/+570) and five deletion fragments based on Shirakawa et al., 1993 and the Ensembl Genome 
Browser. Restriction enzyme sites are numbered relative to the transcription start site (TSS)(+1). (B, 
C) Luciferase activity in RAW 264.7 cells in basal conditions (B) and 18 h after stimulation with 100 
ng/ml LPS (C). Data (mean ± SEM for duplicate samples from four independent experiments) were 
calculated as fold induction relative to the respective basal expression. *p<0.05; **p<0.01 by one-
way ANOVA followed by Tukey’s and Dunnett’s multiple comparison tests. 
 
4.3.2 In vivo characterization of IL-1β promoter fragments  
Next, we examined if the H-IL-1β(-2987/+570) promoter fragment, showing high basal 
activity and strong LPS-induced activation was suitable for in vivo monitoring of the IL-1β 
gene transcriptional activation. We first developed a rAAV8 vector containing GFP under 
control of the H-IL-1β(-2987/+570) promoter fragment. In order to induce a detectable 
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promoter activation, we induced SE in mice (n=4) injected 2 weeks before with the AAV8-
H-IL-1β(-2987/+570)-GFP viral particles. Indeed, 24 h after KA injection, strong GFP 
fluorescence signal was observed in the hippocampal region (Figure 4.5). However, a 
prominent activation of the promoter fragment was observed in neurons (Figure 4.5, 
panels a-c) whereas astrocytes accounted only for about 15% of the total cells expressing 
GFP (Figure 4.5A, panels d-f; Figure 4.5B).  
Figure 4.5. Ectopic neuronal induction of H-IL-1β promoter fragment in neurons after KA-induced 
status epilepticus (SE). (A) Representative photomicrographs of AAV8-H-IL-1β(-2987/+570)-GFP 
transduction in neurons but not in astrocytes 2 weeks after intrahippocampal vector injection. 
Mouse brains were analyzed 24 h after KA-induced SE. GC, granule cells, h, hilus. Scale bar, 100 μm. 
(B) Percent of cell type (mean ± SEM, n=4 mice) expressing the GFP reporter gene under control of 
the H-IL-1β(-2987/+570) promoter fragment. *p<0.05 compared to astrocytes by Mann-Whitney. 
 
Subsequent immunohistochemistry in the hippocampus of SE-exposed and AAV8-H-IL-1β(-
2987/+570)-GFP-injected mice (n=3) demonstrated that the GFP reporter gene did not co-
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localize with the endogenous IL-1β expression (Figure 4.6A) since endogenous IL-1β was 
expressed in activated GFAP-positive astrocytes (Figure 4.6B).  
 
 
 
 
 
 
 
 
 
Figure 4.6. H-IL-1β promoter activation and endogenous IL-1β protein expression after KA-
induced SE. (A) Representative images of IL-1β protein expression in the hippocampus 2 weeks after 
injection of AAV8-H-IL-1β(-2987/+570)-GFP in mice (n=3) killed 24 h after KA-induced SE. The GFP 
signal does not co-localize with endogenous IL-1β expression. (B) Localization of endogenous IL-1β 
protein in GFAP-positive astrocytes in mice killed 24 h after KA. GC, granule cells, h, hilus. Scale bar 
50μm. 
 
Since this result was in contrast with the astrocytic induction of this cytokine after SE, we 
further investigated if the endogenous IL-1β promoter was activated in neurons after SE. 
To this end, we injected mice (n=5) with rAAV1/2-synI-dtTomato which labels neurons and 
2 weeks later mice were exposed to SE and killed 24 h later. RT-qPCR analysis on total 
hippocampal homogenates revealed a massive (up to 500-fold, p<0.05) of IL-1β mRNA 
induction after SE (Figure 4.7A). Subsequent RT-qPCR analysis on Tomato-expressing FACS-
sorted hippocampal neurons showed that IL-1β mRNA was not up-regulated in neurons 
(Figure 4.7B). 
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Figure 4.7. Endogenous IL-1β expression after KA-induced SE. IL-1β mRNA expression levels 
measured by RT-qPCR in hippocampal homogenates (A) and in FACS-sorted neurons (B) from mice 
killed 24 h after KA-induced SE. Data (mean ± SEM, n=5 mice each group) represent the fold-increase 
in mRNA expression levels relative to basal expression measured in vehicle-injected mice (SHAM). 
Bargrams report measures in the hippocampi ipsilateral and contralateral to the injected cortex. 
*p<0.05 compared to SHAM; #p<0.05 compared to ipsilateral by one-way ANOVA followed by 
Tukey’s multiple comparison tests. 
 
4.3.3 In vivo characterization of GFAP promoter  
We evaluated the cell specificity and transduction efficiency of the AAV8-GFAP-GFP-WPRE 
vector containing the 681bp GFAP promoter fragment injected in the hippocampus of naive 
mice (n=3). Mice were sacrificed 2 weeks after the injection and the viral spread (Figure 
4.8) and cellular expression (Figure 4.9) of the GFP reported gene were determined. The 
anteroposterior spread of the virus around the injection sites was ~ 3 mm (from -1.25 mm 
to -3.98 mm relative to bregma) while the medio-lateral spread was ~ 1 mm. The signal was 
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mainly restricted to the dentate gyrus including the molecular and polymorphic layers as 
well as in the stratum radiatum of the CA3 region (Figure 4.8). Notably, the GFP signal co-
localized with GFAP-positive astrocytes (Figure 4.9, panels a-c) but not with NeuN-positive 
neurons (Figure 4.9, panels d-f). 
Figure 4.8. Antero-posterior spread of the GFP reporter gene in the hippocampus of rAAV8-GFAP-
GFP-WPRE-injected mice. Representative fluorescence pictures depicting the hippocampal spread 
( 3 mm) of the GFP reporter gene under the control of the GFAP promoter fragment (panels a-h). 
The GFP signal was mainly localised in the molecular and polymorphic layers of the dentate gyrus 
and stratum radiatum of the CA3 region. Slices close to the injection site are depicted by asterisks 
(c1, e1). Nissl-stained photomicrographs (panels a1-h1) depict the levels of antero-posterior slice 
analysis (Allen Mouse Brain Atlas; http://mouse.brain-map.org). Scale bar 100 μm. 
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Figure 4.9. Induction of the GFAP promoter fragment in astrocytes after KA-induced SE. 
Representative photomicrographs of rAAV8-GFAP-GFP-WPRE-transduced mice (n=3) 24 h after SE. 
GFP reporter gene transduction was observed in astrocytes (a-c) but not in neurons (d-f). GC, granule 
cells, h, hilus. Scale bar, 100 μm. 
 
4.3.4 In vivo bioluminescence imaging of GFAP promoter 
To determine whether the 681bp GFAP promoter fragment could be used for in vivo 
bioluminescence imaging, rAAV8 vector particles harbouring a luciferase gene under 
control of the GFAP promoter fragment were bilaterally infused in the mouse 
hippocampus. Two weeks later, mice (n=6-11) were injected with KA in order to evoke SE. 
Twenty-four hours after SE induction, we detected a 3-fold (p<0.05) increase in 
bioluminescence signal bilaterally in the hippocampus compared to the respective basal 
signal in the same mice (Figure 4.10A, B). A further up-regulation (up to 7-fold, p<0.01) was 
observed 3 days after KA injection (Figure 4.10A, B). 
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Figure 4.10. In vivo imaging of rAAV8-GFAP-LUC-injected mice. Mice were monitored 
longitudinally 24 h and 3 days after KA-induced SE. (A) Data (mean ± SEM, n=6-11 mice) represent 
the fold-induction of bioluminescence activity in the hippocampus relative to the respective basal 
signal in each group. Basal signal did not differ inPBS-injected mice. *p<0.05, **p<0.01 compared 
to the respective basal signal by one-way ANOVA followed by Tukey’s multiple comparison tests. 
Ipsi, ipsilateral to KA injection, Contra, contralateral to KA injection referred to the injected cortex. 
(B) Representative images of mice monitored before KA injection and 24 h and 3 days later. 
 
4.4 DISCUSSION 
Astrocytic activation and induction of IL-1β are two processes which occur concomitantly 
during epileptogenesis (Maroso et al., 2011b; Vezzani et al., 2011b). So far, these 
phenomena have been investigated post-mortem in cross-sectional studies in animal 
models and they have been validated in epileptic foci surgically resected from 
pharmacoresistant human epilepsies (Aronica and Crino, 2011; Vezzani et al., 2011b). In 
vivo bioluminescence imaging is a powerful tool for performing longitudinal studies in 
animals since it allows to follow up the dynamics of these changes during epileptogenesis. 
Moreover, this approach permits to correlate the bioluminescence changes with disease 
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outcomes, and potentially with the therapeutic response to drugs. To this end, we 
developed an in vivo approach for long-term monitoring of the astrocyte activation and the 
related inflammatory response to an epileptogenic stimulus. 
We provide evidence that the IL-1β promoter sequence upstream of the start ATG contains 
important elements for promoter activation in Raw 246.7 cells following inflammatory 
stimuli. Indeed, our in vitro results showed that the three fragments harbouring the 570 
nucleotides downstream the TSS showed sufficient basal activity and were significantly 
activated by LPS. This may be due to the presence of binding sites for transcriptional factors 
that control IL-1β gene induction by LPS in this cell line. However, we observed that the 
3557 kb promoter fragment, which responds to LPS stimulation in vitro, does not reflect 
the endogenous promoter cell-specific expression following SE since the promoter 
expression was observed in hippocampal neurons rather than in astrocytes. Likely, this 
promoter fragment lacks some regulatory elements that are required for the cell-specific 
IL-1β expression upon its transcriptional gene activation and that are instrumental for 
repressing IL-1β gene activation in neurons in vivo.  
We conclude that for in vivo imaging of the IL-1β promoter, the full-length IL-1β should be 
used instead of smaller core-promoter fragments. However, due to the limited packaging 
capacity of rAAVs (maximum of 5.000 basepairs), we could not analyze the full-length IL-1β 
promoter in vivo (Dong et al., 1996; Hermonat et al., 1997). Other types of vectors should 
be considered, such as the lentiviral systems hosting larger sequences of foreign DNA. The 
use of these systems, however, requires a higher level of safety procedures; moreover, 
these vectors are mostly neurotropic although modifications of the capsid serotype may 
help to improve transfection in other cells types (Fassler et al., 2013). The development of 
transgenic mice harboring the luciferase gene under the control of the full H-IL-1β 
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promoter provides another possibility to study the whole body induction of this cytokine 
(Li et al., 2008). 
As an alternative strategy, we studied the GFAP promoter fragment since it has been 
extensively characterized before (Lee et al., 2008). This fragment exhibits high specificity 
for astrocytes and shows prominent activation after SE, as shown by in vivo imaging. We 
used rAAV8 vectors containing the GFAP promoter fragment for delivering the transgene 
expressing luciferase into the hippocampus. Using this approach, we detected a significant 
increase in bioluminescence in astrocytes that expressed IL-1β at representative time 
points of epileptogenesis.  
In conclusion, we developed an efficient in vivo imaging tool for monitoring activated 
astrocytes expressing an inflammatory phenotype after SE. This tool represents a powerful 
approach to monitor the dynamics of glial cell activation during epileptogenesis as well as 
after various acute and chronic CNS injuries associated with an inflammatory component. 
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CHAPTER 5 - CHARACTERIZATION OF ASTROCYTE ACTIVATION 
DURING EPILEPTOGENESIS 
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5.1 INTRODUCTION 
Astrocyte activation in epilepsy importantly contributes to neuroinflammation, neuronal 
network hyperexcitability and hypersynchrony thus promoting the generation and 
recurrence of seizures (Devinsky et al., 2013). Similar to microglia astrocytes have been 
identified to assume either a pro-inflammatory phenotype named A1 or an A2 anti-
inflammatory phenotype (Baldwin and Eroglu, 2017; Liddelow et al., 2017; Zamanian et al., 
2012). Reactive A1-type astrocytes release toxic compounds and pro-inflammatory 
molecules which may lead to tissue damage and neuronal cell death (Devinsky et al., 2013; 
Liddelow et al., 2017). On the other hand, A2 astrocytes upregulate neurotrophic factors 
which promote neuronal survival and synapse repair, thus suggesting a ‘’helpful’’ and 
homeostatic functions (Zamanian et al., 2012). These two types of astrocyte can be 
distinguished based on specific molecular traits. Pentraxin-3 (PTX3), for example, is an anti-
inflammatory protein expressed by A2-type astrocytes and is neuroprotective (Ravizza et 
al., 2001). TNF-α instead is upregulated in activated A1-type astroglia and contributes to 
increase neuronal excitability (Balosso et al., 2013). Similarly, to TNF-α other molecules 
potentially neurotoxic are expressed by A1-type astrocytes such as HMGB1 (Maroso et al., 
2010; Pedrazzi et al., 2007). Collectively, this evidence indicates the importance of 
monitoring astrocytic cell activation and determine their phenotype during epileptogenesis 
in order to understand when and how these cells contribute to epileptogenesis. 
In this study, we investigated the dynamics of phenotypic changes in astrocytes during 
epileptogenesis by combining immunohistochemistry, western blot and in vivo 
bioluminescence imaging approaches.  
Moreover, we also analysed whether drugs that have anti-epileptogenesis effects, as 
previously demonstrated in SE models, such as fingolimod (FTY720), modulate astrocyte 
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activation. We choose this drug since its inhibitory effects on inflammatory A1-type 
astrocytes appear to mediate the therapeutic action in animal models of epilepsy (Gao et 
al., 2012; Pitsch et al., 2018).  
FTY720 is a sphingosine-1-phosphate (S1P) analog that is phosphorylated by sphingosine 
kinase 2 to FTY720-P, the active metabolite and a ligand for S1P 1, 3, 4 and 5 receptors 
receptors (S1PRs) (Spiegel and Milstien, 2011). Microglia and astrocytes both express S1PRs 
mRNA. Loss of S1P1 through functional antagonism by FTY720-P is considered to be the 
primary mechanism of action of the drug in astrocytes (Choi et al., 2011). FTY720 removes 
S1PRs from the cell surface through irreversible internalisation, vesicular storage and 
degradation (Choi et al., 2011; Oo et al., 2007). This accounts for the amelioration of 
experimental autoimmune encephalomyelitis (EAE) by both genetic S1P1 deletion and 
exposure to FTY720 (Choi et al., 2011; Mandala et al., 2002). Interestingly, after the S1P 
receptors are internalised and plasma membrane-dependent signaling responses to 
FTY720 or S1P are reduced, the signaling activated by internalised S1P1Rs persists for hours 
(Mullershausen et al., 2009; Wu et al., 2013).  
 FTY720 was found to reduce astrocytic activation and the expression of pro-inflammatory 
cytokines and to mediate an increase in anti-inflammatory cytokines and neuroprotective 
mediators (Choi et al., 2011; Hoffmann et al., 2015; Rothhammer et al., 2017). In epilepsy 
models, FTY720 reduced astroglia activation and TNF-α expression, and decreased the 
frequency and duration of seizures in pilocarpine- and kainate-induced SE in rodents (Gao 
et al., 2012; Pitsch et al., 2018). In our study, we explored whether FTY720 modulates the 
extent of activation and the A1 vs A2 phenotype of astrocytes during epileptogenesis using 
in vivo bioluminescence imaging of astrocytes, post-mortem immunohistochemistry and 
western blot analyses in a mouse model of epilepsy. 
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5.2 SPECIFIC MATERIALS AND METHODS 
Induction of status epilepticus (SE) 
Kainic acid (0.3 μg in 0.2 μl) was unilaterally injected in the basolateral amygdala to induce 
SE (Section 3.9.1 of General materials and methods). Control mice were injected with saline 
under the same conditions but were not exposed to SE. Mice were not implanted with 
electrodes in order not to interfere with bioluminescence signal. Thus, SE was monitored 
visually by two independent investigators who observed the occurrence of behavioural 
motor seizures for at least 3 hours from KA injection, a condition required for developing 
spontaneous seizures after 7 days on average. Mice injected with KA but displaying SE 
shorter then 3 h were excluded from further analysis. 
Immunohistochemistry 
Mice (n= 5 each group) were exposed to SE and sacrificed at 2 h, 24 h, 3 and 7 days later by 
transcardial perfusion and their brains were collected for immunohistochemical evaluation 
of astrocytes (Figures 5.2 and 5.3), microglia (Figure 5.5) and expression of HMGB1, TNF-α 
and PTX3 (Figures 5.6, 5.7 and 5.8; section 3.10 of General materials and methods for 
details). The cell type expressing HMGB1, TNF-α and PTX3 was identified by co-localization 
with GFAP, CD11b or NeuN (section 3.10.4 of General materials and methods). 
In vivo bioluminescence imaging 
Mice (n=9-12) were injected with AAV8-GFAP-LUC (section 3.4 of General materials and 
methods) 2 weeks before SE induction (Section 3.9.1 of General materials and methods). 
Mice injected with saline but not exposed to SE served as controls. Mice were monitored 
using in vivo bioluminescence imaging before SE induction for baseline measurement, then 
longitudinally at 2 h, 24 h, 3 and 7 days post-SE (Figure 5.4; General materials and methods, 
section 3.11). 
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Pharmacological treatment 
Mice were injected with AAV8-GFAP-LUC 2 weeks before being exposed to SE. One hour 
after SE onset mice were randomly assigned to treatment or saline groups (n=6-12 each 
group).  FTY720 (6 mg/kg, i.p.) was injected according to a treatment schedule previously 
shown to exert anti-inflammatory and anti-epileptogenic effects: i.e., for seven consecutive 
days starting 1 h after SE onset (Figure 5.1). Mice were monitored by in vivo 
bioluminescence analysis and at the end of the last imaging session, they were sacrificed 
for post-mortem immunohistochemistry (Figures 5.9, 5.10, 5.11, 5.12 and 5.13; section 3.10 
of General materials and methods). One additional group of mice was treated with FTY720 
or saline (n=5 each group) and killed after the last imaging session (7 days post-SE). The 
hippocampi ipsilateral to the injected amygdala were dissected out and used for Western 
blot analysis of GFAP, GLT-1 and Kir4.1 (Figure 5.14; Section 3.6.2 of General materials and 
methods). 
 
 
 
 
Figure 5.1. Experimental design in SE-exposed mice treated with FTY720 and monitored by in vivo 
bioluminescence imaging (IVIS). Baseline in vivo bioluminescence imaging measurement was done 
in each mouse 1 day before SE induction (baseline) and imaging sessions were repeated in the same 
animal at 2 h, 24 h, 3 and 7 days post-SE. Mice were sacrificed at the end of the experiment (7 days 
after SE) for either immunohistochemical or western blot analysis of GFAP. Data related to this 
protocol are reported in Figures 5.9, 5.10, 5.11, 5.12, 5.13 and 5.14). 
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Western blot  
At the end of the last bioluminescence imaging session (7 days post-SE), mice exposed to 
SE and treated with saline or FTY720 and control mice (not exposed to SE) (n=5/group) 
were perfused via the ascending aorta with 50 mM cold PBS, pH 7.4 for 1 min, then the 
hippocampi ipsilateral to the injected amygdala were dissected and homogenised for 
immunoblotting (Figure 5.14; section 3.6.2 of General materials and methods). Anti-mouse 
GFAP (1:15000), anti-rabbit GLT-1 (1:1000) and anti-rabbit Kir4.1 (1:2000) were used and 
immunoreactivity was visualised with ECL Luminata solution (Luminata forte, Western HRP 
substrate, Millipore, MA, USA) using peroxydase-conjugated anti-mouse IgG or anti-rabbit 
IgG (1:10000; Sigma, St Louis, MO, USA) as secondary antibodies (section 3.6.2 of General 
materials and methods). 
 
5.3 RESULTS 
5.3.1 Astrocyte activation 
In order to characterise the dynamics and extent of astrocyte activation during 
epileptogenesis, we assessed GFAP immunostaining in hippocampal slices of SE-exposed 
mice and their saline-injected controls (n=5 each group). In the hippocampus ispilateral to 
KA-injected amygdala, the GFAP-positive area was increased up to 2-fold (p<0.01) between 
2 h and 7 days post-SE (Figure 5.2; p<0.01) compared to time-matched controls. A delayed 
increase was observed 3 and 7 days post-SE in the homotypic contralateral area (p<0.05 
and p<0.01). 
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Figure 5.2. GFAP immunohistochemical signal in the hippocampus during epileptogenesis. (A) 
GFAP-positive area in ipsilateral and contralateral dorsal hippocampus of mice sacrificed at 2 h, 24 
h, 3 and 7 days post-SE. (B) Representative photomicrographs of corresponding hippocampal slices 
(CA1 area) stained for GFAP. Data (mean ± SEM, n=5 mice each group) *p<0.05; **p<0.01 compared 
to saline; #p<0.05; ##p<0.01 compared to 2 h and °p<0.05; °°p<0.01 compared to 24 h by one-way 
ANOVA followed by Tukey’s multiple comparison tests. sr, stratum radiatum; slm, stratum 
lacunosum-moleculare. Scale bar, 50 μm. 
 
122 
 
S100β-labeled astrocytes (high percentage of co-localization with GFAP) were also 
increased 3 and 7 days post-SE as shown by counting the number of postive cells and the 
area occupied by the specific signal (p<0.01) in both the ipsilateral and contralateral 
hippocampi (Figure 5.3). 
Figure 5.3. S100β-positive astrocytes in the hippocampus during epileptogenesis. (A) S100β-
positive area and (B) number of cells in the hippocampus of mice sacrificed at 2 h, 24 h, 3 days and 
7 days post-SE. (C) Representative photomicrographs of corresponding hippocampal slices (CA1 
area). Cells expressing S100β (green) were identified as GFAP-positive astrocytes (red). Co-
localization signal is depicted in yellow (insert).  Data (mean ± SEM, n=5 mice each group) **p<0.01 
compared to saline; ##p<0.01 compared to 2 h and °°p<0.001 compared to 24 h by one-way ANOVA 
followed by Tukey’s multiple comparison tests. sr, stratum radiatum; slm, stratum lacunosum-
moleculare. Scale bar, 50 μm. 
 
Next, in vivo bioluminescence imaging was used in order to monitor longitudinally the 
astrocytic cell activation at the same time points analysed by immunohistochemistry. The 
bioluminescence signal was stable over time in the control group (saline-injected mice not 
exposed to SE; n=9). In mice exposed to SE, the GFAP promoter was significantly induced 
during epileptogenesis (n=12) already 2 h post-SE (1.8-fold, p<0.05) and was further 
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increased at 24 h (4-fold, p<0.01) then declining at 3 days (2.8-fold, p<0.01) and returning 
to basal level at 7 days post-SE (Figure 5.4).   
 
 
 
 
 
Figure 5.4. In vivo bioluminescence imaging of activated astrocytes in the hippocampus during 
the epileptogenesis. Mice were injected with AAV8-GFAP-LUC and monitored longitudinally 2 h, 24 
h, 3 and 7 days after SE onset. Data (mean ± SEM, n=9-12 mice) represent fold-increase of reporter 
gene relative to the respective basal signal (before SE) in each group. Basal signal did not differ from 
control mice (saline-injected mice not exposed to SE). *p<0.05; **p<0.01 compared to respective 
basal signal; ##p<0.01 compared to 2 h; °°p<0.01 compared to 24 h; $$p<0.01 compared to 3 d by 
one-way ANOVA followed by Tukey’s multiple comparison tests. 
 
5.3.2 Microglia activation 
We also evaluated the microglia activation during epileptogenesis in order to compare with 
the astrocytic cell response. Microglia was activated as astrocytes from 2 h post-SE until 7 
days (18-fold on average, p<0.01) in the ipsilateral hippocampus (Figure 5.5), and a similar 
pattern of activation, although less pronounced, was detected in the contralateral side. 
 
 
 
 
 
124 
 
Figure 5.5. CD11b-positive cell activation in the hippocampus during epileptogenesis. (A) CD11b-
positive area in the ipsilateral and contralateral dorsal hippocampus of mice sacrificed at 2 h, 24 h, 
3 days and 7 days post-SE. (B) Representative photomicrographs of corresponding hippocampal 
slices stained for CD11b. Data (mean ± SEM, n=5 mice each group) **p<0.01 compared to saline; 
#p<0.05; ##p<0.01 compared to 2 h and °p<0.05 compared to 24 h by one-way ANOVA followed by 
Tukey’s multiple comparison tests. sr, stratum radiatum; slm, stratum lacunosum-moleculare. Scale 
bar, 50 μm. 
 
5.3.3 HMGB1, TNF-α and PTX3 expression in glial cells 
Next, we characterised the phenotype of the astrocytes during epileptogenesis to 
determine their A1- vs A2- phenotype. Thus, we stained hippocampal slices from the same 
mice as above (n=5) for detecting proinflammatory, ictogenic and neurotoxic molecules 
such as HMGB1 and TNF-α (markers of A1 reactive astrocytes) and PTX3, a marker of A2 
anti-inflammatory and neuroprotective astrocytes. 
We found an increased number of HMGB1-positive cells 3 and 7 days post-SE but not at 
earlier time points in both hippocampi. This signal was localized in the nuclei of neurons 
and astrocytes but not in microglia (Figure 5.6). 
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Figure 5.6. HMGB1 expression in hippocampal astrocytes and neurons during epileptogenesis. (A) 
HMGB1-positive cells in the ipsilateral and contralateral dorsal hippocampus of mice sacrificed at 2 
h, 24 h, 3 days and 7 days post-SE. (B) Photomicrographs of corresponding hippocampal slices 
stained for HMGB1. (C) HMGB1 nuclear signal (green) co-localises with the astrocytic marker GFAP 
(red) and the neuronal marker NeuN (red) but not with the microglial marker CD11b (red). Co-
localization signal is depicted in yellow. DAPI-positive nuclei are shown in blue. Data (mean ± SEM, 
n=5 mice each group) **p<0.01 compared to saline; ##p<0.01 compared to 2 h by one-way ANOVA 
followed by Tukey’s multiple comparison tests. sr, stratum radiatum; slm, stratum lacunosum-
moleculare. Scale bar, 50 μm. 
 
While TNF-α staining was virtually absent in control slices, the TNF-α-positive area 
increased from 24 h (8330 ± 833 μm2) until 7 days (53805 ± 8195 μm2) post-SE (Figure 5.7). 
TNF-α-positive cells were detected in both hippocampi from 24 h (1245 ± 167, ipsilateral 
side) until 3-7 days post-SE (1764 ± 310). 
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Figure 5.7. TNF-α expression in hippocampal astrocytes during epileptogenesis. (A) Area occupied 
by the TNF-α signal and (B) the number of cells in the ipsilateral and contralateral dorsal 
hippocampus of mice sacrificed at 2 h, 24 h, 3 days and 7 days post-SE. (C) Photomicrographs of 
corresponding hippocampal slices depicting TNF-α-positive cells. (D) TNF-α (green) co-localises with 
the astrocytic marker GFAP (red) but not with microglia cells marked by CD11b (red). Co-localization 
signal is depicted in yellow. Data (mean ± SEM, n=5 mice each group) °°p<0.01 compared to 24 h by 
one-way ANOVA followed by Tukey’s multiple comparison tests. sr, stratum radiatum; slm, stratum 
lacunosum-moleculare. Scale bar, 50 μm. 
 
PTX3 was not detected in control slices until 24 h post-SE (Figure 5.8). However, 3 days 
post-SE, a strong signal was detected in both hippocampi (183212 ± 55095 μm2, ipsilateral 
side) and this signal further increased at 7 days post-SE (698829 ± 64316 μm2, ipsilateral 
hippocampus). PTX3 was co-expressed with the astrocytic marker GFAP at all time points 
(Figure 5.8, insert).   
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Figure 5.8. PTX3 expression in hippocampal astrocytes during epileptogenesis. (A) Area occupied 
by the PTX3 signal and (B) PTX3 expression in cells with glial morphology at the different time points 
during epileptogenesis. Cells expressing PTX3 (green) were identified as GFAP-positive astrocytes 
(red). Co-localization signal is depicted in yellow (insert). Data (mean ± SEM, n=5 mice each group) 
**p<0.01 compared to 3 days by Mann-Whitney. sr, stratum radiatum; slm, stratum lacunosum-
moleculare. Scale bar, 50 μm. 
 
5.3.4 Effect of FTY72 treatment on astrocyte activation 
The effect of FTY720 (6 mg/kg i.p., 7-day treatment; protocol in Figure 5.1) on astrocyte 
activation during epileptogenesis was assessed first by in vivo bioluminescence imaging 
reflecting GFAP promoter activation (n=9-12). FTY720-treated mice showed a significantly 
higher increase in GFAP promoter activity from 24 h until 7 days post-SE (p<0.01) compared 
to SE-exposed mice injected with saline. At 2 h the promoter activity in FTY720-treated 
mice did not differ significantly from saline controls (p=0.08) whereas it was significantly 
enhanced in SE-exposed mice (p<0.05) (Figure 5.9). 
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Figure 5.9. FTY720 effect on GFAP promoter activity in the hippocampus during epileptogenesis 
assessed by in vivo bioluminescence imaging. AAV8-GFAP-LUC-injected mice were monitored 
longitudinally 2 h, 24 h, and 7 days after SE onset and treated either with saline (KA) or FTY720 
(KA+FTY; 6 mg/kg; i.p. for 7 days). Control mice (n=9) were injected with saline but not exposed to 
SE. Data (mean ± SEM, n=9-12 mice) represent fold-induction of the reporter gene relative to the 
respective basal signal of each group (before SE). *p<0.05 **p<0.01 compared to control group and 
#p<0.05 ##p<0.01 compared to KA+Saline group by one-way ANOVA followed by Tukey’s multiple 
comparison tests. 
 
Next, we analyzed the effect of FTY720 on astrocytes activation and their phenotype by 
immunohistochemical analysis of mouse hippocampi after 7-day treatment. Three groups 
of mice were studied: control mice not exposed to SE and injected with saline (n=6), SE-
exposed mice treated with either saline (n=9) or FTY720 (n=6). GFAP-postitive area was 
higher in SE-exposed mice (p<0.01) and FTY720 further increased the activated GFAP-
positive area compared to the SE-exposed mice (p<0.01; Figure 5.10). FTY720 did not 
modify the S100β-positive area (ipsilateral hippocampus; Saline: 51364 ± 3424 μm2; KA: 
189134 ± 28531 μm2; KA+FTY720: 179365 ± 18644 μm2; Figure 5.11A) or the number of 
S100β-positive cells (ipsilateral hippocampus; Saline: 1852 ± 84; KA: 2873 ± 64; KA+FTY720: 
2927 ± 77; Figure 5.11B). 
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Figure 5.10. FTY720 effect on GFAP-positive astrocytes. (A) GFAP-activated area in mice exposed 
to SE and treated with saline or FTY720 (6 mg/kg; i.p. for 7 days). (B) Representative 
photomicrographs of hippocampal slices from control mice (injected with saline but not exposed to 
SE) and SE-exposed mice treated with either saline or FTY720. Ipsilateral hippocampus (CA1 area) is 
depicted. Data (mean ± SEM, n=6-9 mice each group) **p<0.01 compared to control and ##p<0.01 
compared to KA+Saline by one-way ANOVA followed by Tukey’s multiple comparison tests. sr, 
stratum radiatum; slm, stratum lacunosum-moleculare. Scale bar, 50 μm. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. FTY720 effect on S100β-positive astrocytes. (A) S100β-activated area and number of 
positive cells in mice exposed to SE and treated with saline or FTY720 (6 mg/kg; i.p. for 7 days). (B) 
Representative photomicrographs of hippocampal slices from control mice (injected with saline but 
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not exposed to SE) and SE-exposed mice treated with either saline or FTY720. Ipsilateral 
hippocampus (CA1 area) is depicted. Data (mean ± SEM, n=6-9 mice each group) **p<0.01 
compared to control by one-way ANOVA followed by Tukey’s multiple comparison tests. sr, stratum 
radiatum; slm, stratum lacunosum-moleculare. Scale bar, 50 μm. 
 
Similarly, no effects of FTY720 were detected on TNF-α-positive area (ipsilateral 
hippocampus; Saline: 53805 ± 8195 μm2; KA+FTY720: 56890 ± 6790 μm2; Figure 5.12A) or 
the number of TNF-α-positive cells (ipsilateral hippocampus; Saline: 1764 ± 310; 
KA+FTY720: 1672 ± 147; Figure 5.12B) and on PTX3 expression (ipsilateral hippocampus; 
Saline: 698829 ± 64316 μm2; KA+FTY720: 698435 ± 102019 μm2; Figure 5.13).   
Figure 5.12. FTY720 effect on astrocitic TNF-α expression. (A) TNF-α-positive area and number of 
TNF-α-positive astrocytes in SE-exposed mice treated with either FTY720 (6 mg/kg; i.p.) or saline. 
Controls are mice injected with saline but not exposed to SE.  (B) Representative photomicrographs 
of corresponding hippocampal slices depicting TNF-a-positive astrocytes. Ipsilateral hippocampus 
(CA1 area) is depicted.  Data (mean ± SEM, n=6-9 mice each group). sr, stratum radiatum; slm, 
stratum lacunosum-moleculare. Scale bar, 50 μm. 
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Figure 5.13. FTY720 effect on A2-type astrocytes. (A) PTX3-positive area and (B) representative 
photomicrographs of hippocampla slices (CA1 area) from control mice and SE-exposed mice treated 
with either saline or FTY720 (6 mg/kg; i.p for 7 days). Ipsilateral hippocampus (CA1 area) is depicted.  
Data (mean ± SEM, n=6-9 mice each group). sr, stratum radiatum; slm, stratum lacunosum-
moleculare. Scale bar, 50 μm. 
 
In line with the bioluminescence and immunohistochemical analysis, GFAP levels measured 
by western blot in the hippocampus (n=5) showed a 2-fold increase in protein levels 
(p<0.01) in SE-exposed mice which was higher in mice treated with FTY720 for 7 days 
(p<0.05) (Figure 5.14A). We also measured the protein levels of the GLT-1 glutamate 
transporter and Kir4.1 channel in the same brain homogenates used above to determine 
whether FTY720 treatment may enhance the buffering capacity of astrocytes which is 
compromized during epileptogenesis. We found a 50% decrease (p<0.05) in both proteins 
in SE-exposed mice as previously shown (Hubbard et al., 2016; Ueda et al., 2001; Zurolo et 
al., 2012) as compared to control mice (saline-injected but not exposed to SE) but FTY720 
did not rescue this decrease (Figure 5.14B,C). 
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Figure 5.14. GFAP, GLT-1 and Kir4.1 levels in the hippocampus during epileptogenesis in mice 
treated with FTY720 or saline. (A) GFAP (B) GLT-1 and (C) Kir4.1 protein levels 7 days post-SE in 
mice treated with FTY720 (6 mg/kg; i.p.) or saline.  Representative bands corresponding to GFAP 
levels in the hippocampus ipsilateral to KA-injected amygdala. Controls are mice treated with saline 
but not exposed to SE.  GFAP protein (50 kD), GLT-1 protein (70 kD), Kir4.1 protein (50 kD) and β-
actin (43 kD). FTY720 (6 mg/kg; i.p.) or saline was administered for 7 days during epileptogenesis 
Data (mean ± SEM, n=5 mice each group) are optical density values of the relevant bands normalized 
to the corresponding β-actin or GFAP values. *p<0.05; **p<0.01 compared to control and #p<0.05 
compared to KA by one-way ANOVA followed by Tukey multiple comparison tests. 
 
5.4 DISCUSSION 
Astrocytes have a key role in the innate immune response to epileptogenic insults and they 
are also pivotal cells for maintaining brain homeostasis through regulation of ions, 
metabolites and neurotransmitters (Aronica and Crino, 2011; Danbolt, 2001; Olsen et al., 
2015). During epileptogenesis, numerous pathologic changes occur in astrocyte functions. 
These alterations include increased expression of GFAP denoting their activation state and 
reduced expression of proteins involved in the regulation of extracellular potassium ([K+]o) 
and glutamate. These changes lead to altered tissue homeostasis that results in increased 
neuronal excitability and promote seizure generation (Seifert et al., 2010; Steinhäuser and 
Seifert, 2012). However, there is also evidence of compensatory mechanisms activated in 
astrocytes in order to balance the deleterious alterations occurring during the disease 
course. These include, secretion of growth factors that mediate neuronal survival, 
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generation of anti-inflammatory and proresolving lipids and proteins and PTX3 expression  
that  may  confer  neuroprotection (Borges et al., 2003; Fellin, 2009; Nagao et al., 2013; Pan 
et al., 2018; Ravizza et al., 2001). Thus, understanding how astrocytes respond to 
epileptogenic insults that lead to seizures and the dynamics of these detrimental or 
compensatory responses is important to understand their role in the disease mechanisms, 
hence for the development of drugs that specifically target the pathologic phenotype of 
astrocytes.  
The GFAP protein staining rapidly and progressively increases during epileptogenesis 
indicating that astrocytic activation precedes the onset of the spontaneous seizures. 
Microglia activation also occurs in parallel with GFAP-positive astrocytes showing a rapid 
increase that progresses over time and persists for at least one week post-SE. 
S100 was also induced in astrocytes but with a delay of days compared to GFAP possibly 
revealing the late activation of a specific set of astrocytes. In accord, these two astrocytic 
markers were previously reported to follow a different patter of induction in the 
hippocampus after KA, a phenomenon linked to distinct regulatory mechanisms of the 
respective gene expression (Bendotti et al., 2000). S100 is a calcium-binding protein 
(Donato, 2001; Heizmann, 2002) and its upregulation in the late epileptogenesis phase may 
reflect the activation of a population of astrocytes attempting to buffer the intracellular 
calcium increase which induces gliotransmitters release such as glutamate and D-serine 
(Araque et al., 2014; Bazargani and Attwell, 2016; Yang et al., 2003) or ATP and TNF-α 
(Agulhon et al., 2008, 2012). These gliotransmitters contribute to neuronal network 
synchronization and to neuroinflammation thus promoting seizure generation (Devinsky et 
al., 2013; Robel and Sontheimer, 2016). Notably, S100can be also released extracellularly 
by astrocytes and relatively high concentrations (µM) exert excitatory and neurotoxic 
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effects (Nishiyama et al., 2002; Rothermundt et al., 2003; Sakatani et al., 2008); moreover, 
its hippocampal levels correlate with the severity of epilepsy in animal models (Filibian et 
al., 2012; Pascente et al., 2016). Neurotrophic and gliotrophic effects of relatively low 
S100concentrations (nM) have also been reported (Rothermundt et al., 2003).  
Overall, the early vs late activation of GFAP- and S100-positive astrocytes, respectively 
supports the heterogeneity of the glial cell populations (Höft et al., 2014; Matthias et al., 
2003; Schitine et al., 2015) which may subserve different functions during epileptogenesis. 
It would be important to selectively interfere with these two cell populations to better 
understand their roles. In this respect, the induction of GFAP-positive astrocytes per se 
induces hippocampal hyperexcitability and spontaneous seizures (Ortinski et al., 2010; 
Robel et al., 2015) thus supporting that these cells contribute to the disease and their 
pathologic phenotype during epileptogenesis overcomes their homeostatic functions. 
When interpreting our results, we should also consider that S100labels the soma and 
large astrocytic processes while GFAP is visible also in fine processes, therefore the GFAP 
staining may represent a more sensitive marker for slight morphological modifications of 
astrocytes which cannot be detected by assessing S100 
In vivo bioluminescence imaging of astrocyte activation supports the immunohistochemical 
evidence. The GFAP promoter induction follows the temporal pattern observed by 
measuring GFAP in histological specimens. However, promoter induction elapses between 
3 and 7 days post-SE while the GFAP protein is still upregulated at 7 days. This result is 
compatible with the slow turnover rate of GFAP which levels outlast the gene promoter 
activity (Chiu and Goldman, 1984; DeArmond et al., 1986; Morrison et al., 1985; Price et 
al., 2010).  
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The in vivo monitoring of the GFAP promoter activation provides therefore a longitudinal 
information on the timing of morphological activation of astrocytes although it does not 
directly inform on the A1 or A2 phenotype of these cells or the molecules they might 
release upon cell activation. 
Our cross-sectional study addressed the astrocytic phenotype during epileptogenesis by 
comparing the expression of both A1 and A2 markers. Among the A1 markers we found an 
upregulation in nuclear HMGB1 indicating increased gene transcription of this ictogenic 
and neurotoxic mediator at late time points (3 and 7 days post-SE) matching the timing of 
activation of the S100-positive cells. The ictogenic cytokine TNF-α also showed a relatively 
late induction (from 24 h post-SE) in astrocytes. PTX3 expression (A2-phenotype marker) 
was detectable at 3 and 7 days post-SE. The PTX3 promoter displays a NF-кB-sensitive 
element which responds to both TNF-α and IL-1β (Basile et al., 1997; Goodman et al., 1996). 
Indeed, we showed that PTX3 induction in astrocytes follows that of TNF-α. We observed 
therefore a mixed induction of pathologic (HMGB1 and TNF-α) and homeostatic (PTX3) 
molecules at overlapping time points during epiletogenesis. In accord, both the A1- and A2-
phenotype markers were detected 24 h (TNF-α) and 3 days (HMGB1 and PTX3) but not 
earlier. This late induction (3 and 7 days post-SE) by matching the activation of S100β-
positive astrocytes suggests that it occurs predominantly in these cells although we were 
not able to co-localize S100β with A1- and A2-phenotype markers due to incompatibility of 
the primary antibodies. Although S100β signal highly co-localized with GFAP in astrocytes 
as all A2 and A1 markers, GFAP-positive, but not S100β-positive, astrocytes are rapidly 
activated within 2 h after SE. It would be very informative to determine which are the early 
markers of activated GFAP-positive astrocytes within hours of SE onset by analysing gene 
transcription in cell sorted cells (experiments are in progress).  
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In the second part of our study, we assessed the effect of FTY720 on astrocyte activation 
and their phenotype since this drug provided significant anti-epileptogenesis and 
neuroprotective effects in different animal models which were in part attributed to anti-
inflammatory actions on activated astrocytes (Gao et al., 2012; Pitsch et al., 2018). Our in 
vivo and ex vivo results showed lack of effect of FTY720 on both astrocyte activation and 
proliferation following a treatment schedule that provided anti-epileptogenic effects. 
Similarly, FTY720 did not modify the pro-inflammatory phenotype of astrocytes neither 
boosted the neuroprotective PTX3 expression. On the contrary, FTY720 further increased 
the astrocyte's promoter induction as shown by in vivo bioluminescence analysis reflecting 
activation of pre-existing cells rather than proliferation of new cells since FTY720 treatment 
increased the GFAP-positive area but not the number of positive cells (see also Wu et al., 
2013). However, cell activation was not accompanied by a concomitant induction of GLT-1 
or Kir4.1 therefore indicating the persistence of dysfunctional astrocytes. In accordance 
with our results, FTY720 did not change the mRNA or protein levels of GLT-1 in astrocyte 
cell culture after a pro-inflammatory stimulus (Lee et al., 2017). However, in a murine EAE 
model FTY720 treatment restored the reduced expression of GLT-1 presumably via anti-
inflammatory mechanisms (Lee et al., 2017). The lack of effect of FTY720 on GLT-1 protein 
levels in our model is therefore compatible with the lack of anti-inflammatory effects. 
FTY720 may activate astrocytes primarily through S1P3 and S1P5 receptors whereas S1P1 
signaling appears to inhibit astrogliosis in organotypic cerebellar slice cultures modeling MS 
possibly by inducing the release of factors that modulate the astrocytic cell response 
(Miron et al., 2010). Indeed, S1Ps receptor engagement on astrocytes can induce growth 
factor production which in turn results in increased S1P5 levels (Furukawa et al., 2007; 
Healy et al., 2013; Miron et al., 2010; Sato et al., 1999). These mechanisms may be 
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operative also in our experimetal conditions. Release of growth factors from activated 
astrocytes even in an inflamed environment can afford neuroprotection as suggested by 
evidence in a demyelination model (Janssen et al., 2015).  
The increased GFAP promoter activation and protein levels induced by FTY720 may be 
caused also by epigenetic alterations mediated by the drug. Histone acetylation controls 
GFAP expression (Asano et al., 2009; Hsieh et al., 2004; Zhou et al., 2011). The acetylation 
state of histone proteins is regulated by histone acetylase and histone deacetylase (HDAC) 
enzymes. Inhibition of HDACs results in increased histone acetylation. Indeed, treatment 
with the HDAC inhibitor valproic acid increased histone H3 acetylation at the STAT3-binding 
site leading to enhanced STAT3 binding to the GFAP promoter resulting in gene activation 
(Asano et al., 2009; Cheng et al., 2011; Nakashima and Taga, 2002; Sauvageot and Stiles, 
2002; Taga and Fukuda, 2005). Similarly, nuclear FTY720-P binds to the active site of HDACs 
and inhibits their activity (Gardner et al., 2016; Hait et al., 2014). Moreover, both S1P 
receptor and FTY720-P inhibit HDAC activity and increase histone acetylation at H3K9, 
H4K8, H3K18, and H3K23 (Ebenezer et al., 2016, 2017; Gardner et al., 2016; Hait et al., 
2009, 2015). 
Overall, our study does not support that the anti-epileptogenic effects of FTY720 shown in 
in vivo models are mediated by drug's inhibition of GFAP- and S100-positive astrocytes 
or rescue of their proinflammatory phenotype. Although this mechanism appears to 
mediate the reduction of spontaneous seizure frequency when FTY720 is administered in 
the chronic epilepsy phase (Pitsch et al., 2018), it is unlikely to be involved in the 
epileptogenesis phase preceding the onset of the disease. 
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6.1 EXPERIMENTAL ANIMALS 
Adult C57BL/6N male mice (~50 days, 20-25 g) were obtained from Charles River (Italy) and 
Sprague–Dawley male rats were purchased from Charles River Laboratories (St. Constant, 
Quebec, Canada). Animals were housed at a constant room temperature (23°C) and relative 
humidity (60 ± 5%) with free access to standard food pellet and water, and with a fixed 12 
h light/dark cycle. Adult animals were housed two or four per cage and environmental 
enrichment was used. TICAM knock-out mice were provided by Dr. Cecilia Garlanda 
(Istituto Clinico Humanitas –IRCCS, Rozzano, Italy) and were housed at the same conditions 
described above. 
 
6.2 ANIMAL CARE 
Procedures involving animals were conducted at Istituto di Ricerche Farmacologiche Mario 
Negri IRCCS which adheres to the guidelines of the Italian Governing Law (D.lgs 26/2014; 
Authorization n.19/2008-A issued March 6, 2008 by Ministry of Health); Mario Negri 
Institutional Regulations and Policies providing internal authorization for persons 
conducting animal experiments (Quality Management System Certificate - UNI EN ISO 
9001:2008 - Reg. No. 6121); the NIH Guide for the Care and Use of Laboratory Animals 
(2011 edition); EU directives and guidelines (EEC Council Directive 2010/63/UE) and the 
institutional policies and guidelines of Sainte-Justine Hospital Research Centre and 
Université de Montréal (Montreal, QC, Canada). The Statement of Compliance (Assurance) 
with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory Animals 
has been recently reviewed (9/9/2014) and will expire on September 30, 2019 (Animal 
Welfare Assurance #A5023-01). 
 
142 
 
6.3 IN VIVO MODEL OF ICTOGENESIS 
6.3.1 Intrahippocampal kainic acid in mice 
Adult male mice were surgically implanted under general gas anesthesia (1-3% isoflurane 
in O2) and stereotaxic guidance. Two nichrome-insulated bipolar depth electrodes (60 μm 
OD) were implanted bilaterally into the dorsal hippocampus (from bregma, mm: nose bar 
0; anteroposterior –1.8, lateral 1.5 and 2.0 below dura mater; Franklin and Paxinos, 2008). 
A 23-gauge cannula was unilaterally positioned on top of the dura mater and glued to one 
of the depth electrodes for the intrahippocampal injection of kainic acid (KA; see later). 
Two screw electrodes were positioned over the nasal sinus and the cerebellum, and used 
as ground and reference electrodes, respectively. The electrodes were connected to a 
multipin socket and, together with the injection cannula secured to the skull by acrylic 
dental cement. The correct position of the electrodes and injection needle in each mouse 
was evaluated by post-hoc histological analysis of brain tissue at the end of the 
experiments. 
Intrahippocampal injection of KA in freely moving mice was done 7 days after surgery as 
previously described (Balosso et al., 2008; Iori et al., 2017; Maroso et al., 2010). Briefly, KA 
(7 ng/0.5 μl; Sigma, Saint Louis, MI, USA) was dissolved in 0.1 M phosphate-buffered saline 
(PBS, pH 7.4) and injected unilaterally in the dorsal hippocampus by using a needle 
protruding 2.0 mm from the bottom of the guide cannula. The needle was left in place for 
one additional minute to avoid backflow through the guide cannula and then was removed. 
Mice were freely moving for the rest of the experiment. 
This dose of KA induces EEG ictal episodes in the hippocampus in 100% of mice without 
mortality (Balosso et al., 2008; Maroso et al., 2010). Selective cell loss in CA3 region of the 
injected hippocampus is observed 7 days after KA injection (Balosso et al., 2005, 2008; 
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Ravizza et al., 2006b). Previous experiments demonstrated that this dose of KA provokes 
seizures in rodents that could be either inhibited or exacerbated by pharmacological or 
genetic interventions (Balosso et al., 2005, 2008; Maroso et al., 2010, 2011b; Vezzani et al., 
2000). Thus, this model is suitable, and sensitive enough, to detect changes in seizure 
activity determined by specific target manipulation. 
Figure 6.1. Experimental model of acute seizures and related injection protocol. Brain atlas plate 
depicting kainic acid (KA, 7 ng/0.5 µl) unilateral injection site (black arrow) and the depth bipolar 
recording electrode that was placed in the hippocampus (green line) bilaterally. Schematic skull 
reproduction shows surface electrode placement (green circles) and the position of the guide 
cannula for intrahippocampal injection of KA (black circle). Representative EEG tracings depicting 
baseline recordings (top) and ictal activity after KA injection (bottom) simultaneously occurring in 
the left (LHP) and right (RHP) hippocampus in freely moving mice. 
 
6.3.2 Seizure assessment and quantification 
EEG seizures induced by intrahippocampal injection of KA in freely-moving mice have been 
extensively described before (Balosso et al., 2005, 2008; Ravizza et al., 2006b). A minimum 
of 30 min recording was done before KA injection to assess the basal EEG activity, and then 
recording continued for 180 min after KA injection. At least a 30 min recording similar to 
baseline was required before ending the experiment. Ictal episodes are characterized by 
high-frequency (7-10 Hz) and/or multispike complexes and/or high-voltage (700 µV-1.0 
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mV) synchronized spikes simultaneously occurring in the injected and contralateral 
hippocampi (Figure 8.1). Spiking activity may occur between seizures and after seizures 
subside. Quantification of seizure activity was done by measuring the time elapsed from 
KA injection to the occurrence of the first EEG seizure (onset), the number of seizures and 
the total duration of seizures (sum of the duration of every ictal episode during the EEG 
recording period). Seizures occur with an average latency of 10 min from KA injection, then 
recurred for about 90 min from their onset, and were associated with motor arrest of the 
mice.  
 
 
 
 
Figure 6.2. EEG tracings in KA-induced acute seizures. Representative EEG tracings depicting 
baseline recordings (top) and ictal activity after unilateral intrahippocampal KA injection (bottom) 
simultaneously occurring in the left (LHP) and right (RHP) hippocampus in freely moving mice (Iori 
et al., 2013). 
 
6.4 INTRACEREBROVENTRICULAR ADMINISTRATION OF DRUGS 
Mice were surgically implanted under general gas anesthesia (1-3% isoflurane in O2) and 
stereotaxic guidance (Iori et al., 2013; Maroso et al., 2010) with a guide cannula positioned 
on top of the dura mater (from bregma, mm: nose bar 0; anteroposterior +0.3, lateral 0.9) 
(Franklin and Paxinos, 2008) ipsilateral to the intrahippocampal injection of KA one week 
before treatments. Poly I:C (tlrl-pic, Invivogen) was dissolved in sterile PBS (10 mg/1.5 ml) 
and injected at doses of 33 μg/5 μl, 10 μg/1.5 μl, 1 μg/1.5 μl and 0.1 μg/1.5 μl,  
intracerebroventricularly (i.c.v., 0.5 μl/min) in freely moving mice using a 30-gauge 
injection needle protruding 2.3 mm from the bottom of the guide cannula connected to a 
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10 μl Hamilton microsyringe via PE20 tubing, according to convection-enhanced delivery 
method (Gasior et al., 2007). At the end of infusion, the needle was left in place for one 
additional minute to avoid backflow through the guide cannula, then gently removed.  
 
6.5 INTRAHIPPOCAMPAL ADMINISTRATION OF DRUGS 
Mice were surgically implanted under general gas anesthesia as described above (Section 
6.4) with a guide cannula positioned on top of the dura mater at the same position as for 
intrahippocampal injection of KA (from bregma, mm: nose bar 0; anteroposterior –1.8, 
lateral 1.5) (Franklin and Paxinos, 2008) one week before treatments. Recombinant mouse-
IFNβ (8234-MB, R&D Systems) was dissolved at 100ug/ml in sterile PBS containing 0.1% 
BSA and injected at 50 IU, 500 IU or 5000 IU intra-hippocampally (i.h., 0.5 μl/min, 0.5 μl in 
total) in freely moving mice over 1 min using a 30-gauge injection needle protruding 2.0 
mm from the bottom of the guide cannula connected to a 10 μl Hamilton microsyringe via 
PE20 tubing, as described above (Section 6.4).  
 
6.6 IMMUNOHISTOCHEMISTRY 
6.6.1 Immunohistochemical studies from in vivo preparations 
Mice were deeply anaesthetised with ketamine (75 mg/kg) and medetomidine (0.5 mg/kg) 
and perfused via the ascending aorta with 50mM cold PBS, pH 7.4 and then with 4% 
paraformaldehyde (Merck, Darmstadt, Germany) in PBS. Brains were removed and post-
fixed for 90 min at 4°C and then transferred to glucose solution 20% in PBS for 24 h at 4°C. 
Then brains were frozen by immersion in isopentane at -45°C for 3 min and stored at -80°C 
until assayed. Using a cryostat serial coronal sections (40 μm) were cut and collected from 
-0.94 to -2.80 mm from bregma (Franklin and Paxinos, 2008). Two series of 30 sections each 
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were prepared and three slices per animal were used for GFAP and CD11b staining. Briefly, 
sections were incudated for 1h at RT with 10% normal goat serum, 1% Triton X-100 in Tris-
buffered saline 0.1 m, pH 7.4, then overnight at 4°C with the mouse anti-GFAP (MAB3402, 
Merck, Germany; 1:3500) to mark astrocytes, or rat anti-CD11b (1:1000, MAC-1, Serotec; 
MCA719, Clone 5C6) to mark microglia. Visualization of the signal was done with the 
Vectastain ABC kit (Vector Laboratories), with diaminobenzidine (DAB; or nickel-intensified 
DAB for IL-1β) as chromogen. Matching slices at comparable levels from control mice and 
mice injected with Poly I:C were compared in order to evaluate glia activation.  
Tissue preparation for TLR3 staining differ, since TLR3 antibody does not react with the 
specific antigen in PFA-fixed slices.  Therefore, mice were perfused for 1 min via the 
ascending aorta with 50mM cold PBS in order to remove blood from brain capillaries and 
their brains were carefully removed from the skull and rapidly frozen in −50 °C isopentane 
for 3 min. Serial coronal sections of 14 μm were cut on a cryostat throughout the septal 
extension of the hippocampus (−1.22 to −2.54 mm from bregma; Franklin and Paxinos, 
2008), collected on lysine-coated slides, fixed in acetone for 10 min and kept at −20 °C until 
use.  
Signal in the hippocampus was captured at 20X using a BX61 microscope equipped with 
motorized and digitized platform (Virtual Slider Microscope, Olympus, Germany) and one 
field representing the CA1 area was used for representation. 
 
6.6.2 TLR3 
Slides were incubated at room temperature for 10 min with 0.03% H2O2. After 3 washes in 
PBS slides were incubated with 10% fetal bovine serum (FBS) and 4% BSA in PBS. Then, 
slides were incubated at 4°C overnight in the same solution with rabbit polyclonal anti-TLR3 
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antibody (1:75, IMGENEX, San Diego, CA, USA; IMG-516). Immunoreactivity was tested by 
the avidin–biotin–peroxidase technique (Vector Labs, Burlingame, USA) using DAB as 
chromogen. Sections were dried, dehydrated in graded alcohols, and coverslipped.  
Two additional slides from 5 randomly chosen animals were used for double 
immunostaining to identify the cells expressing TLR3 (Chapter 7). After incubation with the 
primary antibody against TLR3, slices were incubated for 1 h with anti-rabbit secondary 
antibody conjugated with Alexa488 (1:500; Molecular Probes, Leiden, The Netherlands) 
and then overnight with primary antibody against GFAP (1:3500, Chemicon, Temecula, CA, 
USA; #MAB3402) and fluorescence was detected using secondary antibody conjugated 
with Alexa546 (1:500, Molecular Probes, Leiden, The Netherlands). Slide-mounted sections 
were examined with an Olympus Fluoview laser scanning microscope (microscope BX61 
and confocal system FV500) using excitations of 488 nm (Ar laser), 546 nm (He-Ne green 
laser) for fluorescein and Alexa546 respectively. 
 
6.7 RNA ISOLATION AND REAL-TIME QUANTITATIVE POLYMERASE CHAIN 
REACTION 
For RNA isolation, frozen hippocampi dissected from mice perfused via the ascending aorta 
with 50mM cold PBS for 1 min, were homogenized in Qiazol Lysis Reagent (Qiagen Benelux, 
Venlo, The Netherlands). The total RNA including the miRNA fraction was isolated using the 
miRNeasy Mini kit (Qiagen Benelux, Venlo, the Netherlands) according to manufacturer’s 
instructions. The concentration and purity of RNA were determined at 260/280 nm using a 
high-speed microfluidic UV/VIS spectrophotometer QIAxpert (Qiagen, Milano, Italy) and 
the integrity and quality of RNA was evaluated by 4200 Tapestation (Agilent Technologies, 
Santa Clara, CA, USA).  
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cDNA was synthesized from 1000 ng RNA using the high capacity cDNA reverse 
transcription kit (Applied Biosystems, California, USA) following the manufacturer’s 
protocol (Applied Biosystems, California, USA). RT-qPCR experiments were run in triplicate 
for each case to assess technical variability using 384-well reaction plates using an 
automatic liquid handling station (epMotion 5075LH, Eppendorf, Hamburg, Germany), on 
an Applied Biosystems 7900HT System (Applied Biosystems, California, USA). cDNA was 
analyzed using Applied Biosystems TaqMan gene expression assays (IL-1β, NF-kB, HMGB1, 
TLR3, IRF3, IFNAR1, IFN-β, AHR, CYP1B1 and SOCS2) according to protocol’s instructions.  
CT values were obtained using manual threshold and baseline, analyzed using the 2-ΔΔCt 
method and normalized using geometric mean of 3 independent house-keeping genes 
(hprt1, pdg1, sv2b). 
RT-qPCR measurements were performed by Dr. Ilaria Craparotta, Translational Genomic 
Unit, Department of Oncology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, 
Milan, Italy. 
 
6.8 ELECTROPHYSIOLOGY 
6.8.1 Acute hippocampal slices  
Mice were killed by cervical dislocation and brains quickly removed and placed in ice-cold 
modified artificial cerebrospinal fluid (aCSF) containing the following (in mM): 87 NaCl, 2.5 
KCl, 1 NaH2PO4, 75 sucrose, 7 MgCl2, 24 NaHCO3, 11 D-glucose, and 0.5 CaCl2 and bubbled 
with 95% O2 and 5% CO2. Coronal brain slices (350 um thick) were cut with vibrating-blade 
microtome VT1000s (Leica Microsystems GmbH). Slices were then transferred into an 
incubating chamber and submerged in aCSF containing (in mM): 130 NaCl, 3.5 KCl, 1.2 
NaH2PO4, 1.3 MgCl2, 25 NaHCO3, 11 D-glucose, 2 CaCl2 and constantly bubbled with 95% O2 
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and 5% CO2 at room temperature. Slices were incubated in this condition for at least 1 h, 
then transferred in a submerged recording chamber, perfused with oxygenated aCSF at a 
rate of 2 ml/min and a constant temperature of 28-30°C. Extracellular recordings of 
population spikes (PS) were obtained in CA1 pyramidal layer using glass micropipettes filled 
with 3 M NaCl. Stimulation of Schaffer collaterals was delivered by a Constant Voltage 
Isolated Stimulator (Digitimer Ltd., Welwyn Garden City, UK) through bipolar twisted Ni/Cr 
stimulating electrode. PS amplitude was measured as the amplitude of the first negative 
deflection overriding the field EPSP waveform. The input-output curves were plotted as the 
relationship of PS amplitude versus stimulus intensity (2V steps). Four consecutive PS were 
averaged for each stimulus intensity. Data were amplified and filtered (low filter 10 Hz, high 
filter 3 kHz) by a DAM 80 AC Differential Amplifier (World Precision Instruments, Sarasota, 
FL, USA), and digitized at 10 kHz by a Digidata 1322 (Molecular Devices, Foster City, CA, 
USA). 
Electrophysiological measurements were performed by Dr. Milica Cerovic, Laboratory of 
Biology of Neurodegenerative Disorders, Department of Neuroscience, IRCCS - Istituto di 
Ricerche Farmacologiche Mario Negri, Milan, Italy. 
 
6.8.2 Organotypic hippocampal slices 
Male rats at postnatal day 10 (P10) were decapitated, and the brains were quickly removed 
and placed in ice-cold buffer solution optimised for organotypic slice preparation (slicing 
solution), which contained the following: 1x GIBCO Hanks' Balanced Salt Solution (HBSS) 
supplemented with calcium and magnesium (ThermoScientific), 30 mM glucose, and 0.5 
mM kynurenic acid; the pH was adjusted to 7.3-7.4, and osmolarity to 310-315 mOsm/L. 
Under sterile conditions, brains were hemisected and embedded in low melting point 
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TopVision agarose (ThermoScientific) dissolved in 37ºC pre-warmed slicing solution (2% 
weight/volume). After the agarose was allowed to solidify in an ice-bath, the brain-
containing agarose block was mounted on a slicing stage with superglue, and coronal brain 
slices perpendicular to the longitudinal axis of the dorsal hippocampus were cut with 
vibrating-blade microtome VT-1000-S (Leica Microsystems GmbH) at a thickness of 350 µm. 
Dorsal hippocampal slices were then transferred into a Petri dish containing slicing solution 
and incubated at 4°C for at least 1 hour. Then, individual slices were placed on 12 mm, 
PTFE, 0.4 µm Millicell membrane inserts (Millipore, MA, USA) at an interface with culture 
medium in 24-well culture plates and placed in a 5% CO2 incubator at 34ºC. Fresh medium 
was added after 48 hours, and thereafter the medium was replaced every 2-3 days 
throughout the course of the experiment. The composition of the culture medium was the 
following: 50% minimum essential medium with 25 mM HEPES, 20% heat inactivated horse 
serum, 25% HBSS supplemented with calcium and magnesium, 1 mM GlutaMAX, 0.5 mM 
L-ascorbic acid, 55 mM glucose, 50-100 U/mL Penicillin-Streptomycin; pH 7.3-7.4; 310-315 
mOsm/L. All culture medium components were purchased from ThermoScientific. No anti-
mitotics were used in these experiments. 
Whole-cell patch-clamp electrophysiological recordings were conducted between 7 and 11 
days in vitro (DIV). To investigate the effects of Poly I:C and IFN-β on synaptic excitability of 
brain slices, on the day of the recording, 5 μl of Poly I:C (tlrl-pic, Invivogen) or IFN-β (8234-
MB, R&D Systems) were added directly to the media at the doses and incubation times 
indicated in the results section. Following drug incubation, individual slices were 
transferred into a recording chamber, and continuously perfused with an artificial 
cerebrospinal fluid (aCSF), at a rate of 2-3 ml/min, constantly bubbled with 95% O2 and 5% 
CO2, and at a constant temperature of 32-34°C. The composition of aCSF was the following 
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(in mM): 124 NaCl, 3 KCl, 1.3 MgSO4-H2O, 1.4 NaH2PO4, 10 D-glucose, 26 NaHCO3 and 2.5 
CaCl2; pH 7.3-7.4; 320–325 mOsm/L. CA1 hippocampal pyramidal cells were visually 
identified based on cell morphology and the presence of a large apical dendrite with an 
upright microscope (Olympus) mounted on a differential interference contrast optics and 
infrared video camera (Hitachi Kokusai Electric). Recording pipettes pulled from 
borosilicate glass (World Precision Instruments) with a PP‐83 two‐stage puller (Narishige) 
to a resistance of 5–7 MΩ were filled with intracellular solution containing (in mM): 130 K‐
gluconate, 10 HEPES, 5 KCl, 2.5 MgCl2, 1 EGTA, 0.5 CaCl2, 3 Tris-ATP, 0.4 GTP-Li, 5 
phosphocreatine and 2.5 QX314-Cl; pH 7.20-7.25; 300-305 mOsm/L. To establish the 
whole-cell configuration, the membrane of pyramidal cell bodies was ruptured using 
negative pressure after a tight seal (>1 GΩ) is formed between the recording pipette and 
the cell membrane. Then, neurons were held at -60 mV for 5 mins in voltage-clamp before 
experimental recordings. Stimulation of Schaffer collaterals (SC) was achieved by a 
Constant Voltage Isolated Stimulator (World Precision Instruments) through a tungsten 
concentric bipolar stimulating electrode (World Precision Instruments) placed ~100 µm 
from the recording pipette, where 15 µS biphasic pulses were delivered to afferent SC fibers 
with successive incremental intensities of 25 µA ranging in amplitude from 25 µA to a 
maximum of 275 µA. Before placing the stimulating electrode, a cut was made at the CA3-
CA1 junction to prevent anti-dromical evoked stimulation in the CA3 to propagate through 
the SC to recorded cells in the CA1. During SC stimulation, cells were held at -60 mV in 
voltage-clamp in order to eliminate the inhibitory component of evoked responses, mainly 
GABAA receptor‐mediated currents. Recordings were repeated three times for each 
stimulus intensity and average values of evoked currents were used to generate input-
output graphs when plotted against each stimulus intensity. Data was amplified and low-
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pass filtered at 1 kHz using Axopatch 200B amplifier (Molecular Devices), digitized at a 
sampling rate of 10 kHz with a Digidata 1440A analog-digital converter (Molecular Devices), 
and signals were acquired using the pCLAMP software 10.4 (Molecular Devices). 
Data was analyzed using Clampfit 10.4 (Molecular Devices). Only one neuron per slice per 
animal was included in the analysis. Current outputs (I) were normalized relative to the 
maximal current (Imax), where Imax was considered the amplitude of currents evoked in 
response to the maximal stimulation intensity at 275 µA, and results are shown as a ratio 
of Imax, i.e. I/Imax. A sigmoidal curve was fitted to the input-output data using Boltzmann 
equation in order to calculate the stimulation intensity required to evoke half-maximal 
current amplitude.  
Electrophysiological measurements were performed by Dr. Tarek Shaker, Division of 
Neurology, Department of Pediatrics and Neurosciences, CHU Sainte-Justine, University of 
Montreal, Montreal, Quebec, Canada. 
 
6.9 STATISTICS 
Quantification of each experiment was done blindly and sample size was determined a 
priori based on previous experience with the respective models and statistical tests were 
prospectively selected. All efforts were made to reduce the number of animals used to 
minimum. GraphPad Prism 6 (GraphPad Software, USA) for Windows was used for 
statistical analysis using absolute values. Data are presented as mean ± S.E.M. (n indicates 
the number of individual samples). For each variable, differences between the groups were 
assessed using Mann–Whitney U test for two independent groups and one-way ANOVA 
followed by Tukey post-hoc test or Kruskal-Wallis followed by Dunn’s post-hoc test or by 
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two-way ANOVA for repeated measures followed by Bonferroni post-hoc test (details are 
reported in the figure legends). Differences were considered significant with a p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
154 
 
 
 
 
 
CHAPTER 7 - EFFECT OF TLR3 PRIMING ON NEURONAL 
EXCITABILITY AND SEIZURES 
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7.1 INTRODUCTION 
TLR3 is a dsRNA-sensing TLR, known as a regulator of both anti-viral responses and injury 
repair processes since it also detects host-derived RNA. Different from other TLR family 
members, TLR3 does not activate MyD88-dependent signalling but signals through the 
Toll/IL-1 receptor (TIR) domain-containing adaptor TRIF, also known as TIR-containing 
adaptor molecule 1, (TICAM-1) pathway (Takeda and Akira, 2004). TRIF signalling activates 
NF-kB and the nuclear translocation of the transcription factor interferon regulatory factor 
(IRF)-3 that mediate the production of type I interferon (IFN), IFN-inducible products, and 
other inflammatory mediators (Kawai and Akira, 2010).  
TLR3 is primarily expressed intracellularly, in the endosomes, where it acts as a sensor for 
double-stranded RNA, an intermediate product of replicating viruses. In the CNS, TLR3 is 
expressed by neurons, microglia and astrocytes (Bsibsi et al., 2002; Carpentier et al., 2005; 
Farina et al., 2005; Olson and Miller, 2004; Préhaud et al., 2005; Scumpia et al., 2005). In 
glial cells and in neurons, TLR3 is expressed both in the endosomes and at the cell surface 
(Bsibsi et al., 2002; Lafon et al., 2008). Adult human astrocytes express TLR3 constitutively 
and upon TLR3 engagement they regulate immune response following viral infection (Bsibsi 
et al., 2002; Farina et al., 2005). Stimulation of TLR3 in human astrocytes also induces 
several neuroprotective and anti-inflammatory molecules implicated in neuroprotection 
such as brain-derived neurotropic factor, neurotrophin 4, pleiotrophin, TGF-2 and IL-10 
(Bsibsi et al., 2006; Endres et al., 2000; Yeh et al., 1998).  
TLR3 stimulation can have a protective or detrimental effect on tissues depending on the 
type of virus or endogenous activator involved and the cell type mediating the TLR3 
response (Verma and Bharti, 2017). In infection models, TLR3 activation may have 
deleterious effects. For example, TLR3-deficient mice were more resistant to West-Nile 
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Virus (WNV) encephalitis and Rabies virus infection (Ménager et al., 2009; Wang et al., 
2004).  
In epilepsy, TLR3 expression was increased in brain tissue of Rasmussen’s encephalitis 
patients and this expression positively correlated with the extent of brain atrophy (Wang 
et al., 2017). By contrast, other studies showed a protective role of TLR3 stimulation. For 
instance, TLR3 deficiency leads to enhanced viral replication in the primary cortical neuron 
cultures and greater WNV burden in CNS neurons (Daffis et al., 2008). Moreover, TLR3 
deficiency renders mice susceptible to herpes simplex virus infection (HSV-2) and 
astrocytes show a defective type I IFN production (Reinert et al., 2012). Interestingly, 
pretreatment with the TLR3 agonist polyinosinic-polycytidylic acid (Poly I:C), a synthetic 
double-stranded RNA, protected mice against Chikungunya virus (CHIKV) infection (Priya et 
al., 2014).  
Poly I:C mimics the effect of viral infection and leads to the production of type I IFNs, IFN-
α and IFN-β via activation of IRF-3 and IRF-7 (Cunningham et al., 2007; Farina et al., 2005). 
Furthermore, it induces the transcription and biosynthesis of cytokines and chemokines 
(Kirschman et al., 2011; Michalovicz and Konat, 2014). In neonatal animals, Poly I:C exerts 
a pro-inflammatory action associated with increased seizure susceptibility in adulthood 
suggesting that TLR3 activation during brain development has detrimental effects that 
increase vulnerability to later insults (Galic et al., 2009). TLR3 activation was shown to 
modulate hippocampal excitability and alter glutamatergic transmission by IFN-β 
production (Costello and Lynch, 2013). Another study revealed that TLR3 deficiency 
reduced spontaneous seizures, microglia activation and proinflammatory cytokine levels 
indicating a contribution of this pathway to epileptogenesis (Gross et al., 2017). Finally, 
TLR3 activation was shown to mediate working and contextual memory impairment in 
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rodents (Galic et al., 2009; Okun et al., 2010). However, neuroprotective effects have been 
also reported specifically following TLR3 activation in astrocytes due to induction of anti-
inflammatory cytokines and neuroprotective factors (Bsibsi et al., 2006; Li et al., 2015b; Pan 
et al., 2012; Tarassishin et al., 2011b; Zhang et al., 2015b). Therefore, TLR3 may have a dual 
role possibly mediated by different cell types. 
Our main goal was to explore the role of TLR3 activation in acute seizure susceptibility by 
activating these receptors with Poly I:C. Using a mouse model of acute symptomatic 
seizures we measured the astrocytic induction of TLR3. Notably, pre-treatment with Poly 
I:C led to a strong reduction of seizures which was both dose and time dependent. TLR3 
specificity was confirmed in TICAM-1 knock-out mice. Finally, hippocampal excitability in 
brain slices as well as morphological activation of glia and induction of pro-inflammatory 
genes were measured after Poly I:C injection in mice, and the mechanisms underlying its 
neuroprotective effects were explored. 
 
7.2 SPECIFIC MATERIALS AND METHODS 
Kainic acid model of acute seizures 
Mice (n=5-9 mice/group) were implanted with depth electrodes and guide cannula for KA 
injection and intracerebroventricular administration of different doses of Poly I:C and for 
the time-course experiments (Figures 7.2, 7.3; Sections 6.3.1 and 6.4 of General materials 
and methods). TICAM-1 knock-out mice (n=5-6) were implanted as described above and 
treated with 10 µg Poly I:C 6 h before intrahippocampal KA injection (Figure 7.4). Seizures 
occurred with an average latency of 10 min from KA injection in all mice and recurred for 
about 90 min from their onset. Seizure quantification (section 6.3.2 of General materials 
and methods) was done by measuring the time elapsed from KA injection to the occurrence 
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of the first EEG seizure (onset) and the number and total duration of seizures (sum of the 
duration of every ictal episode during the EEG recording period). After the end of the EEG 
recordings mice were sacrificed and the correct position of the electrodes and injection 
needle was evaluated by post-hoc histological analysis of the brain (see section 6.6 of 
General materials and methods). 
Intracerebroventricular administration of Poly I:C 
Mice were implanted with a guide cannula under isoflurane anesthesia (1-3% isoflurane in 
O2) above the left ventricle and injected with saline or 10 µg Poly I:C 1 week after recovery 
from surgery (sections 6.4 of General materials and methods). After 6 h mice (n=16) were 
sacrificed and hippocampal tissue was prepared for either electrophysiological recordings, 
immunohistochemistry or RT-qPCR analysis as previously described (Figures 7.5 and 7.8; 
sections 6.6, 6.7 and 6.8.1 of General materials and methods). Mice (n=16) injected with 
saline served as controls.  
Immunohistochemistry 
Mice (n=5) were implanted with depth electrodes and a guide cannula for KA injection and 
sacrificed 3 h after seizure induction for TLR3 immunohistochemical evaluation (Figure 7.1; 
sections 6.3.1 and 6.6.2 of General materials and methods).  A second group of mice (n=6) 
was implanted with a guide cannula above the left ventricle for intracerebroventricular 
administration of 10 µg Poly I:C and sacrificed 6 h later for glia activation assessment by 
immunohistochemistry (Figure 7.8; sections 6.6.1 of General materials and methods). 
 
 
 
159 
 
RT-qPCR analysis 
Five animals injected with Poly I:C were sacrificed 6 h later and their hippocampi were used 
to measure IL-1β, NFkB1, NFkB2 and HMGB1 mRNA levels as described in section 6.7 of 
General materials and methods (Figure 7.8). HPRT1, PDG1 and SV2B were used as reference 
genes to normalize mRNA levels. 
Electrophysiology 
Mice (n=5/group) were implanted with a guide cannula above the left ventricle and injected 
with 10 µg Poly I:C or saline and sacrificed 6 h later for in vitro electrophysiological 
recording of acute hippocampal slices as described in section 6.8.1 of General materials 
and methods (Figure 7.5).  
Male rats at postnatal day 10 (n=4-9) were used for preparation of organotypic 
hippocampal slices. In one group of slices (n=4-7), Poly I:C (tlrl-pic, Invivogen) was added 
directly to the media at the doses of 1-2 μg, 5-10 μg or 25 μg for 6 h (Figure 7.6). Another 
group of slices (n=4-7) was used for incubation of 25 μg Poly I:C for 6 h continuously or for 
6 h with media replacement overnight or for 24h continuous incubation (Figure 7.7). 
Whole-cell patch-clamp electrophysiological recordings were performed as described in 
section 6.8.2 of General materials and methods. Slices (n=9 in total) incubated with sterile 
water added to the media served as controls (Naïve). 
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7.3 RESULTS 
7.3.1 Effect of TLR3 stimulation on acute seizures 
 First, we investigated the cell type expressing TLR3 using immunohistochemistry in brain 
slices of naïve and KA-injected animals (n=5/group). We found that the specific signal was 
absent in control tissue while the receptor was induced 3 h after seizures onset in GFAP-
positive astrocytes (Figure 7.1).    
 
 
 
 
 
Figure 7.1. TLR3 immunoreactivity in the hippocampus of KA-injected mice. Representative 
photomicrographs from control (saline-injected) and 3 h after KA injection (n=5 each group). CA1 
pyramidal cell layer is shown. Scale bar: 50 µm. 
 
Next, mice (n=5-9/group) were injected into the left ventricle with Poly I:C at different 
doses (0.1, 1, 10 and 33 µg) 6 h before the induction of seizures. This time frame was chosen 
in order to allow sufficient time for transcriptional gene activation and related protein 
synthesis. Doses of 10 µg and 33 µg of Poly I:C mediated anti-ictogenic effects since the 
number (p<0.05; p<0.01) and the time spent in seizures (p<0.05; p<0.01) were significantly 
reduced compared to saline-injected mice (Figure 7.2). Lower doses were ineffective. 
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Figure 7.2. Dose-dependent effects of TLR3 stimulation on seizures. Mice were i.c.v. injected with 
0.1, 1, 10 and 33 µg Poly I:C 6 h before the intrahippocampal injection (unilateral to the Poly I:C-
injected ventricle) of 7 ng in 0.5 µl KA. Data are the mean ± SEM (n=5-9), *p<0.05, **p<0.01 
compared to saline by Kruskal-Wallis followed by Dunn’s multiple comparison test. 
 
In order to study the time course of this anti-ictogenic effect we used 10 µg of Poly I:C, the 
lower effective dose and we injected KA (n=5-9) at 15 min, 1 h, 6 h and 24 h after Poly I:C 
administration. Seizures were unaffected by Poly I:C when the TLR3 agonist was 
administered 15 min, 1 h or 24 h before KA injection (Figure 7.3). However, when Poly I:C 
was injected 6 h before KA it significantly delayed the onset of seizures (p<0.05) and 
reduced the number of seizures and time spent in seizures (p<0.01; Figure 7.3). These data 
indicate that the anti-ictogenic effect of Poly I:C develops over a specific time window 
before seizure induction and is transient since it elapses within 24 h. 
Figure 7.3. Time-dependent effects of TLR3 stimulation on seizures. Mice were i.c.v. injected with 
10 µg Poly I:C at different time points before seizure induction Data are the mean ± SEM (n=5-9), 
*p<0.05, **p<0.01 compared to saline by Kruskal-Wallis followed by Dunn’s multiple comparison 
test. 
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Cytosolic RNA helicases retinoic acid-inducible protein 1 (RIG-1) and melanoma 
differentiation-associated gene 5 (MDA-5) are two additional receptors that are activated 
by Poly I:C. In order to investigate the specific TLR3 involvement in the Poly I:C-mediated 
effects on seizures, we used knock-out mice (n=5-6) for TICAM-1, the adaptor molecule 
TRIF essential for TLR3 signalling. These mice were intrinsically less susceptible to KA-
induced seizures as shown by the increased latency time to the first seizure (p<0.05) and 
the reduction of both the number (p<0.05) and time spent in seizures (p<0.05) as compared 
to wild-type mice. When these mice were injected with 10 µg Poly I:C 6 h before KA, the 
anti-ictogenic effects observed in wild type mice were precluded (Figure 7.4). Thus, the 
anti-ictogenic properties of Poly I:C are specifically mediated by TLR3.
 
Figure 7.4. Effect of Poly I:C on seizures in TICAM-1 KO mice. Wild-type (n=10) and TICAM-1 KO 
(n=5-6) mice were i.c.v. injected with 10 µg Poly I:C (+) or saline (-) 6 h before the intrahippocampal 
injection of KA. Data are the mean ± SEM, *p<0.05 **p<0.01 compared to respective saline; #p<0.05 
and °p<0.01 compared to respective wild-type by Mann-Whitney test. 
 
7.3.2 Effect of TLR3 stimulation on hippocampal neuronal excitability 
We studied the effect of Poly I:C-induced TLR3 stimulation on neuronal excitability in acute 
hippocampal slices obtained from naïve mice injected 6 h before with either Poly I:C or 
saline (n=8-15 slices from 5 mice/each group). We performed extracellular recordings of 
population spikes in CA1 pyramidal cell layer evoked by electrical stimulation of the 
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Schaffer collateral pathway. The relationship between stimulus intensity and population 
spike peak amplitude was used to assess neuronal excitability. Neuronal excitability was 
reduced in slices from Poly I:C-injected mice as shown by a right shift of the input-output 
curve compared to control slices (F1.500= 46.22, p<0.01; Figure 7.5). 
 
 
 
 
 
 
 
 
 
Figure 7.5. Effect of Poly I:C on hippocampal neuronal excitability. Graph reports population spike 
(PS) amplitude of CA1 pyramidal neurons in response to increasing stimulation intensities of afferent 
Schaffer collaterals. Acute hippocampal slices were obtained from naive mice injected i.c.v. with 
either saline (black) or 10 µg Poly I:C (red), 6 h before in vitro stimulation. Insets are representative 
traces of PS obtained in response to 30 V stimulation. PS amplitudes are shown as percent of 
maximal response (mean ± SEM; n=8-15 slices from 5 mice/each group). F1.500= 46.22, p<0.01 by 
two-way ANOVA for repeated measures. 
 
We next evaluated the effects of Poly I:C on excitatory synaptic transmission using whole 
cell patch recording from organotypic hippocampal slices (n=4-9 slices/group). Evoked 
excitatory postsynaptic currents (eEPSC) recorded from pyramidal neurons in CA1 region 
upon stimulation of Schaffer collaterals were reduced after incubation with 25 μg/ml Poly 
I:C for 6 h as shown by measuring both half-maximal eEPSC amplitude (Naïve: 162 ± 10.5; 
Poly I:C 25 μg/ml: 204.7 ± 5.3; p<0.01; Figure 7.6A) and maximal eEPSC amplitude (Naïve: -
1937 ± 98.3; Poly I:C 25 μg/ml: -973.5 ± 108.5; p<0.01 Figure 7.6B). Lower doses of Poly I:C 
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were ineffective. These data are in line with the in vivo data, since the dose of 25 μg/ml 
Poly I:C corresponds to the dose of 10 μg Poly I:C used in the in vivo experiments.  
 
 
 
 
 
 
Figure 7.6. Effect of Poly I:C on hippocampal synaptic excitability. (A) Half-maximal and (B) 
Maximal eEPSC amplitude recorded from CA1 pyramidal neurons of brain slices incubated with 1-2 
μg/ml, 5-10 μg/ml and 25 μg/ml POLY I:C for 6 h. Data are the mean ± SEM (n=4-9), *p<0.05 and 
**p<0.01 compared to naive; #p<0.05 and ##p<0.01 compared to respective POLY I:C 25 ug/ml by 
one-way ANOVA followed by Tukey’s multiple comparison tests. 
 
The reduction of excitatory synaptic transmission mediated by continuous incubation for 6 
h with 25 μg/ml Poly I:C was partially lost after 24 h of incubation. Only maximal evoked 
EPSC amplitude remained reduced while the stimulus intensity required to reach half-
maximal EPSC in treated and naïve slices was not significantly different (Half-maximal 
eEPSC amplitude: Naïve: 162 ± 10.5; Poly I:C 24 h: 118 ± 7.7, Maximal eEPSC amplitude: 
Naïve: -1937 ± 98.3; Poly I:C 24 h: -586.8 ± 80.8; p<0.01; Figure 7.7). Six hours incubation 
with Poly I:C followed by media replacement overnight gave similar results to 6 h 
incubation (Half-maximal eEPSC amplitude: Poly I:C 6 h: 204.7 ± 5.3; Poly I:C 6 h + wash: 
170.2 ± 14.1, Maximal eEPSC amplitude: Poly I:C 25 μg/ml: -973.5 ± 108.5; Poly I:C 6 h + 
wash: -961 ± 143.9; Figure 7.7). 
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Figure 7.7. Effect of incubation time of Poly I:C on hippocampal synaptic excitability. (A) Half-
maximal and (B) Maximal eEPSC amplitude recorded from CA1 pyramidal neurons of brain slices 
incubated with 25 μg/ml Poly I:C continuously for 6 h, or for 6 h with media replacement or 
continuously for 24 h. Data are the mean ± SEM (n=4-9), *p<0.05 and **p<0.01 compared to naive; 
##p<0.01 compare to 6 h group and $p<0.05 compared 6 h+wash group by one-way ANOVA followed 
by Tukey’s multiple comparison tests. 
 
7.3.3 Effect of TLR3 stimulation on glia activation and their phenotype 
Finally, glia activation and induction of pro-inflammatory mediators by Poly I:C were 
studied by immunohistochemistry and RT-qPCR analysis (n=6 each group), respectively. 
There was no morphological activation of astrocytes and microglia and IL-1β, NF-kB and 
HMGB1 mRNA levels were not upregulated in the whole hippocampus by Poly I:C (Figure 
7.8). 
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Figure 7.8. Effect of Poly I:C on morphological activation of glia and pro-inflammatory gene 
transcription. Mice were i.c.v. injected with saline or 10 µg Poly I:C. After 6 h, hippocampal tissue 
was prepared for immunohistochemistry or RT-qPCR analysis. (A) Representativephotomicrographs 
showing CD-11b-immunoreactive microglia (left) and GFAP-immunoreactive astrocytes (right) in 
saline- (a,c,e,g,I,m) and Poly I:C-injected mice (b,d,f,h,l,n) in CA1 (a,b,g,h), CA3 (c,d,i,l) pyramidal 
layers and hilus (e,f,m,n).Scale bar: 100 µm (a-d,g-l), 50 µm (e,f,m,n). DG: dentate gyrus. (B) RT-
qPCR measurement of IL-1β, NF-kB and HMGB1 mRNA in the hippocampus from saline- and Poly 
I:C-injected mice. Data are mean ± SEM (n=6 each group). 
 
7.4 DISCUSSION 
The TLR3 pathway has been studied mostly in animal models of viral infections and little is 
known about its contribution to seizures. The data gathered so far show a dual role of this 
receptor in the immune system response after a challenge.  
We provide novel in vivo and in vitro evidence of a neuroprotective role of TLR3 possibly 
mediated by a priming-like effect after Poly I:C activation. Reduced neuronal excitability 
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and decreased number of seizures were observed when TLR3 stimulation was done hours 
but not minutes before the ictogenic challenge suggesting that a transcriptional pathway is 
involved. Moreover, this phenomenon was transient. In our study Poly I:C did not induce 
pro-inflammatory effects unlike the Poly I:C mediated neuroinflammation and glia 
activation that contribute to epileptogenesis (Dupuis et al., 2016; Galic et al., 2009; Gross 
et al., 2017). In accordance with the inhibitory effects on seizures, our in vivo paradigm of 
Poly I:C injection reduced neuronal excitability in hippocampal slices. Our data therefore 
suggest a novel and protective role of TLR3 stimulation that reduces neuronal excitability. 
Astrocytes were previously shown to be the cells responsible for the neuroprotective 
effects of Poly I:C. In fact, activation of the TLR3 axis by Poly I:C in human astrocytes induced 
expression of anti-inflammatory cytokines and neuroprotective mediators (Bsibsi et al., 
2006; Ghaemi et al., 2016; Tarassishin et al., 2011b). Recent studies have reported 
neuroprotective and anti-inflammatory effects of Poly I:C in cerebral ischemia models 
through downregulation of pro-inflammatory cytokines and expression of anti-
inflammatory cytokines in astrocytes (Li et al., 2015b; Pan et al., 2014; Wang et al., 2014). 
Poly I:C can promote neuronal survival and reduce cell death by oxygen-glucose deprivation 
or oxidative stress (Bsibsi et al., 2006; Marsh et al., 2009; Patel and Hackam, 2014).  
In our seizure model, TLR3 is induced in astrocytes suggesting that this cell-specific TLR3-
mediated pathway may represent a homeostatic attempt to control neuronal 
hyperexcitability.  
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CHAPTER 8 - TLR3-MEDIATED MECHANISMS OF 
NEUROPROTECTION 
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8.1 INTRODUCTION 
IFN-β signalling activation in astrocytes exerts protective effects in experimental 
autoimmune encephalomyelitis (EAE) animal models mediated by the immunomodulatory 
transcription factor AHR, its target cytochrome P4501B1 (CYP1B1) and SOCS2 
(Rothhammer et al., 2016). In EAE, AHR signalling in astrocytes controls inflammatory 
pathways involved in the recruitment of monocytes, glia activation and the neurotoxic 
activities of astrocytes (Rothhammer et al., 2016). IFN-β is used to treat multiple sclerosis 
(MS) and inflammation in EAE animal models (Khorooshi et al., 2015). Moreover, Poly I:C 
increases IFN-β expression and has a therapeutic effect in the disease outcome (Khorooshi 
et al., 2015). In ischemia models, the activation of TLR3 by Poly I:C induces IFN-β and 
mediates neuroprotective effects. Poly I:C preconditioning reduced cerebral ischemia 
injury in a TLR3-dependent manner by IFN-β increased expression in astrocytes and 
inhibition of inflammatory pathways (Gesuete et al., 2012; Kuo et al., 2016; Li et al., 2015b). 
Furthermore, IFN-β was reported to suppress astrocyte activation and glial scar formation 
after spinal cord injury (Ito et al., 2009; Nishimura et al., 2013). 
Based on this evidence, we have investigated the TLR3-mediated mechanisms of 
neuroprotection after Poly I:C stimulation in our experimental setting. 
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8.2 SPECIFIC MATERIALS AND METHODS 
Intracerebroventricular administration of Poly I:C 
Mice (n=6-12) were implanted with a guide cannula above the left ventricle and injected 
with saline or 10 µg Poly I:C. After 6 h, hippocampal tissue was prepared for RT-qPCR 
analysis as previously described (Figure 8.1; sections 6.4 and 6.7 of General materials and 
methods). 
Intrahippocampal administration of drugs 
Mice (n=3/group) were implanted with a guide cannula above the left hippocampus and 
injected with saline or 50, 500, 5000 IU mouse IFN-β 15 min, 1 h, 3h or 6h before 
intrahippocampal KA (Figure 8.2; sections 6.3.1 and 6.5 of General materials and methods). 
Kainic acid model of acute seizures 
Mice were implanted with depth electrodes and guide cannula for KA injection and intra-
hippocampal administration of mIFN-β as described before (see also sections 6.3.1 and 6.5 
of General materials and methods). Groups of 3 mice (n=12-18/group) were used for intra-
hippocampal mIFN-β injections at 15 min, 1h, 3h or 6h before KA injection and seizure 
assessment was done as described before (Figure 8.2; section 6.3.2 of General materials 
and methods).  
RT-qPCR analysis 
Five animals injected with Poly I:C were sacrificed 6 h later and their hippocampi were used 
to measure TLR3, IRF3, IFNB1, IFNAR1, AHR, CYP1B1 and SOCS2 mRNA levels as described 
in section 6.7 of General materials and methods (Figure 8.1). HPRT1, PDG1 and SV2B were 
used as reference genes to normalise mRNA levels. 
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Electrophysiology 
Organotypic hippocampal slices were prepared from male rats at postnatal day 10 (n=6-9) 
as described in section 6.8.2 of General materials and methods. In one group of slices (n=7), 
Poly I:C was added directly to the media of slices (n=7) at a dose of 25 μg for 6 h (Figure 
8.3). Another group of slices (n=6) was incubated with 5 μl of 500 IU IFN-β for 1 h (Figure 
8.3). Whole-cell patch-clamp electrophysiological recordings were performed as described 
in section 6.8.2 of General materials and methods. Slices (n=9) incubated with media and 
sterile water served as controls (Naïve). 
 
8.3 RESULTS 
8.3.1 Effect of TLR3 stimulation on IRF3-mediated pathway activation 
Stimulation with Poly I:C (n=6) induced upregulation of TLR3 (2-fold, p<0.01), IRF3 (6-fold, 
p<0.01) and IFN-β (2-fold, p<0.05) transcripts in the hippocampus 6 h after injection in 
naive mice (Figure 8.1). To further explore IFN-β downstream pathways, we analyzed the 
mRNA levels of AHR, and its targets CYP1B1 and SOCS2. AHR mRNA levels did not change 
but both CYP1B1 and SOCS2 levels were increased 6 h after Poly I:C (CYP1B1: 2-fold. p<0.01 
and SOCS2: 0.5-fold, p<0.05; Figure 8.1). AHR induction might have occurred at earlier time 
points which may account for the lack of changes in this gene.  
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Figure 8.1. Poly I:C  promotes the induction of TLR3, IRF3, IFN-β and IFN-β-regulated genes. Mice 
were icv injected with saline (n=6) or 10 µg Poly I:C (n=6-12) and hippocampal tissue was collected 
6 h later for RT-qPCR analysis. Data are mean ± SEM, *p<0.05 **p<0.01 vs saline by Mann-Whitney 
test. 
 
 
8.3.2 Effect of IFNβ on seizures and synaptic excitability in vitro 
To test the hypothesis that IFN-β mediated and AHR-dependent cascade may be 
responsible for the effects of Poly I:C on seizures, we injected various doses of mouse 
(m)IFN-β into the hippocampus (n=3/group) before inducing seizures in order to mimic the 
endogenous increase provoked by Poly I:C. We found that the dose of 50 IU mIFN-β given 
15 min before kainate increased both the number (p<0.05) and time spent in seizures 
(p<0.01; Figure 8.2). The doses of 500 and 5000 IU given either at 15 min, 1 h, 3 h or 6 h 
before KA had no effect compared to saline treated animals (Figure 8.2). We conclude that 
intrahippocampal injection of mIFN-β at various doses does not reproduce the TLR3-
mediated anti-ictogenic effects of Poly I:C. The lack of evidence for IFN-β involvement may 
be due to biological barriers encountered by IFN-β when injected in vivo which impair the 
efficient activation of its receptors. 
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Figure 8.2. Effects of mIFN-β injection on seizures. Mice were intrahippocampally injected with 50, 
500, 5000 IU mouse IFN-β (n=3 each dose) or saline (n=12) 15 min, 1 h, 3h or 6h before 
intrahippocampal KA. Data are the mean ± SEM, *p<0.05, **p<0.01 compared to saline by by 
Kruskal-Wallis test multiple comparison tests. 
 
We tested therefore the effect of IFN-β on synaptic excitability using in vitro slices and 
compared with Poly I:C effects. 500 IU of IFN-β for 1 hour resulted in similar reduction of 
synaptic excitability as seen with Poly I:C since both half-maximal and maximal eEPSC 
amplitude values were significantly decreased (Half-maximal eEPSC amplitude: Naive: 162 
± 10.5; Poly I:C 25 μg/ml: 204.7 ± 5.3; 500 IU mIFN-β: 211.6 ± 8.8, p<0.01; Maximal eEPSC 
amplitude: Naive: -1937 ± 98.3; Poly I:C 25 μg/ml: -973.5 ± 108.5; 500 IU mIFN-β: -911.7 ± 
82.7, p<0.01; Figure 8.3). 
These data suggest that IFN-β may mediate the Poly I:C effects on synaptic excitability, 
hence the anti-ictogenic effects observed in vivo after TLR3 stimulation.  
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Figure 8.3. Effect of incubation with IFN-β on hippocampal synaptic excitability. (A) Half-maximal 
and (B) Maximal eEPSC amplitude recorded from CA1 pyramidal neurons of brain slices incubated 
with 500 IU IFN-β for 1 h. Data are the mean ± SEM (n=6-9), *p<0.05, **p<0.01 compared to naïve 
by one-way ANOVA followed by Tukey’s multiple comparison tests. 
 
8.4 DISCUSSION 
IFN-β is a first line drug in MS treatment and is effective in the EAE animal model. Poly I:C 
injection in mice at the initial stages of the disease has therapeutic effects by inducing the 
expression of type I IFN genes by TLR3 activation (Khorooshi et al., 2015). In our 
experimental conditions, we found induction of IRF3 and IFN-β genes that may mediate the 
reduction in neuronal excitability and seizures due to TLR3 stimulation. IRF3 is a key 
element of the TLR3 pathway and its activation in glia cultures can switch the cytokine 
expression profile from pro- to anti-inflammatory and mediate neuroprotection 
(Tarassishin et al., 2011a, 2011c). In particular, IRF3 suppresses the expression of miR-155 
and miR155* in astrocytes which are involved in pro-inflammatory gene induction by 
targeting SOCS1 (Tarassishin et al., 2011a). IFN-β regulates inflammatory responses and 
provides neuroprotection in models of ischemic stroke (Liu et al., 2002; Marsh et al., 2009; 
Veldhuis et al., 2003). Our results indicate an activation of IFN-β pathway after Poly I:C 
challenge. Moreover, we found increased levels of CYP1B1, downstream target of AHR, and 
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SOCS2 that provide further support to a IRF3/IFN-β-mediated cascade responsible for the 
inhibitory effects of Poly I:C on seizures and neuronal excitability. In fact, in a model of EAE, 
IFN-β administered intranasally, resulted in reduced inflammation and improvement of 
clinical scores that were attributed to astrocytic AHR and SOCS2 signalling (Rothhammer et 
al., 2016). However, in our study, IFN-β injected directly into the brain failed to reproduce 
the TLR3-mediated anti-ictogenic effects of Poly I:C. This may be due to the inability of an 
exogenous application of the cytokine to activate the relevant signalling cascade induced 
when IFN-β is endogenously increased. Therefore we explored the possibility to reproduce 
the protective effect of Poly I:C in brain slices by direct incubation with IFN-β and indeed 
found an inhibitory effect on neuronal excitability similarly to that mediated by Poly I:C. 
Previous studies associate IFN-β with enhanced synaptic excitability in the hippocampus 
and other neocortical areas (Beyer et al., 2009; Costello and Lynch, 2013; Hadjilambreva et 
al., 2005). However, we report a reduction of evoked excitatory postsynaptic currents 
(eEPSC) within 6 hours indicating an inhibitory effect of IFN-β on neuronal excitability. The 
apparent discrepancy may be due to differences in the administration route, doses or the 
need for an additional trigger for enveiling the inhibitory effects.  
In conclusion, this study shows a new mechanism of neuroprotection mediated by the TLR3 
stimulation and subsequent induction of IFN-β involving astrocytes. 
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CHAPTER 9 - GENERAL DISCUSSION 
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Neuroinflammation is a key process for the pathogenesis of seizures as suggested by 
experimental studies and clinical data. Inflammatory pathways are commonly activated 
following various epileptogenic insults leading to the overexpression of molecules such as 
IL-1β, TNF-α and HMGB1 in seizure generating brain areas in both animal models and brain 
tissue from patients with parmaco-resistant epilepsy. Notably, these molecules possess 
neuromodulatory functions that contribute to seizure generation and recurrence (Aronica 
and Crino, 2011; Aronica et al., 2017; Vezzani et al., 2011b, 2011a, 2015).  
Glia and in particular astrocytes have been the focus of the research project described in 
this thesis since these cells are key modulators of brain homeostasis and neuronal function 
and their dysregulation, which includes an inflammatory phenotype, contributes 
significantly to experimental epilepsy development. It is crucial, therefore, to develop 
means to monitor the activation of the inflammatory pathways or the cells generating this 
response in the brain in order to interfere and possibly revert their detrimental effects in a 
timely manner. To be able to define the optimal time window for therapeutic interventions 
at the various stages of the disease may determine the success of disease-modifying or 
anti-epileptogenic therapies.  
One of our attempts was to monitor in vivo the activation of IL-1β in astrocytes using an 
adeno-associated virus. However, manipulation of gene promoter sequences was 
challenging since it resulted in ectopic gene expression and thus alternative approaches 
were required. To this end, we developed an in vivo imaging tool that allowed to monitor 
astrocyte activation during the disease and compare the time course of activation with 
their phenotype in post-mortem brain tissue. This comparison is important since astrocyte 
may have either a pro-inflammatory or an anti-inflammatory phenotype during 
epileptogenesis which will impact on their pathophysiological effects. Our data show an 
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activation of their pro-inflammatory phenotype as exemplified by TNF-α and HMGB1 
induction. However, we also identified increased PTX3 expression at the later stages of 
epileptogenesis possibly representing a homeostasic tissue response. These data suggest 
that pharmacological treatments that inhibit the inflammatory response should be 
administered promptly after the inciting event and that boosting the anti-inflammatory and 
neurotrophic phenotype of astrocytes may help to resolve the pro-inflammatory pathways’ 
activation.   
Anti-inflammatory drugs clinically available for other indications such as autoinflammatory 
or autoimmune disorders may offer a facilitated translation to the clinic. Recent studies 
have provided evidence that FTY720, a drug used for MS therapy, can exert anti-
inflammatory and anti-epileptogenic effects in animal models of epilepsy (Gao et al., 2012; 
Pitsch et al., 2018). Nevertheless, in our study, FTY720 failed to reduce astrocytic activation 
and proliferation and to alter the expression of both TNF-α and PTX3 during the 
epileptogenesis phase. Notably, FTY720 further increased the GFAP promoter activity and 
protein levels during the treatment period. We attribute this effect to additional 
mechanisms of action of this drug such as HDAC inhibition and activation of other S1P 
receptors, such as S1P3 and S1P5, that in turn activate astrocytes rather than inhibiting 
astrogliosis through the S1P1 pathway (Miron et al., 2010). Additionally, FTY720 did not 
restore the protein levels of GLT-1 and Kir4.1 during epileptogenesis. These data indicate 
that the anti-epileptogenic effects of previous studies (Gao et al., 2012; Pitsch et al., 2018) 
are likely mediated by mechanisms of action that do not involve modulation of astrocytic 
cell phenotype or their activation during the epileptogenesis phase. Our in vivo 
bioluminescence approach can therefore highlight if and how drugs affecting 
epileptogenesis impact on astrocytes, and could be also exploited for correlating the extent 
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of astrocytic acivation with the disease outcomes (e.g., seizure frequency, progression of 
seizures or comorbidities) using models of epileptogenesis where only a cohort of animals 
develops the disease (Brandt et al., 2003; Dube et al., 2006; Kharatishvili et al., 2006b; 
Nissinen et al., 2000; Pascente et al., 2016). 
The second part of this thesis is focused on the role of astrocytic TLR3 in ictogenesis. Innate 
immune system activation after pathogen invasion or cell damage is an important 
mechanism to fight infections or repair tissue by re-establishing homeostasis. TLR3 are 
amongst the pattern recognition receptors (PRRs) with a fundamental role in igniting innate 
immune responses to viral infections. There is limited investigation of their role in neuronal 
excitability. Moreover, the activation of TLR3 in the CNS has been associated with variable 
outcomes ranging from providing neuroprotection to provoking neuropathology.  
Viral infections and specifically viral encephalitis can cause seizures and epilepsy that 
appear to be dependent on the type of virus and multifactorial mechanisms (Vezzani et al., 
2016). Specifically, epilepsy development following viral encephalitis is probably due to 
neuronal cell loss and persistent neuronal hyperexcitability (Libbey and Fujinami, 2011). 
Patients with infection-related seizure disorders are often refractory to the available ASDs 
(Libbey and Fujinami, 2011). 
So far, various studies support that TLR3 activation promotes neuronal excitability. In fact, 
activation of TLR3 receptors in immature brain led to pro-inflammatory cytokine expression 
that in turn contributes to epileptogenesis and the associated comorbidities in adulthood 
(Galic et al., 2009; Okun et al., 2010). Moreover, TLR3-deficient adult mice showed a 
delayed epiletogenesis and less frequent spontaneous seizures than wild-type mice  (Gross 
et al., 2017).   
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On the other hand, a beneficial outcome of TLR3 stimulation in astrocytes has been 
suggested both in vitro and in vivo. TLR3 activation in astrocytes by its synthetic agonist 
Poly I:C results in the production of neurotrophic factors and type I IFNs that exert 
neuroprotective effects in animal models of ischemia, and EAE as well as in human 
organotypic brain slices (Bsibsi et al., 2006; Li et al., 2015b; Pan et al., 2014; Rothhammer 
et al., 2016; Tarassishin et al., 2011a).  
In line with this set of data, we report a reduced neuronal excitability, as shown by reduced 
seizures evoked in mice by KA, several hours after TLR3 stimulation with Poly I:C. In this 
seizure model, TLR3 is induced in astrocytes. This reduced neuronal excitability in vivo was 
reinforced by in vitro data showing a decrease in hippocampal neuronal excitability in both 
acute and organotypic brain slices after long lasting application of Poly I:C. 
Further evidence attributes this neuroprotective effect of Poly I:C to IRF3 axis activation 
and IFN-β expression whereas pro-inflammatory pathways involving IL-1β, HMGB1 and NF-
kB were not activated in our experimental paradigm. Previous evidence has shown that 
IFN-β expression in astrocytes mediates neuroprotective effects in CNS disease models 
(Marsh et al., 2009; Rothhammer et al., 2016; Tarassishin et al., 2011b). We propose 
therefore that TLR3 priming of astrocytes before a convulsive challenge activates an 
alternative neuroprotective mechanism which differs from the pathway favoring seizure 
generation in epilepsy models. 
This evidence also underscores that fine tuning of TLR3-activated pathway may be required 
at the appropriate time of disease development to attain therapeutic effects without 
interfering with the neuroprotective signalling mediated by astrocytes. Astrocytic TLR3 
could therefore represent a target for promoting neuroprotective mediators and anti-
inflammatory cytokines. The complexity of the mechanisms involved in epileptogenesis 
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after viral infections argues for a more careful evaluation of the results obtained in 
experimental studies since the same TLR may have a dual role depending on the cell type, 
the timing and persistence of activation in brain tissue.   
In conclusion, astrocytes are dynamic cells that react to an epileptogenic insult by rapid and 
lasting changes in their phenotype which involve both pro- and anti-inflammatory 
pathways. Dysfunction of astrocytes can contribute to seizure generation and recurrence 
and targeting this cell population during the critical phase of epileptogenesis may represent 
a promising avenue for drug development. 
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